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Abstract 
Laboratory diagnosis of tuberculosis is often difficult and time consuming. This study 
has evaluated some new strategies for improved isolation and detection of 
Mycobacterium tuberculosis in clinical specimens. This work was conducted over 
several years examining samples from the a high tuberculosis prevalence population in 
Jeddah, Saudi Arabia and in the low tuberculosis prevalence setting in Queensland, 
Australia. Commercial nucleic acid amplification technologies were evaluated and 
compared with in-house real-time quantitative PCR strategies for both pulmonary and 
extrapulmonary specimens and for paraffin embedded tissue samples. The study 
examined strategies for the detection of multidrug resistance strains through the use of 
Lipa assay to detect mutations in the rpoB gene. Variable numbers of tandem DNA 
repeat (VNTR) typing was applied to samples from Saudi Arabia and Queensland, 
Australia to assess their discriminatory power and to demonstrate the diversity and 
uniqueness of strains of M. tuberculosis in distinct geographical regions. A combination 
of VNTR typing targeting six ETR loci and an additional three polymorphic MIRU loci 
was applied to a strains of MTB to enhance discrimination of strains. The results 
demonstrated that culture remains the "gold standard" for diagnosis and that a liquid 
culture system is essential for timely isolation of mycobacteria. Direct nucleic acid 
techniques are valuable diagnostic tools in samples where AFBs can be demonstrated 
but have markedly reduced sensitivity in AFB smear negative MTB culture positive 
samples. A combination of VNTR and MIRU typing provides excellent discrimination 
of strains of Mycobacterium tuberculosis. This stable typing strategy relies on PCR 
which allows for real-time epidemiology of transmission to be monitored. 
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Chapter 1: General Introduction 
In recent years there has been a resurgence of tuberculosis which has been a companion 
of the human race since prehistoric times. Tuberculosis is reappearing in many 
countries as a public health crisis. Thus, if not an emerging disease, it is an important 
reemerging disease, and though ancient, is not a disease of the past (Navin et al. 2002). 
In fact, tuberculosis is slowly and inexorably spreading. Victims of tuberculosis are 
everywhere in the world, but more than 90% of them are in the Third World. (Chretien 
1998). It can strike anyone, anywhere, at any time, but is nevertheless most active 
amongst the poorest nations and societies. Tuberculosis is still a common disease and 
poses a major public health problem in both developed and developing countries due to 
their communicability. The World Health Organisation estimates that there were 8.4 
million new tuberculosis cases in 1999, up from 8.0 million in 1997. (Anon. 2001). This 
is largely due to a 20% increase in incidence in African countries most affected by the 
epidemic of HIV/AIDS. Each year more than 3 million deaths are directly attributed to 
the disease (Nolte et al. 1995). 
The causative agent of tuberculosis in humans is the Mycobacterium tuberculosis 
complex which consists of M tuberculosis, M africanum, M. bovis, and M. microti 
(Nolte et al. 1995). These organisms are acid-fast, aerobic, non-motile, non-spore 
forming, slow-growing bacteria. Tuberculosis has increasingly gained in importance 
since its resurgence in the nineteen eighties in many parts of the world, the cause of 
which has been multifactorial. The most important factor is due to suboptimal 
tuberculosis control programmes, whether due to lack of resources as seen in 
developing countries or due to a breakdown in existing tuberculosis control 
programmes as seen in the United States (Brundney et al. 1992). Factors such as the the 
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impact of HIV infection in sub-Saharan Africa, the emergence of multi-drug resistant 
tuberculosis, and increased migration and population displacement has exacerbated the 
problem (Bloom 1994). 
M. tuberculosis is spread by aerosolized droplet nuclei with the respiratory tract being 
the initial site of infection. M. tuberculosis can cause disease in almost every organ 
system but most predominantly in the lungs and are classified as either extrapulmonary 
or pulmonary tuberculosis (Leowski 1988). The most effective way to combat the 
spread of organisms and disease is through rapid diagnosis, thorough contact tracing 
and prompt initiation of appropriate therapy. In 1993, the Centres for Disease Control 
and Prevention made recommendations that the results from concentrated acid fast 
smears should be reported within 24 hours of specimen collection, culture in liquid 
media should be performed in order to detect the growth of M. tuberculosis within 10 to 
14 days, and antimicrobial susceptibility tests should be complete within 15 to 30 days 
after collection of the initial diagnostic specimen (Tenover et al. 1993). These 
recommendations were apparently relaxed to results in less than 21 days in a 1997 
commentary (Styrt et al. 1997). The question arises as to whether this standard can be 
reasonably achieved using current "state of the art" diagnostic methods. In this study, 
conventional and new molecular technologies were investigated in a routine 
mycobacteriology laboratory at the King Khalid National Guard Hospital in Jeddah, 
Saudi Arabia over a two-year period from January 1996 to January 1998. Clearly from 
the literature, there is no simple diagnostic solution for the identification M. 
tuberculosis in clinical specimens and combinations of various technologies are 
required in order to achieve the CDC prevention recommendations. 
A steady decrease in the incidence of infections with M. tuberculosis in the developed 
world had been reported (Leowski 1988). However, more recently, there has been 
resurgence of infections many attributed to AIDS patients and the emergence of 
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multiple-drug resistant M tuberculosis (Bloom et al. 1992). This problem is 
exacerbated in developing countries where overcrowding and poor nutrition contribute 
to reduced immunity and increased susceptibility to infection. In Saudi Arabia, accurate 
data on the incidence of tuberculosis is not available although it is estimated to be 30 
cases per 100,000 persons with the highest figures in Jeddah. These figures represent 
an incidence 2-4 times higher than that of developed countries (Al-Kassimi 1994). 
Resistant strains of M. tuberculosis are common in Saudi Arabia with resistance to 
isoniazid being most common (Al-Orainey et al. 1989). Rifampicin has been widely 
used in the treatment of tuberculosis and for other endemic conditions including 
brucellosis and leishmaniasis. Thus, rifampicin resistance is prevalent (Al-Orainey et al. 
1989). In the Saudi Arabian patient population, patients with positive AFB smears and 
pulmonary symptoms with or without radiological findings are frequently started on 
anti-tuberculosis therapy pending the results of culture which may take up to 12 weeks. 
It has been observed in the Southern region of Saudi Arabia that up to 50% of healthy 
individuals harbor NTM in their mouths and throats (Nsanze et al. 1993). The high 
incidence of NTM complicates the diagnosis of tuberculosis and frequently results in 
the unnecessary administration of anti-tuberculosis drugs. Tests which can provide a 
high specificity for MTB in smear positive specimens will therefore prove cost effective 
in reducing use of anti-tuberculosis drugs, contact investigations and isolation facilities. 
1.1 Laboratory Diagnosis 
Definitive diagnosis of respiratory tract tuberculosis is made by first concentrating, 
digesting and decontaminating respiratory tract specimens (expectorated or induced 
sputa, bronchoalveolar lavage or gastric lavage) and then performing both acid fast 
microscopy and culture on the processed specimens. Acid-fast microscopy results can 
be reported in 24 hours or less but the method lacks sensitivity and is unable to 
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distinguish between different species of mycobacteria (Kent et al. 1985). Growth on 
selective agar is slow, with visible colony growth taking at least three weeks and 
usually 4-6 weeks. Traditional methods for diagnosis of tuberculosis rely on 
microscopy using Zeihl-Neelson or Auramine stains to demonstrate acid fastness and 
culture on to selective media for isolation of M tuberculosis. Both the acid fast stains 
and cultural methods are insensitive. It is estimated that 5,000-10,000 organisms per ml 
of sputum are required for smear positivity (Kent et al. 1985) and that only 50% of 
clinically diagnosed cases are culture positive (Daniel 1990). 
The Bactec TB-460 system (Becton Dickinson, Sparks, Md. ) uses a radiometric method 
of detection of mycobacterial growth and has been widely used to detect positive 
cultures more rapidly than conventional culture. However, on average the time 
required to detect growth is 13 days (Abe et al. 1992) but can be up to 15 to 22 days 
(Woods 1993). The BACTEC 460 system has been marketed since 1977 (Nolte et al. 
1995). The Middlebrook 12B medium for this system contains 14C-labelled palmitic 
acid as the substrate. During mycobacterial growth, 14C-labelled CO2 is produced and 
released into the headspace air of the vials. A 14 CO2 detection device allows early 
determination of mycobacterial growth. However, this system requires radioactive 
reagents, causing waste problems, and vials have to be handled and punctured for 
readings at least eight times during the six to eight weeks of incubation, requiring a 
considerable amount of work and increasing the risk of cross-contamination. Other 
limitations include the inability to observe colony morphology, mixed cultures and 
hazards of using needles. In Saudi Arabia, the use of radioactive materials in the 
laboratory setting is strongly discouraged and alternative non-radioactive liquid culture 
systems have been pursued. Certain improvements have been reported with manual 
systems, such as the Septi-Check system (Becton Dickinson) (Sewell et al. 1993), the 
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MB redox system (Biotest, Heidelberg, Germany) (Naumann et al. 1997) and the 
Mycobacteria growth indicator tube (MGIT, Becton Dickinson: Pfyffer et al. 1997). 
However, all of these systems still require much handling. In 1995, the BacT/Alert 
(Organon Teknika) fully automated system for isolation of mycobacteria from both 
respiratory specimens and normally sterile body fluids (other than blood) was 
developed and approved by the Food and Drug Administration in July 1996 (Rohner et 
al. 1997). Both the BACTEC and MB/BacT systems detect microbial growth by 
monitoring changes in CO2 as organisms grow in the culture bottles. The primary 
differences are that the BacT/Alert uses a colorimetric detection method, tests each 
bottle every 10 minutes and uses a growth detection algorithm that monitors each bottle 
for an increased rate of change and/or sustained increase in CO2 concentration (Wilson 
et al. 1992). The Bactalert system has a marked advantage over the BACTEC 460 
system in that it is a completely automated, non-radioactive system which employs 
continual, non-invasive monitoring of cultures. 
Liquid culture coupled with radiometric or colorimetric detection methods offer 
excellent sensitivity but, the slow rate of growth of the organism, requiring on average 
at least 13 days for detection of Mtuberculosis, and definitive species identification 
requiring biochemical tests, nucleic acid hybridization or chemical analysis of mycolic 
acids (Thibert et al. 1993) makes for a delayed diagnosis. Direct nucleic acid 
hybridization, however, lacks the sensitivity of culture methods. 
1.2 Immunopathology 
Tuberculosis is a unique infection which requires cellular immune responses for its 
control (Collins 1982). The main defense of the lung is the alveolar macrophage and 
following inhalation into the alveolar spaces, tubercle bacilli are phagocytosed. 
Infected macrophages may spread throughout the body, probably randomly according to 
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blood flow, and can lodge in virtually any organ. The most important areas are those 
that favour bacillary growth: the lymph nodes, kidneys, epiphyseal areas of the long 
bones, vertebral bodies, meninges and, most importantly, the apical-posterior areas of 
the lungs (Bloom 1994). M. tuberculosis has evolved the ability to grow in unactivated 
alveolar macrophages and can grow unimpeded both in the initial focus and in the 
lymphohaematogenous metastatic foci for 4-8 weeks until cell mediated immunity 
develops (Wardle 1995). All people have a population of lymphocytes capable of 
recognising tubercle antigen processed by macrophages. When such lymphocytes 
encounter the macrophage-antigen complex, they are activated to divide, producing a 
progeny of similarly reactive cells. These in turn replicate and produce cytokines with 
the capacity to attract, retain, and stimulate macrophages at the antigen site. Activated 
macrophages develop high concentrations of lytic enzymes that greatly increase their 
mycobactericidal activity and also cause tissue necrosis when released from 
degenerating cells (Bloom 1994). When the population of activated lymphocytes 
reaches a certain size, cutaneous delayed reactivity to tuberculin or tissue 
hypersensitivity occurs, generally between 6-14 weeks after infection. At the same 
time as enhanced macrophage microbiocidal activity, cell mediated immunity appears. 
Not all persons infected with M. tuberculosis will develop disease. In healthy well- 
nourished subjects, approximately 95% of primary infections heal and remain healed 
throughout life (Onwubalili 1995). However, after even an inapparent tuberculous 
infection heals, the lungs may contain one or more small encapsulated caseous foci. In 
such foci, tubercule bacilli may persist in a dormant or nonmetabolizing state. The 
bacilli may remain viable in the host for life and cause active disease when the hosts 
immune function is compromised. Several conditions associated with reduced cellular 
immunity predispose to disease. These include malnutrition, uraemia, diabetes, 
leukaemia, lymphomas, alcoholism, immunosuppressive therapy and intercurrent 
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infection with HIV (Bloom 1994). It is the presence of these bacilli that necessitates 
prolonged (6-month) courses of chemotherapy, with the resulting problems of cost, 
compliance and drug resistance. It is not certain that drugs able to kill dormant or 
stationary-phase mycobacteria can be devised, since most microbicidal agents depend 
on actively metabolizing or dividing cells. The tubercule bacilli are believed to persist 
within macrophages as forms with unusual cell walls. Persistence of viable tubercule 
bacilli may also be the reason why the positive tuberculin reaction is usually maintained 
for life. Each time the bacillus multiplies, the immune system may be stimulated. 
(Bloom 1994). The epidemiological and clinical consequences of infection with 
M. tuberculosis are dependant on interplay of host, environmental and bacterial factors. 
Two bacterial properties that affect the transmissibility and virulence can be measured 
epidemiologically and clinically: (1) infectivity, the capacity of an organism to establish 
an infection in the human host and (2) pathogenicity, the capacity of the bacterium to 
produce disease. The success of Mtuberculosis as a pathogen is attributed directly to 
its ability to manipulate the phagosome that it resides in and to prevent the normal 
maturation of this organelle into an acidic, hydrolytic compartment. As the macrophage 
is key to clearing the infection, the interplay between the pathogen and its host cell 
reflects a constant battle for control (Russell 2001). 
1.3 Disseminated Tuberculosis 
There are three distinct patterns of disseminated tuberculosis, viz. acute miliary 
tuberculosis, cryptic miliary tuberculosis and chronic disseminated tuberculosis. 
Lymphohematogenous spread of M tuberculosis, usually at the time of primary infection 
and less commonly from established foci, can affect almost any organ. Tuberculosis of 
the lymph nodes is the commonest of the several manifestations of disseminated 
tuberculosis (Thompson et al. 1992). M bovis was once considered a common cause of 
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cervical adenitis but, by 1910, M. tuberculosis was identified as the cause of 70% of 
mycobacterial cervical lymphadenitis in children and, in 1951, M. tuberculosis was shown 
to be responsible for all except a few cases of lymph node disease (Park et at 1910, Lester 
1951). Diseases caused by atypical mycobacteria became increasingly apparent as 
tuberculosis rates in developed countries declined and reports of cervical lymphadenitis 
caused by atypical mycobacteria began to appear in the 1950s (Prissick et al. 1956). 
Changes in the pattern and frequency of tuberculosis have strikingly altered the aetiology 
of mycobacterial lymphadenitis. The possibility that the natural population of the Mavium 
complex and Mscrofulaceum is changing is supported by evidence that there has been a 
shift in the frequency of isolation of non-tuberculous mycobacteria recovered from 
children suffering from cervical lymphadenitis. Up to 1979, M scrofulaceum was the 
most frequent cause of cervical lymphadenitis in children (Wolinsky 1979). In contrast, 
recent reports have established that Mavium is the most common causative agent of 
lymphadenitis in children in both the United States (Wolinsky 1995) and England (Colville 
1993). From the review of the literature, it appears that in adults not infected with HIV, 
the disease is caused predominantly by M tuberculosis. In areas where the incidence of 
both tuberculosis and HIV infection is high, notably Africa, mycobacterial 
lymphadenopathy is caused almost exclusively by Mtuberculosis (Morrissey et at 1992). 
In developed countries where the incidence of tuberculosis is comparatively low, HIV 
patients, are more susceptible to disseminated mycobacterial infections caused by M. avium 
and up to 50% of AIDS patients in the United States and Europe were infected with non- 
tuberculous mycobacteria (Falkingham 1996). However, it cannot be assumed that all 
cervical lymphadenitis in children is caused by atypical mycobacteria because up to 10 % 
may be caused by tubercle bacilli. In Saudi Arabia, the incidence of tuberculosis is 2 to 4 
times that of developed countries (Milaat et al. 1994, Al-Kassimi 1994) and the incidence 
of HIV infection low. In Saudi Arabia, there are few reports on the epidemiology of 
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cervical lymphadenopathy in either adults or children. In 1984, Thabit et al. reported that 
approximately 50% of neck masses were associated with tuberculous lymphadenopathy. 
Similar figures have been reported from neighbouring Sudan where lymphadenopathy is a 
common clinical problem (Kheiry et al. 1992). As both tuberculous and non-tuberculous 
lymphadenopathy call for different treatment modalities, careful laboratory diagnosis is 
warranted. 
The most common clinical presentation of tuberculous lymphadenitis is that the patient 
observes a lump in the neck which is often painless. Occasionally the node many be 
painful and there may be fever in the early stages of the illness. The node is firm and 
mobile at first, but becomes fixed when periadenitis supervenes. Abscess formation, 
involvement of the skin and sinus formation may follow. During treatment, some of the 
nodes may enlarge and give rise to abscess or sinus formation. Furthermore, new nodes 
may appear. This is rarely due to the failure of treatment but is believed to be associated 
with variation of tuberculin sensitivity or with a secondary bacterial infection from the 
upper respiratory tract. Sinuses may persist for many months before healing finally 
occurs. 
The location of tuberculous adenitis was cervical or supraclavicular in over 90 % of cases, 
in 80 % only a single node was involved, and evidence of other tuberculosis was present in 
18% (pulmonary, 7%; mediastinal nodes 9%; other 2 %) (Summers et at 1980). 
Diagnosis was made by biopsy and AFB were demonstrated on stains in slightly over half 
of the cases. The only major diagnostic difficulty is granulomatous lymphadenitis due to 
mycobacteria other than M tuberculosis, the clinical and histological features of which can 
be identical, and differentiation is possible only by culture and not by histology. For 
optimal histological diagnosis of mycobacterial lymphadenopathy, three main diagnostic 
criteria should be demonstrated: (a) presence of AFB in sections, (b) presence of caseating 
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necrosis (c) epithelioid granulomata. However, the majority of histological diagnoses are 
made without all of these criteria being achieved. In a review of 89 cases of 
extrapulmonary tuberculosis, Cutler et al. (1994) determined that only 6/89 (7%) met all 
three of the diagnostic criteria. In the majority of cases (60/89; 67%), both caseating 
necrosis and granulomata were demonstrated. In the remaining 20/89 cases (22%), 
however, histological diagnosis was made on the presence of granulomata alone. 
Granulomas characterised by epithelioid multi-nucleate giant cells as seen in tuberculosis 
are also seen in a range of infectious and noninfectious diseases including cat scratch 
disease, fungal and helminth infections, sarcoidosis and neoplasms (Aranaz et al. 1996) 
and more specific diagnostic criteria are necessary for accurate diagnosis. 
The technological advances in the rapid diagnosis of infectious diseases have been applied 
to mycobacteria. Nucleic acid probes and polymerase chain reactions have been 
developed to detect mycobacterial DNA in clinical specimens, which allow for the 
detection of low numbers of both viable and non-viable bacilli (D'Amato et al. 1995, Kolk 
et al. 1992, Carpentier et al. 1995). Since AFBs are demonstrated in less than half of 
lymph node biopsies histologically diagnosed as tuberculous lymphadenopathy (Freidig et 
al. 1986), their utility is limited when assessing the sensitivity and specificity of a 
molecular assay. However, of greater interest will be to determine the sensitivity and 
specificity of a molecular method in comparison with histological diagnosis which at 
present must represent the single most diagnostic test for tuberculous lymphadenopathy 
although fraught with limitations. 
1.4 Treatment 
Before the availability of effective drug therapy, approximately half of patients with 
active pulmonary tuberculosis died within two years, a quarter recovered, and a quarter 
survived with chronically active disease. Treatment regimens are divided into the initial 
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phase (two months)) and the continuation phase (four to six months). During the initial 
phase the bactericidal effect of treatment leads to rapid bacteriological sputum 
conversion and improvement of clinical symptoms. During the continuation phase, 
consisting usually of fewer drugs given either daily or intermittently, the sterilising 
effect of therapy eliminates remaining bacilli and prevents relapse. The objectives of 
standard treatment regimens are to cure all infectious and non-infectious tuberculosis 
patients and to prevent relapses and the selection of resistant bacilli in infectious 
patients. In smear negative pulmonary and extrapulmonary cases (non-infectious 
cases), the risk of selection for resistant bacilli is small: the appropriate short-course 
chemotherapy includes three drugs in the initial phase and two drugs in the continuation 
phase. In smear-positive pulmonary tuberculosis (infectious cases), however, there is a 
risk of selecting resistant bacilli. Therefore, new cases should be given four drugs 
during the initial phase and two drugs in the continuation phase. This regimen is as 
effective for patients with sensitive organisms as for those with primary drug resistance 
(Anon. 2001). The drugs used in the initial phase are Isoniazid (H), Rifampicin (R), 
Pyrazinamide (Z) with Ethambutol (E) or Streptomycin (S). The drugs used in the 
continuation phase are combinations of H and E, or H and R. Previously treated cases 
(relapse, failure, return after interruption of therapy) should be given first 5 and then 4 
drugs in the initial phase and three drugs in the continuation phase. Using these drugs in 
conjunction with each other reduces antitubercular therapy from 18 months to 6 months. 
Therefore, the emergence of strains resistant to to any of these drugs causes major 
concern, as it leaves only drugs that are far less effective, have more toxic side effects, 
and result in higher death rates. 
1.5 Directly Observed Treatment 
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Patients must take all their medication daily or intermittently so that they become non- 
infectious and are cured with a minimum risk of future relapse. Yet it is well 
documented that at least 30% of patients receiving self-administered treatment in the 
initial phase will not adhere to treatment. The best way to ensure patients compliance 
with therapy is to observe patients taking their drugs. This is directly observed 
treatment. The World Health Organization (WHO) has established Observed Treatment 
Short-Course (DOTS) as a key strategy to tuberculosis control (Kochi 1991). The 
WHO case-management strategy has five elements: (1) a political commitment to a 
national and permanent TB programme; (2) Case detection by microscopy in 
symptomatic patients; (3) implementation of directly observed, standardized, free-of- 
charge, short-course chemotherapy (4) regular supply of all essential anti-TB drugs and 
(5) monitoring of case detection and treatment outcomes. Administration of DOTS 
appears to be the most effective way to ensure a decrease in primary resistance, 
acquired resistance and relapses (WHO 2001). During 1999,127 countries (an increase 
of 8 countries from 1998) were implementing DOTS strategy at least as a part of their 
national tuberculosis control programmes achieving good cure rates. (Anon. 2001). 
1.6 Molecular Diagnosis 
An alternative to amplification of mycobacteria by culture is amplification of 
mycobacterial nucleic acid followed by specific identification by hybridization. 
A number of nucleic acid amplification methods are being developed for mycobacterial 
testing including polymerase chain reaction (PCR) and ligase chain reaction (LCR). 
Any of these methods could significantly reduce the time required for diagnosis of 
infection with M. tuberculosis, perhaps to one day. It is not clear how these methods 
will be accepted in the routine clinical microbiology laboratory; hence, more 
information on the clinical utility of these methodologies is required. 
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1.7 Ligase Chain Reaction 
Ligase chain reaction (LCR) is a probe amplification technique first described in 1989 
(Wu and Wallace 1989). LCR amplification is based on sequential rounds of template 
dependant ligation of two adjacent oligonucleotide probes. Linear amplification of the 
specific probes is achieved when a single pair of oligonucleotides probes are ligated. 
Exponential amplification is achieved when two pairs of oligonucleotides probes, one 
complementary to the upper strand and one complementary to the lower strand are used. 
In the first step of LCR, two sets of oligonucleotide probes are allowed to anneal to 
their target DNA at 65°C. When complementary base pairing occurs, thermostable 
ligase (Barany 1991) will link the adjacent probes to yield a longer product. The 
reaction is then heated to 94°C to denature the ligated product and cooled to 65°C to 
allow annealing and ligation. The process is then repeated to achieve exponential 
amplification of ligated products (Podzorski et al. 1995). Two factors can critically 
affect the outcome of this reaction, particularly in the first cycles where the DNA in the 
specimen is the primary target for ligation. Firstly, the specificity of DNA ligase in the 
first cycles of the reaction where single base-pair mismatches prevents the adjacent 
probes from being ligated. In subsequent cycles where the ligation products form the 
predominant templates, the reaction is not susceptible to single base pair discrimination. 
Secondly, if there is ligation of probes independent of the target DNA early in the 
reaction these may serve as templates for amplification and result in blunt-end ligation 
products (Wu and Wallace 1989). 
This procedure was further modified in 1991 to overcome the problems with blunt-end 
ligation products and the intrinsic specificity of the reaction in detecting single base 
mismatches. The four oligonucleotide probes are designed in pairs that hybridize to 
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complementary single-stranded target sequences exposed after the DNA is denatured by 
heating to 95°C. When a pair of probes has hybridised to the target sequence on a 
single strand of DNA, there is a gap of a few nucleotides between the probes. The 
addition of a DNA polymerase into the reaction acts to fill in this gap between the 
probes by incorporating nucleotides. Once the gap is filled, ligase can covalently join 
the pair of probes to form an amplification product that is complementary to the original 
target sequence and can itself serve as a target in subsequent cycles of amplification 
(Birkenmeyer et al. 1991). 
Abbott Diagnostics (Chicago Ill. ) have obtained the rights to this technology (Weiss 
1991) and have adapted their IMx instruments referred to as LCx for the detection of 
amplified ligated target DNA. Methodologies using LCR were initially developed for 
the detection of Chlamydia trachomatis (Dille et al. 1993) and Neisseria gonorrhoea 
(Ching et al. 1995) in clinical specimens. Using culture as the "gold standard" for 
detection of C. trachomatis, LCR and Amplicor PCR have a specificity of 99.6% 
compared to culture (de Barbeyrac et al. 1995). This methodology has now been 
applied for the detection of Mycobacterium tuberculosis in respiratory specimens. The 
LCR target nucleic acid sequence for the M. tuberculosis LCR assay is found within the 
single copy chromosomal gene of M. tuberculosis which encodes for protein antigen b 
(Bengard et al. 1989). This gene sequence appears to be specific to the M. tuberculosis 
complex and has been detected in all M. tuberculosis complex strains examined to date 
(Sjobring et al. 1990). A preliminary report has shown that the LCR assay for the 
direct detection of M. tuberculosis in respiratory specimens has a high degree of 
specificity and sensitivity in smear positive respiratory samples, however, the sensitivity 
of the test was diminished in smear negative specimens (Ausina et al. 1997). 
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1.8 Amplicor Polymerase Chain Reaction 
Polymerase Chain Reaction is a technique for the in vitro amplification of specific DNA 
target sequences by the simultaneous primer extension of complementary strands of 
DNA. The PCR method was devised and named by Mullis and colleagues at the Cetus 
Corporation (Mullis et al. 1987). Polymerase chain reaction (PCR) has recently been 
used in the diagnosis of many infectious diseases by enabling specific detection of small 
numbers of nucleic acid molecules (Hayden et al. 1991). The diagnosis of tuberculosis 
is one of the more appropriate applications for PCR as undiagnosed cases have a 
potentially fatal outcome. Several investigators have therefore applied PCR for the 
direct detection of M. tuberculosis in clinical specimens (Altamirano et al. 1992, 
Eisenach et al. 1991). Contamination of samples during amplification giving false 
positive results is a major problem and must be taken into consideration (Noordhoek et 
al. 1994). 
The Amplicor M. tuberculosis PCR assay (Roche Molecular Systems, Branchburg, 
N. J. ) has overcome many of the contamination problems through the incorporation of 
AmpErase in the assay prior to amplification. Amperase contains the enzyme uracil N- 
glycosylase (UNG), which recognises and catalyses the destruction of deoxyuridine- 
containing DNA. Deoxyuridine is always present in amplicons because of the use 
deoxyuridine triphosphate in place of thymidine triphosphate in the amplification 
reagent (Longo et al. 1990). AmpErase prevents any residual uracil-containing 
amplicons created during previous cycles from being amplified again (Beavis et al. 
1995). The Amplicor PCR assay has good correlation with conventional culture 
although inconsistent results have been detected (Beavis et al. 1995, D'Amato et al. 
1995, Moore et al. 1995). These have been attributed to the presence of inhibitors, low 
organism numbers resulting in sample variation and the detection of non-viable 
organisms (Beavis et al. 1995)). The Amplicor PCR assay has the ability to detect 
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DNA from both viable and non-viable organisms and can detect M. tuberculosis after 
therapy has been initiated. (Beavis et al. 1995) PCR is an extremely specific and 
sensitive method of DNA amplification that is capable of identifying as little as a single 
copy of a given DNA sequence (Schluger et al. 1994). Since no "gold standard" 
methodology for diagnosing M. tuberculosis infection exists, laboratory diagnosis is 
complex (Narita et al. 1992). The utility of molecular methods for tuberculosis depends 
on the clinical situation in which the assays are performed. In patients with a history of 
infection, these molecular techniques may not be able to distinguish active from prior 
infection, particularly in patients with bronchiectasis (Schluger et al. 1994). Rapid 
results with these molecular methods may have large impact on hospital costs with 
respect to the management and isolation of patients suspected of having tuberculosis. 
Clarridge et al., in a study investigating 623 samples culture positive for AFB, 
determined that if all patients who had AFB positive sputum smears were placed under 
AFB isolation precautions, 28% of these would be isolated unnecessary as they did not 
have Mtuberculosis and 29% of patients infected with tuberculosis would not be 
isolated because of negative AFB smears (Clarridge et al. 1993). 
1.9 Real-time PCR detection 
Technological advances at Applied Biosystems (Foster City, Ca) have made fully 
automated real-time detection of specific products possible. The 7700 sequence 
detection system integrate four major elements; (1) fluorogenic chemistry for target 
specific oligonucleotide probes, (2) exploitation of the polymerisation dependant 5' 
nuclease activity of DNA, (3) instrumentation to measure fluorescence signal with a 
closed PCR reaction vessel, and (4) software that processes and analyses the data. 
(Bassam et al. 1996). The ABI Prism 7700 Sequence Detection System (TaqMan) has 
been shown to be a rapid and sensitive method for quantification of PCR products (Heid 
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et al. 1996). The system uses a fluorogenic probe, and the amount of fluorescence 
detected is proportional to the amount of accumulated PCR product. Quantification of 
PCR products occurs in real time during the amplification process, with no post- 
amplification handling being necessary. This eliminates potential sources of carryover 
contamination and reduces handling time. (Desjardin et al. 1998). 
More investigations are required to interpret nucleic acid amplification methods with 
culture positive and smear negative sputum samples. Although rapid diagnosis is 
essential for individual patient management, further work is required to understand 
sources of infection and means of transmission in order to control the disease. 
1.10 Detection of multi-drug resistance 
A particularly pernicious feature of the current epidemic is the concurrent increase in 
the prevalence of disease caused by strains of MTB that are resistant to multiple first- 
line anti-tuberculous drugs. Multiple-drug resistant tuberculosis is difficult to treat 
effectively and to cure. As a result, such patients may remain contagious for prolonged 
periods, leading to increased risk of transmission to contacts (such as family and health 
care workers), and subsequently into the community, hence, further compromising our 
ability to control the present epidemic and the occurrence of future cases (Hyman et al. 
1993). 
1.11 Types of resistance 
WHO/IUALTD studies use the term primary resistance to define the presence of drug 
resistance to one or more anti-tuberculous drugs in a new tuberculosis patient who 
presents to a treatment centre. This category includes those patients with primary 
resistance as well as those patients with undisclosed acquired resistance who either do 
not remember prior treatment, refuse to divulge the information on past treatment or had 
an incomplete clinical history recorded. Initial resistance does not include chronic 
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patients. Primary resistance is defined as the presence of drug resistance to one or 
more anti-tuberculous drugs in a tuberculous patient who has never received prior anti- 
tuberculous therapy. It is caused by infection with drug-resistant organisms from 
another patient who had acquired resistance either due to inadequate chemotherapy or 
because of infection with primary drug-resistant organisms (Vareldzis et al. 1994). The 
WHO/IUATLD (Anon. 2001) now recommend the use of the term resistance among 
new cases when patients deny any prior anti-TB treatment and, in countries where 
adequate documentation is available, no documented evidence of prior treatment exists. 
In the United States from 1982 to 1991, the incidence of primary drug resistance has 
increased from 0.5 to 3.1% (Anon. 1992). The frequency of primary drug resistance to 
one or more drugs is estimated to be about 5% in technically advanced countries while 
it is substantially higher in some developing countries. Although Saudi Arabia has no 
reliable TB notification system (Al-Kassimi et al. 1993), primary drug resistance is 
estimated to be approximately 15% with rifampicin resistance being most prevalent 
(Ellis et al. 1996, Jarallah et al. 1992). 
Ninety percent of rifampicin resistant strains are also isoniazid resistant. (Drobniewski 
et al. 1998). This high prevalence of resistance to both rifampicin and isoniazid makes 
rifampicin a suitable marker to monitor multi-drug resistant MTB (Drobniewski et al. 
1998). Acquired resistance is defined as resistance to one or more anti-tuberculous 
drugs which arises during the course of treatment usually as a result of delayed 
diagnosis, non-adherence to the recommended regime following diagnosis or faulty 
prescribing (Vareldzis et al. 1994). Acquired resistance can be determined only in 
countries with the resources to perform serial susceptibility testing. (Anon. 2001). A 
proxy for acquired drug resistance is to measure Resistance among previously treated 
patients. The WHO/IUATLD recommend that this group be subdivided into four groups 
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as follows; (1) treatment failures; (2) treatment relapse; (3) return for treatment 
following treatment default; and (4) chronic cases. (Anon. 2001) 
1.12 Mechanism of resistance 
Of concern is the emergence of drug resistant strains in recent years, and efforts have 
been made to unravel the mechanisms of action and to understand the molecular basis 
of resistance to these antibiotics. Deviations in structural genes encoding target proteins 
may lead to differences in secondary structure of such proteins, and therefore loss of 
functionality. These differences cause insufficient binding of the antibiotic to its target, 
and ultimately lead to antibiotic resistance (Pretorius et al. 1996). 
The term multidrug resistance refers to simultaneous resistance to at least rifampicin an 
isoniazid (Vareldzis et al. 1994). Genetic and molecular analysis of drug resistance in 
MTB suggests that resistance is usually acquired by the bacilli either by alteration of the 
drug target through mutation (Spratt 1994), or by titration of the drug through 
overproduction of the target (Davis 1994). Resistant mutations to any single antibiotic 
occur readily at random in bacilli undergoing replication and may be selected for by not 
using the appropriate combination of drugs. In tubercle bacilli, the sites of resistance to 
TB drugs are chromosomally located and are not plasmid borne. Thus, the likelihood of 
occurrence of a mutant resistant simultaneously to two drugs is the product of 
individual probabilities (Vareldzis et al. 1994). It appears clear there is no novel 
resistance determinant causing multi-drug resistance but rather an accumulation of 
individual mutational events in genes encoding drug targets (Morris et al. 1995). 
Development of resistance to rifampicin in MTB follows a single step high-level 
resistance pattern. Mutants arise spontaneously in strains not exposed previously to the 
antibiotic at a rate of one mutation per 107 to 108 organisms (Telenti et al. 1993 a). 
Because patients with cavitary pulmonary lesions may harbour 106 to 108 tubercle 
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bacilli, any patient treated with only a single effective drug has a very high probability 
that the resistant ones will be present and will continue to grow. Conversely, a patient 
treated with two or more drugs, in concentrations to which the strain is susceptible, has 
a very high probability of escaping the fate of incurable drug-resistant tuberculosis. 
The role of chemotherapy is paramount in production of all clinically important drug 
resistance (Rieder 1994). 
Drug resistance and the highly contagious nature of tuberculosis highlight the need for 
better surveillance programs and means of rapidly detecting resistant strains. It is now 
known that high-level resistance to isoniazid is associated with mutations to the catalase 
peroxidase gene katG. The mechanisms of action of isoniazid, as well as the 
mechanisms conferring isoniazid resistance, are complex and not completely 
understood. Activation of isoniazid to an unstable electrophilic intermediate requires 
the enzyme catalase peroxidase (KatG, coded by katG). However, mutations in the 
katG gene only correlate with less than 70 % of isoniazid resistant strains. (Kapur et al. 
1995, Morris et al 1995) . Efforts to determine the factors involved 
in resistance to 
isoniazid led to the discovery of the inhA locus, which was proposed as the primary 
target for coresistance to isoniazid and ethionamide (Banjeree et al. 1994). InhA is an 
enoyl-ACP reductase which catalyses an early step in fatty acid synthesis among 
enterobacteria. A T-*G transversion, observed in a few of the resistant strains, at 
position 280 in the inhA gene, results in ser94 to a1a94 replacement (Banerjee et al. 
1994). This replacement, thought to alter the binding affinity of InhA to NAD(H), 
ultimately results in isoniazid resistance (Dessen et al. 1995). Mutations in the inhA 
locus and isoniazid resistance have only shown approximately 10% correlation (Kapur 
et al. 1995, Morris et al. 1995). Isoniazid resistance has also been reported with 
mutations in aphC which encodes the alkyl hydroperoxide reductase C (Telenti et al. 
1997), and oxyR which is the oxidative stress regulator (Drobniewski et al. 1998). To 
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detect isoniazid resistance multiple systems are required that are capable of detecting 
multiple sites simultaneously to predict isoniazid resistance only in approximately 85% 
of resistant cultures (Telent et al. 1997). It has been shown that resistance to rifampicin 
and streptomycin arise from missense mutations in the genes encoding for bacterial 
RNA polymerase and certain ribosomal subunits respectively (Heym et al. 1993). 
It is known from studies on E. coli that resistance to rifampicin occurs due to missense 
and other mutations occurring in a discrete region of the rpoB gene. Telenti et al. 
(1993a) cloned and sequenced the cognate region of the Mtuberculosis gene by using 
sequence information available from the Mleprae rpoB gene (Honore et al. 1993). The 
data was used to formulate oligonucleotide primers for amplification and sequencing of 
a 411-bp fragment of rpoB from 66 rifampicin resistant and 56 rifampicin susceptible 
strains recovered from patients from several continents (Musser 1995). Approximately 
95% of rifampicin resistant isolates had mutations in the 69-bp region corresponding to 
codons 511 to 533 of the rpoB gene previously recognised as a prominent region for 
mutations conferring rifampicin resistance in E. coli. (Waterson et al. 1998). Fifteen 
distinct mutations involving eight conserved amino acids clustered in this 69-bp region 
have been identified (Musser 1995). The most commonly reported mutations have been 
missense mutations and amino acid substitutions at one of two positions (residues 526 
and 531) and these account for 80% of the resistant strains (Musser 1995). Additional 
mutations have subsequently been reported in the 81bp Rifampin resistance- 
determining region (RRDR) of the rpoB gene corresponding to codons 507 to 533 
(E. coli numbering system) (Mani et al. 2001). Different groups from diverse regions of 
the world have thus far reported around 65 substitutions, 12 deletions, and 4 insertions 
in the RRDR region of the rpoB gene. (Mani et al 2001). Further mutations which also 
confer rifampicin resistance have been reported at codons 381 (Taniguchi et al. 1996), 
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481 (Nash et al. 1997), 505 (Matsiota-Bernard et al. ), 508 (Matsiota-Bernard et al. ), and 
509 (Nash et al. 1997). The mechanism of resistance in the remaining 5% of isolates 
remains undecided but suggests that at least one additional molecular mechanism 
mediates rifampicin resistance in M. tuberculosis. Potential mechanisms include 
alterations in rifampicin permeability and mutations in other RNA polymerase subunits 
(Musser 1995). 
1.13 Rifampicin Resistance 
The gold standard method for the detection of mutations is DNA sequencing as it 
provides definitive identification of any mutation present. In the case of rifampicin, the 
presence of mutations appears to be fully predictive of resistance. This is not necessarily 
the case with other genes associated with drug resistance as silent mutations occur that 
do not lead to any significant change in phenotype e. g. katG gene, a common site for 
mutations within the C-terminal region has little effect on the activity of the catalase 
enzyme (Drobniewski et al. 1998). DNA sequencing requires a high level of technical 
competence and although this technique can provide accurate sequence data within 24 - 
48 hours the tests are costly and relatively expensive to maintain making this technique 
not cost effective for most laboratories. 
As an alternative to DNA sequencing Heteroduplex analysis, PCR single stranded 
conformational polymorphism (SSCP), and mismatch analysis have been used to detect 
mutations in the rpoB gene of MTB. Heteroduplex analysis uses amplified DNA from 
the test strain and DNA from a reference rifampicin susceptible strain mixed, denatured 
and cooled to produce a double stranded hybrid through complementary base pairing. 
In a resistant strain where mutations have occurred, there will be a mismatch of the two 
strands and the resulting heteroduplex will run with a different mobility to the 
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homoduplex (where the test strain has no mutations) on a denaturing electrophoresis gel 
system (Williams et al. 1994). 
SSCP utilises the complex tertiary structure of single stranded DNA to detect mutations 
in the rpoB gene. PCR is utilised to amplify the 81bp region of the rpoB gene of a test 
strain and the product is denatured to a single stranded DNA. If any two stands of 
DNA differ by one or more base pairs, they will fold into different tertiary structures 
with different mobility on a polyacrylamide gel (Telenti et al. 1993b). 
The mismatch assay is based on the ability of double stranded RNA to withstand 
digestion with the RNA polymerase, RNase A. Target DNA is amplified by using 
primers which incorporate T7 RNA polymerase and SP6 RNA polymerase promoters in 
opposite directions allowing RNA to be transcribed by using the PCR product as a 
template. A rifampicin-sensitive wild-type strain (H37Ra) is also amplified by using the 
same primers but with SP6 and T7 promoters incorporated in the strands 
complementary to the test strain. The test PCR product and reference PCR product are 
combined in a transcription reaction using either T7 or SP6 RNA polymerase. The 
complementary transcripts from the test and reference products are allowed to 
hybridise, and the resulting hybrids are treated with RNase. Any mutation in the test 
transcript will not pair with the reference transcript, and so the hybrid will be cleaved at 
that point. Undigested transcripts and cleavage products can be detected by analysis 
using agarose gel electrophoresis (Nash et al. 1997). 
The Innolipa Line probe assay using solid phase hybridisation analysis has been 
developed commercially by Innogenetics, (Ghent, Belgium). This system uses PCR to 
amplify the 260bp region the rpoB gene with the resulting biotinylated PCR products 
being reverse hybridised to oligonucleotide probes immobilised as parallel lines on a 
membrane strip. The oligonucleotides include five overlapping probes corresponding to 
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sequences present in the wild-type, rifampicin sensitive gene (SI-S5), together with four 
overlapping probes (R2, R4a, R4b and R5) corresponding to the most frequently 
observed resistance mutations including the two commonest His 536-*Tyr and Ser 
531-+Leu which account for up to 73% of rifampicin resistance (Cooksey et al. 1997) . 
The LiPA test is an easy-to-use format for the rapid detection of rifampicin resistance. 
The test, available in a kit format, is especially useful in laboratories that are not 
capable of carry out DNA sequencing. (De Beenhouwer et al. 1995, Rossau et al. 1997). 
In this study, In the United States, the assay was used for the rapid identification of 
rifampicin resistance in a collection of 51 rifampicin resistant cultures. Nine distinct 
rpoB mutations were detected and concordance with standard phenotypic rifampicin 
susceptibility results was 90.2%. (Cooksey et al. 1997). 
Of all these assays described for the detection of resistance mutations the Line Probe 
assay is probably the simplest post PCR procedure to perform and interpretation of the 
banding pattern allows for quick identification of the most common resistance 
mutations. This method has been applied successfully for the detection of mutations 
both in cultures and clinical specimens (De Beenhouwer et al. 1995). Although 
providing clear results SSCP, heteroduplex analysis and RNA mismatch analysis are 
unable to identify the actual mutation. However, silent mutations or missense mutations 
not directly related to rifampicin resistance may occur. This means that phenotypically 
rifampicin susceptible strains with the silent mutations would yield an altered SSCP 
pattern and heteroduplex analysis and be subsequently interpreted as resistant (Kim et 
al. 1997). In addition, these methods have not been applied successfully for the 
detection of resistance mutations in clinical samples and are more technically 
demanding than the Line Probe assay (Waterson et al. 1998). To date no assessment of 
the types of rifampicin mutations observed in Saudi Arabia has been undertaken. 
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Identification of the various types of mutations observed in Saudi Arabia may elucidate 
clustering of specific mutations and contribute to epidemiological investigations and 
mechanisms of transmission. 
1.14 Molecular epidemiology 
The control of mycobacterial disease requires powerful methods for detecting cases and 
tracing sources of infection, so that effective treatment can be correctly targeted and 
suitable public health measures implemented. Conventional epidemiological 
investigations have relied on phenotypic markers such as biochemical reactions, 
specific antigens, phage sensitivity and antibiotic resistance patterns which largely show 
low discrimination among strains (Butcher et al. 1996). Phage typing was the only 
method available for typing isolates of M. tuberculosis until the advent of the genotypic 
methods. A panel of phages were initially tested by a World Health Organisation 
working group in 1971 and initially showed poor interlaboratory reproducibility. An 
improved scheme was developed by Jones et al. which used four major phages to divide 
strains into three main groups. These three groups could be further subdivided by six 
auxiliary phages. Phage typing, however, requires technical skill for reproducibility and 
interpretation and its use limited in epidemiological studies (Jones et al. 1978). 
The recent application of discriminatory molecular methods for typing of 
M. tuberculosis strains plays a potentially important role in the investigation of 
community or nosocomial outbreaks investigations, confirming laboratory 
contamination and tracking sources of transmission. It is important to consider whether 
the disease results from reactivation of a previous infection or from active transmission 
and to understand the risk factors associated with transmission of tuberculosis so that 
health care resources can be used optimally and control measures implemented. 
(Gutierrez et al. 1998). Over the past few decades, numerous outbreaks of tuberculosis 
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have been reported in hospitals, prisons, schools and homeless shelters. In some 
outbreaks, the transmission of M. tuberculosis was limited whereas in others, there were 
high rates of transmission (Valway et al. 1998). Similarly, transmission has been 
reported after minimal exposure to an infectious patient. The variability of transmission 
rates has been attributed to the environment in which the outbreak occurred and to the 
clinical characteristics of the source patient. Sreevatsan et al. studied selected 
M. tuberculosis from Texas and New York associated with increased rates of IS6110- 
based clustering, a potential measure of increased virulence (Sreevatsan et al. 1997). In 
that study, M. tuberculosis complex were classified into three distinct groups based on 
single nucleotide polymorphisms in the catalase-peroxidase (katG463) and gyrase 
(gyrA95) gene sequences. (Sreevatsan et al. 1997). Genotypic Group 1 organisms 
included Mafricanum, M. bovis, Mtuberculosis and Mmicroti. Groups 2 and 3 only 
included strains of M. tuberculosis. Strains devoid of IS6110 and the Beijing Family 
strains including the W strain also made up Group 1 strains. Rhee et al. used molecular 
beacon technology to determine that genotypes classified using the katG-463 and gyrA- 
95 based system, were not associated with increased infectivity or pathogenicity (Rhee 
et al. 1999) 
1.15 Restriction fragment length polymorphism 
Repeated DNA sequences have been found to occur in the chromosomes of a wide 
variety of bacteria. The identification and characterisation of a series of repeated DNA 
fragments in the Mtuberculosis genome that show polymorphism between unrelated 
strains, has opened a new avenue for epidemiological study of tuberculosis. These 
include the insertion sequence, IS6110, the direct repeat (DR) sequence (Hermans et al. 
1992), the polymorphic GC-rich repetitive sequences (Ross et al. 1992), the major 
polymorphic tandem repeats (Hermans et al. 1992) and an element containing repeats of 
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GTG nucleotide triplets (GTG)5 oligonucleotides (Wild et al. 1994). Although these 
elements have shown some value in epidemiological studies, they have not proved as 
discriminatory as IS6110 restriction fragment length polymorphism (IS6110-RFLP) in 
strain differentiation. Three copies of the element (originally designated IS6110, IS986 
and IS987) have been isolated from different M. tuberculosis or Mbovis strains. These 
have been sequenced and found to differ in only a few nucleotides. IS6110 is present in 
the other species of the MTB complex although not in more distantly related 
mycobacteria (Stanley et al. 1998). The DNA fingerprinting method based on (IS6110- 
RFLP) is the method most extensively used and is the current standard method for 
Mtuberculosis strain differentiation (van Embden et al. 1993). This method has been 
shown to be a reliable, stable and reproducible method for differentiating 
Mtuberculosis strains (Goyal et al. 1994). In principle, this method involves the 
extraction of chromosomal DNA from mycobacteria harvested from culture, the 
digestion of this DNA using the restriction enzyme PvuII, which cleaves mycobacterial 
DNA at a point within the insertion sequence IS6110, and the separation of the resulting 
bands on an electrophoretic gel. Following electrophoresis the separated DNA 
fragments are denatured and blotted onto a nylon membrane, the position of the 
fragments is determined by hybridisation with a single-stranded 245bp DNA probe 
complimentary to a region of the insertion sequence downstream of the PvuII cleavage 
site. A characteristic profile of bands is produced reflecting the number of IS6110 
copies and their position within the chromosome, each copy producing a separate band. 
These RFLP patterns can then be analysed by computer, so that related strains can be 
identified easily and potential outbreaks quickly recognised. However, the IS6110 
RFLP technique has its own limitations as it requires culturing, DNA extraction, 
southern hybridisation and results can be obtained only weeks or even months after the 
initial presentation of the patient at clinic. In addition, the Mtuberculosis strains from 
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various parts of the world differ in the proportion of strains with few copies of IS6110. 
For example, in Spain and in parts of Africa there are few strains with less than five 
copies of IS6110 while such low copy strains make up a large proportion of the isolates 
from Southeast Asia. Discrimination with the RFLP technique is poor in these IS6110 
low copy strains of MTB; hence, the interpretation of clustering among these strains 
requires the use of a secondary or alternate typing method (Yuen et al. 1993). 
DNA fingerprinting of Mycobacterium tuberculosis isolates has been used increasingly 
in epidemiological studies. Restriction fragment length polymorphism (RFLP) analysis 
based on the genetic marker insertion sequence IS6110 is most frequently used to 
distinguish Mtuberculosis isolates. (van Embden et al. 1993). Insertion sequences (IS 
elements) are mobile DNA elements capable of transposition into diverse sites within 
the genome. It has been shown that the transposition rates of insertion elements are 
much higher than the rates of other heritable changes in the genome, such as nucleotide 
mutations, whereby, IS elements may transpose (jump) to a new locus by a replicative 
mechanism. (Stanley et al. 1996). They are parasitic DNA elements which are 
maintained in bacterial populations even under adverse natural selection because they 
can replicate and transpose independently of chromosome replication. Thus IS insertion 
patterns are subject to continuous variation during the history of a bacterial strain. The 
insertion sequence IS6110 has been of particular interest because of its potential 
diagnostic and epidemiological applications. IS6110 is a 1360-bp element with 
imperfect 28-bp inverted repeats at either end. Flanking the element are 3-bp repeats, 
probably resulting from target site duplication. Analysis of strains of M. tuberculosis 
and M. bovis possessing only one copy of IS6110 have shown that it is inserted 
conservatively into one of an array of 36-bp directly repeated (DR) sequences with 
unique intervening sequences between the DRs. (Herman et al. 1991). The most 
common insertion site is the direct repeat between spacer 24 and 25 (Benjamin et al. 
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2001). Investigations of a single strain with multiple copies of the IS6110 show distinct 
insertion sites suggesting that random transposition events have occurred in this strain 
(Mendiola et al. 1992). The extent of random versus site-specific transposition remains 
unclear. Different sites within the genome of M. tuberculosis have been reported as hot 
spots for the integration of IS6110 (Fomukong et al. 1998). These include the ipl locus 
(Fang and Forbes 1997), the DKl locus and the dnaA-dnaN region (Kupepina et al. 
1998). This suggests that the integration of IS6110 is not a truly random event and the 
frequency of transposition is influenced by the site of insertion within the mycobacterial 
genome (McHugh et al. 1998). The identification of IS6110 insertion hot spots may 
complicate the interpretation of IS6110 RFLP data. For strains containing low copy 
numbers of IS6110 integration hot spots may produce false clusters which must be 
subdivided by a second typing method independent of IS6110 (Barlow et al. 2001). 
Different M. tuberculosis strains show great variability in the chromosomal copy 
number and location of IS6110 against a stable genetic background. Consequently, 
restriction fragments carrying the element are highly pleomorphic. Appropriate 
interpretation of RFLP patterns may elucidate much about the epidemiological and 
evolutionary genetics. This application is based on the assumption that persons infected 
with strains of M. tuberculosis that have identical genotypes ("fingerprints") are 
epidemiologically linked, whereas those with different genotypes are unrelated. Studies 
from many countries report "clustering" of isolates, a cluster being defined as two or 
more isolates with fingerprints that are identical or at least similar. It is generally 
assumed that that the proportion of clustered isolates in a population reflects the amount 
of recent transmission of M. tuberculosis. (Glynn et al. 1999). This assumption relies 
on the assertions that the DNA genotype of a given strain remain constant and that 
changes in genotypes over time generate considerable genotypic diversity within a 
population. (Yeh et al. 1998). For correct interpretation of molecular typing in the 
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epidemiology of tuberculosis, it is essential to know the rate at which IS6110 RFLP 
patterns change, as an estimated rate of change may or may not support the utility of 
IS6110 typing for identifying tuberculosis cases associated with recent transmission. (de 
Boer et al. 1999). If IS6110-based genotypes change rapidly, it would obscure 
epidemiologic links and underestimate transmission, whereas, if genotypes change too 
slowly, then IS6110-based RFLP analysis would link cases that are only distantly 
related, overestimating transmission. The extent of the difference between two strains 
is therefore a function not only of the evolutionary or epidemiological distance between 
them but also the rate of transposition of IS6110 (Dale et al. 1999). In 1994, Cave et al. 
examined sequential IS6110 genotypes of M. tuberculosis in 18 patients and found that 
the genotypes were identical for 17 of them. In contrast, in a study of 49 patients in San 
Francisco, Yeh et al. (1998) found that 29% of serial isolates of patients whose cultures 
spanned greater than 90 days had changed RFLP patterns. The primary conclusion that 
can be drawn from the latter study is that DNA genotypes of M. tuberculosis change at a 
relatively rapid rate. This rate of change suggests that strains with identical genotypes 
are likely to be epidemiologically linked and supports the use of RFLP for tracking 
transmission. In contrast, Warren et al. (1996) have postulated that that IS6110-based 
RFLP analysis overestimates recent transmission by grouping distantly related strains 
with genotypes that have remained identical for large amounts of time. If few strains 
predominate over a long time-period, clustering cannot be assumed to represent recent 
transmission. The strain variation seen in a population will reflect the number of 
introductions of M. tuberculosis into the population (very many in Europe over many 
centuries, relatively few in parts of Africa) and the stability and relative fitness of the 
strains (Glynn et al. 1999). Fewer introductions of M. tuberculosis may explain the 
relative homogeneity of isolates seen in Ethiopia and Tunisia compared to the 
Netherlands. (Hermans et al. 1995) In contrast, the widespread occurrence of the 
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"Beijing family" of strains in Asia is likely to be due to stability of pattern and/or 
relative fitness of the strain. (van Soolingen et al. 1995). An alternative hypothesis is 
that certain RFLP types are endemic within a region during long periods and that 
remote transmission of such strains with a period of latent disease prior to reactivation 
could result in matching types among long-standing residents of the area (Bradden et al. 
1997). In 1998, Bishai et al. tested this hypothesis in the city of Baltimore, USA by 
examining the demographic and behavioural traits of clustered patients who lacked 
epidemiological links and found that they most resembled patients with DNA 
fingerprint matches and firm epidemiologic links who almost certainly had had recently 
transmitted tuberculosis. This study suggests that remote transmission does not account 
for a significant proportion of clustering in Baltimore. There are still unresolved 
questions about the stability of strains. The rates of change of molecular markers have 
been loosely described in terms of `molecular clocks" by analogy with those used to 
describe the molecular evolution of proteins. In addition, the discriminatory power of 
IS6110 as an epidemiological marker greatly depends on the IS copy number per strain, 
and isolates harbouring low copy numbers of IS6110 can be incorrectly grouped in the 
same cluster. It is widely recognised that strains with low number copies of IS6110 
(fewer than five) show little polymorphism and identical patterns are commonly found 
for strains from apparently unconnected patients (Dale et al. 1999). 
Evaluation of persons exposed to newly reported cases of tuberculosis is undertaken 
with the dual goals of finding other new cases and also identifying persons with 
tuberculous infection who are candidates for preventative therapy. (Behr et al. 1998). In 
some studies, it has been possible to establish epidemiological links between clustered 
cases, and in these circumstances it is reasonable to accept that the cases are part of the 
same chain of transmission either directly or indirectly from common sources. In 1994, 
Small et al. investigated patients in the San Francisco area and found only 10% of 
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epidemiological links by RFLP typing were also found by conventional contact tracing 
investigations. Only 5% of strains linked by RFLP were confirmed by contact tracing 
investigating patients in the Netherlands. (van Duetekom et al. 1997). An important 
theme from these studies is that despite diligent efforts, most case clusters are not 
recognised by the traditional tuberculosis-control strategies such as contact 
investigation. This relatively low reliability of conventional contact tracing may reflect 
the importance of casual contact in the transmission of Mtuberculosis. Population 
based studies using RFLP typing of Mtuberculosis have indicated an unexpectedly high 
degree of ongoing transmission in regions with low incidence suggesting that 
apparently casual contact can be sufficient to transmit infection (Yaganehdoost et al. 
1999). 
1.16 PCR based typing methods 
Since the RFLP typing method requires cultured isolates to provide sufficient DNA, 
various investigators have concentrated on developing typing techniques based on PCR 
which potentially may be applied directly to clinical specimens. Three approaches have 
been used to detect polymorphisms: first the use of non-specific primers, second the use 
of primers based on the polymorphism of the IS6110 flanking regions and thirdly the 
use of primers based on the direct repeat region. Most of the PCR-based techniques 
have been developed in order to amplify polymorphic DNA regions flanking IS6110 by 
PCR with oligonucleotide primers to the end of IS6110 (Ross and Dwyer, 1993). A 
simplified version of this IS6110-based PCR was developed using a single 
oligonucleotide primer complementary to the inverted repeat of IS6110. The 3' end of 
the primer is directed outwards from both sides of the element (Niemark et al. 1996). 
This DNA fingerprinting assay allows for a characteristic fingerprint from a single 
reaction tube and has been applied in the typing of cultures, in direct respiratory 
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specimens and in positive liquid BACTEC cultures (Otal et al. 1997). This method is of 
value in providing rapid information in outbreak situations and in ruling out 
contamination in a clinical laboratory, however, its limited discriminatory power limits 
its use in epidemiological investigations (Otal et al. 1997). Like the standard RFLP 
assay, the IS6110-based PCR tests are dependant on the presence of multiple copies of 
the insertion element for their increased discriminatory power and are unlikely to be of 
great benefit in resolving low copy IS6110 strains of M. tuberculosis. 
In 1991, Hermans et al. described a unique chromosomal locus in M. bovis BCG 
containing a large number of 36bp direct repeats (DR) which are interspersed by unique 
spacer sequences, varying in size from 35-41 bp. One DR plus the adjacent unique 
spacer sequence is termed a "direct variable repeat" (DVR) and is numbered according 
to the archetype DVRs in M. bovis BCG P3. (Groenen et al. 1993). When the DR 
regions of several isolates were compared, it was observed that the order of spacers was 
about the same in all isolates but deletions and insertions of DVRs occurred. The 
polymorphism in various isolates comprises the absence or presence of one or more 
DVRs. DRs are invariably and exclusively present in strains of the M. tuberculosis 
complex. In a study investigating over 1000 M. tuberculosis strains, Kamberbeek et al. 
(1997) found all strains to contain this multicopy target. Analysis of part of the DR 
cluster in various Mtuberculosis strains showed that this chromosomal region 
undergoes frequent genetic rearrangements with the number of DRs being variable in 
different isolates of Mtuberculosis. The polymorphism observed in this region is 
attributed to two types of genetic rearrangements which occur in this region. (Groenen 
et al. 1993). One type consists of the variation of one or a few discrete, contiguous DRs 
plus spacer sequences. This variation is probably driven by homologous recombination 
between adjacent or distant DRs. The other type of polymorphism is probably driven 
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by transpositional events of the insertion sequence, IS6110, which is almost invariably 
present in the DR cluster of M tuberculosis strains. Kamerbeek et al. (1997) developed 
a novel approach to exploit the polymorphism in the DR region by developing a PCR 
based method to amplify and label all DNA sequences in the DR region. The method 
referred to as spacer oligotyping or spoligotyping detects the presence or absence of 
spacer DNA of known sequence in an isolate in two steps. PCR is used to amplify the 
spacers between the DRs. The reverse primer used in the PCR is biotin labelled, so 
that all reverse strands synthesised are labelled. Individual spacers are then detected by 
hybridisation of the biotin-labelled PCR product containing spacer DNA to a membrane 
to which 37 oligonucleotides derived from spacers in M. tuberculosis H37Rv and six 
spacers from M. bovis BCG have been covalently linked. The resulting patterns look 
reminiscent of a bar code. (Kamerbeek et at. 1997). Compared to traditional IS6110 
fingerprinting, the degree of strain differentiation of M. tuberculosis by spoligotyping 
was lower for strains carrying five or more IS6110 copies and higher for Mtuberculosis 
strains harbouring fewer than five IS6110 copies. More recently, (Wilson et al. 1998) 
compared these three major strategies for molecular fingerprinting and found that using 
the standard spacer regions as probes, spoligotyping was not discriminatory enough to 
be used as a sole typing method but was of value when used in conjunction with other 
techniques. Similarly, IS6110-based PCR generates only one to three bands after 
agarose gel electrophoresis, and isolates cannot be clustered by identity of a single band 
only (Wilson et al. 1998). Although spoligotyping and IS6110-based PCR are simpler 
to perform than RFLP their reduced discriminatory power makes their utility limited to 
a primary screening method or alternatively used together in a dual typing strategy 
(Wilson et al 1998). 
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1.17 Variable numbers of Tandem DNA repeats 
Genetic loci containing variable numbers of tandem repeats (VNTR loci) form the basis 
for human gene mapping and identification, forensic analysis and paternity testing. A 
multiplex PCR assay co-amplifying nine STR loci and Amelogenin now forms the 
standard method for DNA fingerprinting in humans. In the human genome, these 
represent between 3-6% of the interspersed DNA. Interspersed repetitive DNA has 
been found in nearly all genomes studied so far. The function of the interspersed 
repetitive sequences remains largely unknown. It has been proposed that they may 
play a role in chromosome structure and rearrangement, tandem duplications, 
differential translation of genes, mRNA stability or transcription termination (Supply et 
al. 1997). Although the roles of these elements are not yet well defined, they may be 
very useful for a variety of applications, including genetic fingerprinting of 
mycobacterial strains. 
Frotthingham et al. detected eleven repeat loci by reviewing published literature and 
searching cosmid sequences from M. tuberculosis H37Rv (Frothingham et al. 1998), 
although it is estimated that there may be as many as 40-50 repetitive sequence loci in 
the MTB genome (Supply et al. 1997). These repeat loci consist of six exact tandem 
repeat (ETR) loci containing large DNA repeats with identical sequences in adjacent 
repeats and five major polymorphic tandem repeat (MPTR) loci containing 15-bp 
repeats with substantial sequence variation in adjacent copies. In this study 
Frotthingham et al. undertook a systematic analysis of the variability of tandem repeat 
loci by testing 48 strains of the Mtuberculosis complex including 23 substrains of 
Mbovis BCG. The VNTR loci of these strains were amplified by PCR and length 
polymorphisms were identified on agarose gels. Based on the size of the PCR products 
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the exact number of tandem repeats at each locus in each strain was determined. The 
results of this study showed that one of the five MPTR loci and all six ETR loci had 
length polymorphisms corresponding to insertions or deletions of tandem repeats. By 
assembling a profile based on the number of tandem repeats at each locus a distinct 
reproducible allele profile can be generated for each strain. 
The combined analysis of the seven polymorphic VNTR loci differentiated 
M. tuberculosis complex strains with reasonable power; however, IS6110 fingerprinting 
appears to be more discriminatory than VNTR typing in strains with high IS6110 copy 
numbers. IS6110 RFLP was less discriminative than VNTR analysis for the M. bovis 
BCG substrains, all of which had only one or two copies of IS6110 (Frothingham et al. 
1998). The stability of VNTR allele profiles in M tuberculosis has not been determined 
to date. Mtuberculosis H37 was isolated in 1905, and the two variants H37Rv 
(virulent) and H37Ra (avirulent) were identified in the 1930s. These variants showed 
different IS6110-RFLP profiles but still share the same VNTR profile (Bifani et al. 
2000). The estimated minimum time for a single step transition at a VNTR locus is at 
least 65 years, which is slower than the predicted rate of change for an IS6110-RFLP 
pattern (Yeh et al. 1998). It has been reported that IS6110-RFLP fingerprints in 
documented transmission chains allow a higher degree of stability than that observed 
for serial patient-derived isolates. Since VNTR allele profiles are stable over long 
periods of time, it is likely that VNTR profiles of serial patient-derived and 
epidemiologically related isolates will remain constant over time, unlike IS6110-RFLP 
fingerprints which are reported to vary by one or two bands (Barlow et al. 2001, Savine 
et al. 2002). 
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There are considerable advantages for the development of a PCR based method for the 
typing of mycobacterial strains independent of the IS6110. Firstly, since MTh is a 
very slow growing organism significant time can be saved if the culture step required 
for RFLP typing could be reduced or eliminated as is possible with a PCR based 
method. This is of particular importance in the investigation of outbreaks of MTB 
especially if multi-drug resistance is a factor. Secondly, PCR based methods are not 
technically demanding and known controls prepared from heat killed typed strains can 
be incorporated into each PCR reaction. Thirdly, interlaboratory comparisons of 
different strains isolated from different countries could be compared on a numerical 
database, since the PCR method of typing would yield a numerical allele profile number 
unlike comparisons with IS6110 RFLP which require complex computer programs for 
pattern comparisons. Finally, since PCR requires only small amounts of DNA there is 
the potential for performing VNTR typing directly on clinical samples or for performing 
VNTR typing on archive material for both epidemiological and evolutionary 
investigations. As more VNTR loci are detected, they can be applied to further 
discriminate clusters of identical VNTR allele profiles and, equally importantly, could 
be used to differentiate between primary, reactivated and new infections with MTB. 
Since VNTR typing may be a useful epidemiological alternative to RFLP 
fingerprinting, it is proposed that the five ETR loci (A, B, C, D and E) which have 
shown the highest degree of polymorphism among the MTB strains should be utilised 
as the targets for preliminary VNTR typing (Frothingham et al. 1998). 
1.18 Mycobacterial Interspersed Repetitive Units (MIRUs) 
In recent years, additional polymorphic regions have been identified as targets to 
discriminate unrelated strains of M. tuberculosis. Supply et al. (1997) reported the 
identification of minisatellite-like structure in the Mycobacterium tuberculosis genome. 
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These structures are typically of 51-77 bp repetitive sequences called mycobacterial 
interspersed repetitive units (MIRUs) and have been identified in 41 locations 
throughout the chromosome of H37Rv (Supply et al. 2000). The MIRUs have been 
classified into three major types. Type 1 sequences contain roughly 77bp. Type 2 and 
type 3 MIRUs are characterised by a gap of 24 bp and 15 bp corresponding to the 3' and 
5' portions of type 1 sequences respectively (Supply et al. 2000). PCR and sequence 
analysis of 31 different strains of M tuberculosis from distinct geographical regions 
have shown 12 of the MIRU loci have shown variations in the numbers of repeats. 
These correspond to MIRU 2,4,10,16,20,23,24,26,, 27,31,39,40. Loci 4 and 31 had 
previously been described as VNTR D and VNTR E respectively (Frothingham et al. 
1998). MIRU differ from ETR in that they contain repeats with minor sequence 
variations between them, which consist of a few substitutions, insertions or deletions. 
The repeat variants are distributed non-randomly in the arrays. ETRs are identical 
repeats clustered in blocks of contiguous units (Supply et al. 2000). In 2001, Supply et 
al. investigated the use of a 12-locus MIRU-VNTR (Mazars et al. 2000) approach for 
high resolution genotyping of M. tuberculosis. Analysis of a blinded set of 90 strains 
from 38 countries (Kremer et al. 1999) MIRU-VNTR typing was found to be 100% 
reproducible, sensitive and specific for Mtuberculosis complex isolates, a performance 
that has not been achieved by any other resolution typing method, including IS6110 
RFLP (Supply et al. 2001). In that study, the discrimination power of MIRU-VNTR 
typing was reported close to that of IS6110 RFLP (78 compared to 84 patterns 
respectively). More recently, Cowan et al. (2002) studied a set of 180 M. tuberculosis 
and Mbovis isolates with low copy numbers of IS6110 by MIRU-VNTR. The results 
were compared with IS6110 RFLP and spoligotyping analysis; MIRU-VNTR proved 
most discriminatory (Cowan et al. 2002). Other VNTR loci, in addition to ETR A-E, 
have since been identified at Queens University Belfast (Roring et al. 2002). It appears 
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that a combination of of VNTR , MIRU and other polymorphic loci will greatly 
improve the discriminatory power of DNA repeat polymorphisms. 
1.19 Aims of the Study 
The aims of the study were to evaluate molecular strategies which could be applied to 
patient samples, archive material and mycobacterial cultures to expedite tuberculosis 
diagnosis in patients. Direct nucleic acid detection methods and sample extraction 
methods are assessed to determine their utility as clinical diagnostic tools and to 
develop an understanding of their limitations. The study aimed to understand when 
patient samples should be tested in order to reduce the time for diagnosis of 
tuberculosis and thereby reduce further transmission of disease. Treating patients with 
multidrug resistant strains of MTB is difficult and necessitates diagnostic tools to 
identify such patients. This study aimed to assess the utility of these diagnostic tools. 
DNA typing methods were investigated in this study to determine the diversity of 
strains in distinct geographical regions, to monitor transmission, and to understand what 
host, environmental or organism factors are at play. The study aimed to determine the 
"best practice" approach for first line typing of strains of MTB and assess the utility of 
investigating other VNTR or MIRU targets. In addition, a combination of ETR loci and 
MIRU loci showing the greatest polymorphisms were applied to investigate their 
discriminatory power amongst the common clades. 
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Chapter 2.0 Materials And Methods 
2.1 Overview of Specimen processing 
Specimens were held at 4°C until processed by standard laboratory procedures. 
Respiratory specimens were processed within 24 hours by a standard N-acetyl-L- 
cysteine sodium hydroxide method and were centrifuged at 3,000 xg for 20 minutes. 
The final pellet was resuspended to 1.5 - 2.0 ml in sterile saline. Fluids from normally 
sterile sites and tissues were not decontaminated. Tissues were homogenized in a tissue 
grinder. All procedures were carried out in accordance with established CDC safety 
recommendations (Kent et al. 1985). 
2.2 Inoculation of Media 
For each specimen, two Lowenstein-Jensen slopes were inoculated with 0.2m1 of 
specimen and a smear was prepared for auramine-phenol staining. Flurochrome staining 
was performed by standard procedures and all positive smears were counterstained by 
the ZN stain. Slope cultures were examined weekly for 8 weeks. 0.5 ml of the 
processed sediment was inoculated into a MB/BacT (Organon Teknika, Durham, N. C. ) 
process bottle containing Middlebrook 7H9 broth, Tween 80 (0.4% w/v), Glycerol (5% 
w/v), Amaranth (0.002% w/v) and an antibiotic supplement containing Amphotericin B 
(0.018% w/v), Azlocillin (0.0034% w/v), Nalidixic acid (0.04% w/v), Polymixin B 
(10,000 units) and Trimethoprim (0.0105% w/v). Liquid cultures were monitored 
continuously in the MB/BacT 2400 cabinet (Organon Teknika) for up to 8 weeks. The 
time for culture positivity was recorded in days for MB/Bact bottles and in weeks for 
solid culture. All positive isolates with positive ZN stain and characteristic 
morphological appearance were confirmed as Mycobacterium sp. isolates. 
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2.3 Auramine Phenol stain 
Smears were heat fixed for 20 min. on a heating block. The slide was flooded with 
auramine-phenol auramine 10g. 1"; phenol 30g. 1'ß; ethanol 95%v/v) for 10 minutes. 
Slides were washed with tap water and decolorised with 0.5%v/v HCl in 70%v/v 
ethanol for 5 min. Slides were counterstained with 0.5g1'ß potassium permanganate 
(KMnO4) in distilled water. Smears were examined under fluorescent microscopy using 
25x and 40x objectives for apple green fluorescing bacilli. 
2.4 Ziehl Neelson (ZN) Stain 
0.3g basic fuchsin in 10ml of 95% ethanol, combined with 90ml of a 5% aqueous phenol 
soln., was filtered and flooded onto a heat fixed smear for 10min. Slides were rinsed 
with tap water and decolorised with 3%v/v HCl in 95% ethanol. A counterstain of 0.3 
gl" methylene blue in distilled water was applied for 30 seconds. Smears were 
examined under light microscopy with an oil immersion 100x objective. 
2.5 Amplicor PCR 
2.5.1 Sample Preparation 
100µ1 of decontaminated and concentrated sediment was added to 5O0µ1 of sputum 
wash solution and pelleted by centrifugation. Samples were incubated at 60°C for 45 
minutes. Following incubation, 100µl of neutralization reagent was added to each 
sample preparation tube. 
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2.5.2 Amplification 
50µ1 of prepared specimens and controls were added to each amplification tube 
containing 50µ1 of working master mix containing amperase. PCR tubes were loaded 
into a GeneAmp 2400 thermal cycler (Applied Biosystems). Thermal cycler was 
programmed as follows: 
2min @ 50°C: 
2 cycles @ 98°C 20 sec, 62°C 20 sec, 72°C 45 sec; 
35 cycles @ 94°C 20 sec, 62°C 20 sec, 72°C 45 sec; 
2.5.3 Detection 
Denaturation reagent (l00µ1) was added to each PCR tube and incubated at room 
temperature for 10 min. Hybridisation buffer (l00µ1) and denatured amplicons (25µl) 
were added to each well of aa microwell tray containing the bound amplicon specific 
oligonucleotide probe and incubated at 37°C for 90 min. Microwell plates were washed 
5 times in a microplate washer. A colour reaction was developed in the dark at room 
temperature following the addition of conjugate and substrate. Optical densitity (OD) 
was determined at A450 and an OD >0.50 was reported as a positive result. 
2.6 Abbott LCx MTB Assay 
2.6.1 Sample Preparation Processed Sediments 
500µ1 of decontaminated and concentrated sediment, was added to a LCx-MTB sample 
preparation tube and pelleted by centrifugation at 1500g for 10 minutes. The 
supernatant was aspirated and the pellet washed by the the addition of 1000µ1 of LCx 
tuberculosis resuspension buffer. The sample tubes were centrifuged for 10 min at 
1500g, supernatant was aspirated and a further 500µ1 of LCx tuberculosis resuspension 
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buffer was added to each tube. Sample tubes were incubated at 95°C for 20 minutes in 
a LCx covered dry bath (Abbott LCX Probe System). Sample tubes were allowed to 
equilibrate to room temperature before loading onto the LCx lysor (Abbott LCx Probe 
System) for sonication. 
2.6.2 Sample Preparation for positive MB/BacT cultures 
500µ1 of positive MB/BacT culture was aspirated using a tuberculin syringe and added 
to a LCx-MTB sample preparation tube. Samples were then assayed as processed 
sediments in section 2.6.1. 
2.6.3 Amplification 
l00µ1 of prepared samples and controls were added to each amplification tube and were 
loaded into a GeneAmp 2400 thermal cycler (Applied Biosystems). Thermal cycler 
was programmed as follows: 
37 cycles @ 94°C lsec, 64°C 1 sec, 69°C 40 sec; Hold: 25°C 
2.6.4 Detection 
Following amplification the amplification tubes were loaded into the LCx analyser 
(Abbott LCx Probe system) with the LCx detection reagents. By relating the LCx MTB 
Assay results for the specimen to the cutoff value (CO), the presence or absence of M. 
tuberculosis complex DNA was determined. The CO rate was the mean rate of the 
positive calibrator controls multiplied by 0.30. The S/CO value was determined by 
calculating the ratio of the sample rate (S) to the CO. A specimen with an S/CO reading 
equal to or greater than 1 was considered positive, and a specimen with an S/CO 
reading less than 1 was negative for the presence of M. tuberculosis complex DNA 
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2.7 Identification by DNA Probe 
A loopful of mycobacteria was added to 100µ1 of Accuprobe (Gen-Probe Accuprobe 
system, San Deigo Ca. ) lysis reagent in a transfer tube. The suspension was sonicated 
and boiled for 10 minutes to complete cell lysis. 100µl of lysate was added to an 
Accuprobe tube containing a single stranded DNA probe with a chemiluminescent label 
complementary to the ribosomal RNA of MTB. Hybridization was achieved by 
incubating the tube at 60°C in a dry heat block for 10 minutes. Detection was achieved 
by measuring photometric light units using a luminometer (Gen-Probe). 
2.8 Dedicated Laboratory Areas 
2.8.1 Sample Preparation 
Sample preparation was completed in a dedicated area (Area 1) of the laboratory. Area 
1 was used for processing samples (specimens, specimen processing controls, PCR and 
LCx tuberculosis positive and negative controls), and the addition of processed samples 
to LCx tuberculosis amplification vials. A Class II biological safety cabinet (BH2000 
series, Clyde-Apac) and aerosol contained centrifuge (Megafuge 2.0, Heraeus 
Instruments) were used until the specimens had been heat-inactivated. All reagents and 
equipment used in area 1 (such as pipettors, centrifuges, Abbott LCx covered dry bath 
and LCx lysor) remained in this dedicated area at all times. Area 1 items were never 
used when working with the amplification product and the amplification product was 
never brought into this area. Specimens, specimen processing controls, and activated 
negative and positive controls were stored separately from amplification vials. 
Pipetting was performed using aerosol barrier tips that were used only once. 
Amplification and detection of amplification product was completed in the second 
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dedicated area (Area2). All equipment in Area 2 was dedicated for specific use in that 
area. 
2.8.2 Aerosol Containment 
To reduce the risk of DNA contamination due to aerosols formed during pipetting. 
Pipettors with aerosol barrier tips were used for all pipetting except in the removal of 
supernatant during specimen preparation where a single-use, plastic disposable pipette 
was used. 
2.8.3 Inactivation ofAmplification products. 
To reduce the risk of amplification product contamination, at the end of the LCx MTB 
assay amplification product is automatically inactivated by using a two-reagent, 
chemical inactivation system. Both reagents (a chelating metal complex and an 
oxidizing reagent) are delivered into the LCx reaction cells by the LCx analyser after 
the amplification product has been detected. The ensuing reaction results in the near 
complete destruction of any nucleic acid present. This effectively reduces the risk of 
contamination of the laboratory by amplification products. 
2.9 LCx-MTB assay for detection of Mycobacterium tuberculosis DNA in 
paraffin embedded tissues 
2.9.1 Sample description 
One hundred paraffin embedded lymph node biopsies were selected for this study from 
Histopathology archives at The King Khalid National Guard Hospital.. Each specimen 
was fixed with formalin, embedded in paraffin, sectioned and stained with hematoxylin- 
eosin for examination of histopathological changes in addition to staining using the 
Ziehl-Neelsen procedure for the identification of AFB's. 
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2.9.2 Sample Population 
The biopsy samples were grouped according to histological evaluation. 
Group 1 comprised 17 biopsies showing evidence of granulomatous lymphadenitis and 
demonstrating acid-fast bacilli. 
Group 2 comprised 41 biopsies showing evidence of granulomatous lymphadenopathy 
with negative AFB in sections. 
Group 3 comprised 42 lymph node biopsy specimens which had histological diagnoses 
of reactive hyperplasia, malignancy and normal morphology were used as the control 
group of specimens. 
2.9.3 Amplification and Detection 
50µl aliquots of the DNA suspension and 50µl of LCx tuberculosis resuspension buffer 
containing 27 mmol/ml MgCl2 were added to an LCx MTB amplification vial and 
tested by the LCR Mycobacterium tuberculosis assay (Abbott LCX Probe system, 
Abbott Diagnostics, Chicago, Ill. ) according to the manufacturer's directions. 
Amplification was carried out using a 37-cycle program in a Perkin-Elmer thermal 
cycler (Abbott LCX Probe system). Detection was achieved by loading amplification 
vials directly into a carousel for automated detection in the LCx analyser (Abbott LCx 
Probe system). Two negative and two positive reagent controls and one saline negative 
and positive (4000- 6000 cfu/ml MTB) processing control were included in each batch 
of samples assayed. The cut-off value for the assay was determined at 0.3 times the 
mean positive reagent control rate. The sample results were calculated as the ratio of 
the sample rate (S) to the cut-off rate (CO) i. e. (S/CO). Samples in the ratio range 
S/CO 0.3-1.0 were considered equivocal while ratios greater than 1.0 were considered 
positive for MTB. 
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2.9.4 Second round amplification 
All equivocal and positive samples were retested by a dual amplification method to 
confirm the presence of DNA. 50µ1 of DNA suspension was added to an LCx 
Amplification vial and loaded in the Thermal cycler as described above. Prior to the 
detection step, the amplified vials were transferred to a DNA free laboratory and 10µl 
of the first round amplification vial was transferred to a new LCx amplification vial. In 
addition, 90pl of LCx resuspension buffer was added to each second round 
amplification vial to achieve a final volume of 2O0pl. Detection was achieved by 
loading both first and second round amplification vials directly into a carousel for 
automated detection in the LCx analyser (Abbott LCx Probe system). 
2.10 DNA Extraction from Paraffin Tissue 
2.10.1 Phenol Chloroform Method 
Paraffin blocks were cooled on ice for 30 minutes prior to sectioning. Disposable 
microtome blades were used for each sample and microtome, forceps and surrounding 
bench cleaned with xylene to prevent cross contamination. Five 10µm sections from 
each tissue block were transferred to a sterile 1.5m1 microfuge tube. Sections were 
deparaffinised with xylene and wash with absolute ethanol. Following centrifugation 
at 13,000 rpm for 10 minutes the supernatant was removed to discard and the resulting 
pellets air-dried. 250µl of a digestion buffer containing 1% sodium dodecyl sulphate 
(Sigma Aldrich), 50mM Tris-HC1 (pH8.0), lmg/ml Proteinase K (Sigma Aldrich) was 
added to each tube and incubated in a dry heat bath at 56°C for 18-24 hrs. The nucleic 
acid was extracted by the standard phenol / chloroform method and precipated with 
ethanol and 3M sodium acetate (pH 5.0) overnight at -20°C. The DNA is pelleted by 
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centrifugation and resuspended in 250µ1 of LCx Resuspension buffer. (Abbott LCx 
Probe system) 
2.10.2 Nucleospin column Method (Nucleospin Tissue Kit, Machery Nagel) 
Three 12-micron sections were cut each paraffin block with a microtome blade. To 
prevent carryover tissue contamination of the samples, the microtome blade was 
cleaned with xylene and 100% ethanol after sectioning each sample. Sections were 
transferred to a microcentrifuge tube deparaffinised with xylene, washed twice with 
absolute ethanol and pelleted by centrifugation. The resulting pellet was resuspended in 
1800 Lysis Buffer and 25µl of proteinase K stock solution and incubated at 56 °C until 
all tissue fragments have been digested. Samples were vortexed each 15-30 minutes for 
2-4 hours to aid digestion process. 200µl of a binding buffer was added to each tube 
and incubated at 70°C for 10 minutes. 210µl ethanol was added to each sample tube 
and transferred to a Nucleospin column unit. Following washing the nucleospin matrix 
the DNA was eluted in to a clean tube using 1001il of elution buffer. 
2.11 DNA Extraction from Processed Specimen Sediments 
2.11.1 Nucleospin column Method (Nucleospin Tissue Kit, Machery Nagel) 
500µ1 of processed sediments were transferred to a microfuge tube containing 500µ1 
sterile water and pelleted by centrifugation at 13,000 rpm for 10 minutes and the 
supernatant discarded. The pellets were resuspended in 180µl of lysis buffer and 
incubated at 95°C for 10 minutes in a dry heat bath. 251il of proteinase K stock solution 
was added and incubated at 56 °C for approximately 15 minutes. 200111 of a binding 
buffer was added to each tube and incubated at 70°C for 10 minutes. 210µl ethanol 
was added to each sample tube and transferred to a Nucleospin column unit. Following 
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washing the nucleospin matrix the DNA was eluted in to a clean tube using 100µ1 of 
elution buffer. 
2.12 DNA Extraction from Bacterial Cells 
2.12.1 Nucleospin column Method (Nucleospin Tissue Kit, Machery Nagel) 
A loopful of freshly grown bacterial cells (3 to 5 weeks) were transferred to a microfuge 
tube containing 500µ1 sterile water and pelleted by centrifugation at 13,000 rpm for 10 
minutes and the supernatant discarded. The pellets were resuspended in 180µl of lysis 
buffer and incubated at 95°C for 10 minutes in a dry heat bath. 25gl of proteinase K 
stock solution was added and incubated at 56 °C for approximately 15 minutes. 200µ1 
of a binding buffer was added to each tube and incubated at 70°C for 10 minutes. 
210µl ethanol was added to each sample tube and transferred to a Nucleospin column 
unit. Following washing the nucleospin matrix the DNA was eluted in to a clean tube 
using 1 00µl of elution buffer. 
2.12.2 Instagene Matrix (BioRad Laboratories) 
A colony of M. tuberculosis was scraped from a Lownwstein Jensen slope using 
a disposable loop and resuspend in 1. Oml of sterile water in a microfuge tube. Sample 
was centrifuged at 10,000 rpm for 10 minutes and the supernatant discarded. 200µl of 
InstaGene matrix (BioRad Laboratories) was added to the pellet and incubated at 56°C 
for 30minutes. The suspension were heat treated at 95°C for 20 minutes before a final 
centrifugation at 10,000 rpm for 3 minutes. 
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2.13 Quantitation of DNA 
Control MTB DNA was prepared by extracting DNA from a loopful of bacterial cells 
from a four-week-old culture of H37Rv growing on Lowenstein-Jensen medium. DNA 
was extracted using the mycobacterial cell protocol 2.9.2 Nucleospin tissue kit. The 
extracted H37Rv DNA was diluted 1: 1000 with sterile injection water and quantified by 
spectrophotometry using a UV Mini 1240 Spectrophotometer (Shimadzu Corporation, 
Kyoto, Japan). l00µ1 of a 1: 1000 dilution of H37Rv was loaded into a cuvette in the 
spectrophotometer and using A26o quantitated the DNA. 
2.14 Gel electrophoresis 
2g of DNA grade agarose (Sigma Aldrich) was dissolved in 100md 1xTAE buffer 
(Sigma Aldrich) by heating for 90 seconds in a microwave on high. Upon cooling 
approximately 4µd of 10mg/ml ethidium bromide (BioRad Laboratories) solution was 
added and the molten agarose was poued into gel casting tray with a gel comb (BioRad 
Laboratories). 
l Oµl of each contol or PCR product were mixed with 2µl of 6x gel loading dye (BioRad 
Laboratories) and loaded into wells on the gel. 100bp ladders (MBI Fermentas) were 
interspersed every 6 wells to size the amplified products. Gel and casting tray were 
loaded into a Wide Mini Sub Cell GT (Biorad Laboratories) electrophoresis tank and 
covered with 1x TAE buffer (Sigma Aldrich). Electrophoresis was performed used a 
BioRad 300 Power Pak for 60 minutes at 100 volts. 
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Following electrophoresis products were visualised using UV light on a transilluminator 
( UVTec Limited, Cambridge, England) and photograhed using a (Polaroid Gel Cam) 
camera using (Polaroid 667) film. 
2.15 RT PCR TaqMan assay for the direct detection of MTB-DNA in clinical 
specimens and paraffin embedded tissues 
2.15.1 DNA Extraction 
DNA extractions from paraffin tissue, processed sediments and bacterial cells were 
performed using specific protocols with the Nucleospin tissue kit. (sections 2.10.2, 
2.11.1 and 2.12.1 respectively) 
2.15.2 Assay Design 
Version 1.5 of Primer Express software (Applied Biosystems) was used to design a 
TaqMan probe and complementary primers to target a region of the insertion sequence 
IS6110. 
2.15.3 TaqMan Probe 
The TaqMan probe was designed using the following guidelines as recommended by 
Applied Biosystems: 
(12) Avoid probes with a guanine residue at the 5' end of the probe, as a guanine 
residue adjacent to the reporter dye will quench the reporter fluorescence. 
(12) Probes were selected with an estimated melting temperature (Tm) of 68-70°C. 
(12) Taqman probe was selected as short as possible not exceeding 30 nucleotides. 
(12) Runs of identical nucleotides were avoided. This especially applied to guanine 
where runs of four or more were avoided. 
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The internal oligonucleotide probe was labelled with the fluorescent dyes 5- 
carboxyfluroscein (FAM) on the 5' end and N, N, N', N'-tetramethyl-6-carboxyrhodamine 
(TAMRA) on the 3' end. 
5' -(6-FAM) CCACGCCGCCAACTACGGTGTTTAC 
(Tamra)(phosphate)-3' (Genset Pacific, Lismore, Australia). Manufactured as 
a 210µM concentration 
This Taqman probe corresponds to the region of IS6110 from base 578 to base 602 
(bases are numbered as for the sequence with the Genbank accession no. X17348). The 
probe was 25bp in length with a Tm of 69°C and a 60% GC. 
2.15.4 Assay Primers 
After selecting the probe for the assay, primers were selected using the following 
guidelines. 
(a) Runs of identical nucleotides were avoided. This especially applied to guanine 
where runs of four or more were avoided. 
(b) Primers were selected with an estimated melting temperature (Tm) of 58-60°C. 
(c) Keep the guanine + cytosine content within 20-80%. 
(d) Ensure the last five nucleotides at the 3" end contain no more than two guanine 
+ cytosine residues. 
(e) Place the forward and reverse primers as close as possible to the probe without 
overlapping it. 
Forward primer: 5' AACTCAAGGAGCACATCAGCC 3' (Genset Pacific, 
Lismore, Australia). 
Manufactured as a 100µM concentration 
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Reverse primer: 5' CCACACTTTGCGGGCAC 3' (Genset Pacific, Lismore, 
Australia). 
Manufactured as a 100µM concentration 
The forward primer corresponds to the region of IS6110 from base 553 to base 573 
(bases are numbered as for the sequence with the Genbank accession no. X17348). The 
forward primer is 21bp in length with a Tm of 58°C and a 52% GC content. 
The reverse primer corresponds to the region of IS6110 from base 620 to base 604 
(bases are numbered as for the sequence with the Genbank accession no. X17348). The 
reverse primer is 17bp in length with a Tm of 58°C and a 65% GC content. 
2.15.5 PCR Reagents 
Brilliant Quantitative PCR core reagent kit (Stratagene) containing: 
SureStart Taq DNA polymerase 5U/µl 
Core PCR Buffer lOx 
Magnesium chloride 50mM 
dNTP mix 20mM (5mM each of dATP, dTTP, dGTP, and dCTP) 
Reference dye (dilute 1: 50 with Core PCR Buffer Ix) 
Optical tubes and caps (Applied Biosystems) 
2.15.6 Optimization of Primers and Probe 
Primers were diluted 1: 10 with sterile injection water to obtain a working concentration 
of 10µM. Probe was supplied as a 210µM concentration was diluted 1: 84 to obtain a 
working concentration of 2.5µM. A primer concentration matrix (125,250,500 and 
1000nmol of each primer) and a probe concentration titration (50,125,250 and 500 
nmol) were performed to determine the concentrations which provided the smallest Ct 
value and highest fluorescence for a given target concentration. Final optimised 
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concentrations for the primers were 500nmol and probe 125nmol in each 50µ1 PCR 
reaction. 
2.15.7 PCR Reaction mix 
Core PCR Buffer lOx Nx5.0µl 
Magnesium chloride 50mM Nx5.0µl 
IS6110 (fwd) primer (500nmol) Nx2.5µ1 
IS6110 (rev) primer (500nmol) Nx2.5pl 
ISO 10 probe (125nmol) Nx2.5µl 
dNTP mix Nx2. Oµ1 
Reference dye NxO. 75µ1 
SureStart Taq DNA polymerase 5U/µl Nx0.5µl 
DNA template 29.25 pl 
2.15.8 Amplification and Detection ABI 7700 (Applied Biosystems) 
Amplification occurs using a PCR protocol of 50°C 2 minutes; 95°C 10 minutes 40 
Cycles: 95°C 15 seconds, 60°C 1 minutes. During PCR, a multiplexer directs an argon 
ion laser through fiber optic cables that terminate above each position on the 96-well 
plate. The light passes through the MicroAmp Optical caps and, for adefault time of 25 
milliseconds, the laser excites the fluorescent dyes present in each well. The fibre optic 
cables then collect the fluorescence emission between 500nm and 660 run from each of 
the wells. A system of lenses, filters, and a dichroic mirror focus the fluortescence 
emission into a spectrograph. The sequence detection application collects the 
fluorescent signals and applies data analysis algorithms. 
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2.15.9 Determination of the Limit of Sensitivity of the Assay 
H37Rv control DNA was prepared by extracting DNA from a loopful of bacterial cells 
from a four-week-old culture of H37Rv growing on Lowenstein-Jensen medium. DNA 
was extracted using the mycobacterial cell protocol of the Nucleospin tissue kit. 
(section 2.12.1) The extracted 1137Rv DNA was diluted 1: 1000 with sterile injection 
water and quantified by spectrophotometry (section 2.12). Once quantified the DNA 
was subsequently diluted from 103 to 1011 and assayed in the Taqman assay to 
determine the Ct for each dilution. The limit of detection of the assay was determined as 
the as the highest dilution demonstrating a Ct less than 40.0. 
2.16 Comparative study: TaqMan Assay versus LCx-MTB assay 
2.16.1 Sample population 
Five groups of three types of samples (paraffin embedded tissues, processed sediments 
of clinical samples and mycobacterial cells were analysed: 
Group 1: 35 AFB smear positive processed sediments, culture positive for MTB 
Group 2: 23 AFB smear negative processed sediments, culture positive for MTB 
Group 3: 18 processed sediments, culture positive for NTM 
Group 4: 50 AFB smear negative processed sediments, culture negative for 
mycobacteria. 
Group 5: 41 paraffin blocks histologically consistent with mycobacterial infection. 
2.17 Protein antigen B PCR for DNA sequencing 
2.17.1 DNA Extraction 
DNA extractions from bacterial cells were performed using specific protocols with the 
Nucleospin tissue kit. (sections 2.12.1) 
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2.17.2 Primer Design 
Version 1.5 of Primer Express software (Applied Biosystems) was used to design an 
additional reverse primers pab4 outside the target a region of the previously described 
primers MT1 and MT2 (Sjobring et al. 1990). 
The forward primer MT1 corresponds to the region of pab gene from base 233 to base 
252 (bases are numbered as for the sequence with the Genbank accession no. M30046). 
This primer is 20bp in length with a Tm of 70°C and a 67% GC content. 
The reverse primer MT2 corresponds to the region of pab gene from base 649 to base 
629 (bases are numbered as for the sequence with the Genbank accession no. 
M30046). This primer is 21bp in length with a Tm of 66°C and a 67% GC content. 
The reverse primer pab4 corresponds to the region of pab gene from base 1476 to base 
1458(bases are numbered as for the sequence with the Genbank accession no. M30046). 
This primer is 19bp in length with a Tm of 65°C and a 65% GC content 
2.17.3 Primer sequences(Genset Pacific, Lismore, Australia). 
Primer name Primer sequence 
MT1 5'-ACGGCAGGCTGGTGGAGGA-3' 
MT2 5'-GATCTGCGGGTCGTCCCAGGT-3' 
Pab4 5'-GAGCCTGATCGCACCCATCG 
Manufactured as a 100µM concentration 
2.17.4 PCR Amplification Reagents (Sigma Aldrich) 
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MT1 (forward) 100µmol Nx0.5µ1 
MT2 (reverse) 100µmo1 OR Nx0.5µ1 
Pab4 (reverse) 100µmol 
10 x Gene Amp PCR buffer II Nx5.0µ1 
MgC12 (2.0mM) Nx4.0µl 
dNTP mixture 200gmol Nx4.0µl 
JumpStart Taq (2.5units/µl) Nx0.5µ1 
Sterile injection water Nx29.5µ1 
Template Nx5.0gl 
Total Volume 5Oµ1 
Amplification using Perkin Elmer 460 thermalcycler (Applied Biosystems) 
12min@94°C; 40cycles 94°C 2min, 60°C 1min, 72°C 2min 
2.17.5 Detection 
PCR products were detected by 2% agarose gel electrophoresis stained with ethidium 
bromide as in 2.14. 
2.18 DNA sequencing 
Double stranded products were purified by nucleospin extract column (Macherey- 
Nagel, Duren, Germany), the sequencing reaction was performed with the ABI Big Dye 
Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) using 3.2pmol 
of sequencing primers: 
MT I 5'-CCACCGAGCGGTTCGCCTGA-3' 
pab4 5'-GAGCCTGATCGCACCCATC-3'. 
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The sequencing products were purified by sodium acetate-ethanol precipitation and the 
reaction loaded onto the ABI prism 310 Genetic Analyser in accordance with the 
manufacturers' instructions (Applied Biosystems). The DNA sequencing reaction was 
performed at Queensland Health Scientific Services, Coopers Plains, Australia. The 
results of the sequence reaction were analysed using Sequencher Version 3.0 (Gene 
Codes Corporation, Ann Arbor, MI). Analysis was performed by comparing sequences 
obtained against Gen Bank Accession M30046. 
2.19 Line Probe Assay 
2.19.1 Sample population 
Twenty rifampicin resistant isolates of M. tuberculosis isolated between 1997-1998 at 
the King Khalid National Guard Hospital in Jeddah, Saudi Arabia and 8 rifampicin 
susceptible strains including H37Rv were tested by the line probe assay. One water 
blank was tested as negative controls for the assay 
2.19.2 DNA extraction 
DNA was extracted from bacterial cells using the Instagene Matrix (BioRad 
Laboratories) method in 2.12.2. 
2.19.3 Primer Sequences (Innogenetics Rif Th Kit, Ghent, Belgium) 
Primer name Primer sequence 
IP 1 5'-GGTCGGCATGTCGCGGATGG-3' 
IP2 5'-GCACGTCGCGGACCTCCAGC-3' 
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2.19.4 PCR reaction mixture 
Amplification buffer nx 10µ1 
Rif Tb primer mix nx l01il 
25mmol MgC12 nxl Oµ1 
Jumpstart Taq 2.5Units/µl (Sigma Aldrich) nx1 unit 
Sterile injection water nx 18µl 
Total Volume Nx 48µl 
Amplification using Perkin Elmer 460 thermalcycler (Applied Biosystems) 
min, 72°C 10 min. 
2.19.5 Hybridization 
l0µ1 of each amplified biotinylated PCR product was added to l0µ1 of denaturation 
solution in a test trough, was mixed by gentle pipetting and allowed to stand at room 
temperature for 5 minutes. Iml of hybridization solution prewarmed to 62°C was added 
to each trough. An InnoLipa strip (Innogenetics) was completely submerged in each 
trough and incubated in a covered twin shaking waterbath (Robbins Scientific, 
Sunnyvale Ca. ) rotating at approximately 80rpm for 30 minutes. Following 
hybridization the Innolipa strips were washed with a stringent wash solution and 
incubated with 1ml of wash solution in the covered twin shaking water bath at 62°C for 
10 minutes. 
2.19.6 Detection 
lml of conjugate (streptavidin labelled with alkaline phosphatase) was added to each 
trough containing an Innolipa strip and placed on an orbital shaker (Labline 
Instruments Inc. Melrose Park, Ill. ) rotating at approximately 160 rpm for 30 minutes at 
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room temperature. Each strip was washed twice with a rinse solution and incubated with 
lml of substrate buffer on the orbital shaker for 30 minutes at room temperature. Color 
development was stopped by washing strips with lml of distilled water while agitating 
troughs on the orbital shaker for 5 minutes. Strips were allowed to air dry and the 
patterns of purple/brown lines corresponding to the hybridization of the immobilised 
probes and biotinylated PCR products were recorded. 
2.20 VNTR typing 
2.20.1 Source of isolates of M. tuberculosis 
85 isolates from patients at the King Khalid National Guard Hospital in Jeddah, Saudi 
Arabia between 1997-1998. 
201 isolates from patients at the Queensland Mycobacterium Reference Laboratory, 
Brisbane, Australia between 1999-2001 were tested. 
2.20.2 DNA Extraction 
DNA was extracted from bacterial cells using the Instagene Matrix (BioRad 
Laboratories) method in 2.12.2. 
2.20.3 Primer Sequences (Genset Oligos, Lismore, Australia) 
Frothingham et al. 1998 
Locus GenBank Location in primer sequence 
name Accession H37Rv 
No 
ETR A S77045 743-1163 5'-AAA TCG GTC CCA TCA CCT TCT TAT-3' 
5'-CGA AGC CTG GGG TGC CCG CGA TTT-3' 
ETR-B Z70283 7929-8220 5'-GCG AAC ACC AGG ACA GCA TCA TG-3' 
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5'-GGC ATG CCG GTG ATC GAG TGG -3' 
ETR-C Z77162 11647- 5'-GTG AGT CGC TGC AGA ACC TGC AG-3' 
11922 
5'-GGC GTC TTG ACC TCC ACG AGT G-3' 
ETR-D Z77162 14948- 5'-CAG GTC ACA ACG AGA GGA GAG C-3' 
15257 
5'-GCG GAT CGG CCA GCG ACT CCT C-3' 
ETR-E Z74024 10409- 5'-CTT CGG CGT CGA AGA GAG CCT-3' 
10632 
5'-CGG AAC GCT GGT CAC CAC CTA AG-3' 
2.20.4 Additional VNTR Primer Sequences (Genset Oligos, Lismore, Australia) Mazars 
et al 2001. 
Locus GenBank Location in primer sequence 
name Accession H37Rv 
No 
ETR F Z74697 17693- 5'-CTC GGT GAT GGT CCG GCC GGT CAC-3' 
18168 
5'-GGA AGT GCT CGA CAA CGC CAT GCC-3' 
MIRU 10 AL022004 56176- 5'-GTT CTTGAC CAA CTGCAG TCG TCC-3' 
56818 
5'-GCC ACC TTG GTG ATC AGC TAC CT -3' 
MIRU 16 AL021184 4382-5073 5'-TCG GTG ATC GGG TCC AGT CCA AGT A-3' 
5'-CCC GTC GTG CAG CCC TGG TAC-3' 
MIRU 40 Z84395 17494- 5'-GGG TTG CTG GAT GAC AAC GTG T-3' 
17901 
5'-GGG TGA TCT CGG CGA AAT CAG ATA-3' 
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2.20.5 PCR Amplification Reagents (Sigma Aldrich) 
Primer 1 (forward) 100µmol 
Primer 2 (reverse) 100µmo1 
10 x Gene Amp PCR buffer II 
25mmol MgC12 
4% DMSO (except ETR-A) 
dNTP mixture 200pmo1 
Sterile injection water 
JumpStart Taq (2.5units/µl) 
Total Volume 
Nx0.5µ1 
Nx0.5µ1 
Nx2.5µ1 
Nx2.0µ1 
Nx l . 0µl 
Nx2.0µ1 
Nx12µ1(Nx13µ1 for ETR-A) 
Nx 0.625 units 
Nx 22.5µ1 
Amplification using Perkin Elmer 460 thermalcycler (Applied Biosystems) 
12min@95°C; 35cycles 94°C 30sec, 60°C 1min, 72°C 2min 
2.20.6 Detection 
PCR products were detected by 2% agarose gel electrophoresis stained with ethidium 
bromide as in 2.14. Interspersed controls of known VNTR alleles were interspersed as 
controls. 
2.20.7 Lineage assignment using UPGMA 
Analysis was undertaken using the program S. T. A. R. T. (Sequence type analysis and 
recombinational tests) available for download from 
http: //outbreak. ceid. ox. ac. uk/software. htm. 
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Lineage assignment was performed using Unweighted Pair Group Method with 
Arithmetic Mean (UPGMA) (Sneath et al. 1973). The method used a sequential 
clustering algorithm, in which local homology between operational taxonomic units 
OTUs were identified in order of similarity, and the tree was built in a stepwise manner. 
The two OTUs most similar to each other were first determined and then these were 
treated as a new single 'composite' OTU. Subsequently from among the new group of 
OTUs (composite and simple), the pair with the highest similarity was identified and 
clustered. This continued until only two OTUs are left. The algorithm assumes that the 
two most closely related OTUs are more similar to each other than they are to any other. 
The algorithm used here utilises a distance matrix constructed from allelic profile data 
only. Allele sequences are not used, so each allele number difference is treated 
identically. 
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Chapter 3. MB/BacT isolation of mycobacteria and MTB culture confirmation 
using the LCX MTB assay. 
3.1 Patient population and clinical specimens. 
This study was conducted in the Microbiology Division of the King Khalid National 
Guard Hospital (KKNGH), Jeddah, Saudi Arabia. KKNGH is a 350-bed general 
teaching hospital which provides primary and secondary health care to Saudi Arabian 
National Guardsmen and their dependants with access to all Saudis. The Microbiology 
Division is a referral centre for specimens from four primary health care clinics in both 
Jeddah and Taif which investigates approximately 1500 specimens annually for the 
presence of mycobacteria. Two-thousand nine-hundred consecutive specimens, both 
pulmonary and extrapulmonary, from patients being investigated for tuberculosis were 
investigated over a two-year period from January 1996 and January 1998. 
3.2 Results 
Mean days until detection of a positive culture by MB/Bact The results of the 
comparison between detection of MTB on Lowenstein-Jensen medium and the 
MB/BacT are shown in Table 1. From 460 MB/Bact culture bottles culture positive for 
Mycobacterium sp., 250 samples were culture positive for MTB. Overall, the mean time 
for detection for these isolates was 18.5 days with 71.2% of isolates being detected in 
less than 21 days. In the group of patients whose specimens were AFB smear positive 
on initial examination (58.4%), the time for detection was 16.0 days and 82.2% of these 
cultures could be detected in less than 21 days. In the AFB smear negative specimens 
(41.6%), the mean time for detection was 22.1 days with only 50.9% of these cultures 
being detected in less than 21 days. 
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The 210 MB/Bact bottles culture positive for NTM were detected on average in 13.7 
days with 91.4% being identified in less than 21 days. AFB smear was positive in 36 
(17.1%) of the 210 NTM positive cultures and the mean time for detection was 12.0 
days with 94.4% detected within 21 days. In the AFB smear negative NTM culture 
positive group the mean time of detection of these 174 (82.9%) cultures was 14.0 days 
with 90.8% of these cultures being detected in less than 21 days. 
For all the 460 positive cultures for Mycobacterium sp. the mean time for detection was 
16.3 days with 80.4% of cultures being detected in less than 21 days. 
The number and type of Mycobacterium sp. isolated from both the pulmonary and 
extrapulmonary specimens investigated are shown in Table 2. The results show that the 
sensitivity and specificity of the LCx-MTB for M. tuberculosis in detecting and 
differentiating MTB from NTM in positive MB/Bact cultures was excellent. All 250 
MB/Bact bottles culture positive for MTB were detected by the LCX-MTB and all 210 
NTM positive MB/Bact cultures gave negative results. 
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Table 1. Mean days until detection of a positive culture by MBBacT 
No Mean time Minimum Maximum Standard Number and 
of time of time of deviation percentage of 
detection detection detection isolates 
(days) (days) (days) detected 
under 21 days 
MTB Culture 146 16.0 5 46 6.4 82.2% 
positive (120) 
AFB smear 
positive 
MTB Culture 104 22.1 11 48 6.9 50.9% 
positive AFB (58). 
smear negative 
All MTB Culture 250 18.5 5 48 7.3 71.2% 
positive 178 
NTM Culture 36 12.0 4 24 4.5 94.4% 
positive 34 
AFB smear 
positive 
NTM Culture 174 14.0 3 56 6.49 90.8% 
positive 158 
AFB smear 
negative 
All NTM 210 13.7 3 56 6.24 91.4% 
Culture positive 192 
All Mycobacteria 182 13.2 3 21 4.2 84.6% 
(Including MTB (154) 
and NTM) 
AFB smear 
positive 
All Mycobacteria 278 17.1 4 56 7.7 77.8% 
(Including MTB (216) 
and NTM) 
AFB smear 
negative 
All 460 16.3 3 56 7.2 80.4% 
Mycobacteria (370) 
(Including MTB 
and NTM) 
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Table 2. Mycobacterium sp. isolated according to site with LCx-MTB result from 
MB/BacT bottle. 
Mycobacterial isolate Sputum/ Sterile Tissue Abscess Urine Percentage of LCR positive 
n=460 BAL* fluid results from MB/BacT bottle 
M. tuberculosis 202 12 24 12 
n=250 (80.8%) (4.8%) (9.6%) (4.8%) 
Mchelonae 9 
n=9 
Mfortuitum 18 
n=19 
Mgordonae 4 
n-4 
M. kansasii 2 
n=1 
1 Mmalmonese 
100 
0 
10 
0 
0 
0 
n=1 
M. simiae 38 -1-20 
n=41 
M. terrae 7----0 
n=7 
Mycobacterium avium 107 
complex 
n-111 
Environmental 16 
scotochromogens 
n=16 
* BAL Bronchoalveolar lavage 
40 
0 
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3.3 Discussion 
Following the epidemic of tuberculosis in the United States in the early 1990s the 
Centres for Disease Control instituted recommendations for diagnostic laboratories 
designed to improve detection of MTB infection and facilitate prompt isolation and 
treatment of infected persons. (CDC 1997, Tenover et al. 1993). These 
recommendations stated that results from concentrated acid-fast smears should be 
reported within 24 hours of collection, culture in liquid medium should be performed in 
order to detect growth of MTB within 10 to 14 days and that susceptibility tests be 
performed within 15-30 days following collection. In a commentary by Styrt et al. 
(1997) these recommendations were later relaxed to identification within 21 days. 
The aim of the study was to assess the performance and implementation of the 
MB/BacT liquid culture system to endeavour to achieve the CDC guidelines for rapid 
turnaround times for mycobacterial detection and identification. The results showed that 
of the 2900 consecutive samples processed, 460 (15.9%) were positive for mycobacteria 
and 250 (8.6%) were positive for M. tuberculosis. Using the MB/BacT culture 71.2% of 
MTB isolates were detected within the recommended 21 days with a mean time to 
detection of 18.5 days. AFB smear positive MTB culture positive samples were grown 
more rapidly with 82.2% of isolates being detected within 21 days. In 1997, Rohner et 
al. compared the MBBacT with the BACTEC 460 observed isolation of M. tuberculosis 
with a mean time to detection of 17.5days and 14.3 days respectively. 
The mean time to detection of MTB using the MB/BacT was longer in this study and 
the work of Rohner et al. than that observed by Benjamin et al. (1998) comparing the 
MB/BacT system with the BACTEC 460 system. In that study a mean time to detection 
of 13.7 days was observed using the MB/BacT. A major reason for the longer time to 
detection observed in this study is that consecutive samples were evaluated and 
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therefore some samples would have come from patients already on anti-tuberculosis 
therapy. The CDC guidelines were intended to apply to the first diagnostic specimen 
from each patient. Subsequent specimens are collected to monitor treatment and often 
have delayed growth. 
The BACTEC 460 TB system has been the benchmark for sensitivity and speed of 
mycobacterial detection reducing the average detection time of both AFB smear 
positive and AFB smear negative samples using conventional solid media by nearly 
50% (Morgan et al. 1983, Roberts et al. 1983). The limitations of the BACTEC 460 
system have lead to the development of a continuously monitored, nonradiometric 
system. Despite the 2-3 day increase in the time to detection of Mtuberculosis growth 
in the MBBacT versus the BACTEC 460 an alternative nonradiometric system was 
essential in Saudi Arabia as disposal of radioactive waste is restricted (Benjamin et 
al. 1998, Rohner et al. 1997). This increase in time to detection is about the maximum 
increase which is clinically acceptable (Benjamin et al. 1998). However, specimens 
positive in the MBBacT are identified immediately since they are monitored 
continuously, those positive in the BACTEC 460 would be identified only when the 
specimens are tested according to the laboratory protocol. 
LCx-MTB assay was used to directly identify M. tuberculosis from MB/BacT bottle 
which signalled positive. Although the use of the LCx-MTB assay directly on fluid 
from positive MB/BacT bottle was not specifically endorsed by the manufacturer, when 
applied to an aliquot of a positive MB/BacT bottle, a sensitivity and specificity of 
100% was obtained for the detection and differentiation of MTB from NTM. Tortoli et 
al. (1998) applied the LCx-MTB assay to positive BACTEC 12B as soon as a positive 
signal was detected and were able to detect 106 of 108 MTB isolates (Tortoli et al. 
1998). Other approaches to rapid identification of liquid mycobacterial cultures have 
used commercial DNA probes to identify the common organisms such as MTB and 
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MAC. These organisms accounted for 54.3% and 24.1% of isolates in this study 
respectively. Benjamin et al. (1998) reported that although BACTEC 12B cultures may 
become positive more quickly than MB/BacT cultures DNA probes typically will be 
negative if tested on a BACTEC vial as soon as it becomes positive. In contrast, 
MB/BacT cultures can be reliably identified by specific DNA probe on the day the 
bottle is flagged positive by the instrument. Other approaches have used PCR (Forbes 
et al. 1994), direct DNA sequencing (Rogall et al. 1990) or restriction enzyme analysis 
(Telenti et al. 1993c) Although all these methods can provide useful diagnostic 
information, the key point is which ever method is employed must be able to reliably 
identify and differentiate MTB from NTM. 
In 1996, in Jeddah, Saudi Arabia molecular biology facilities were in a developmental 
stage and the application of LCx-MTB assay by this means was a rapid cost effective 
way of screening NTM from MTB. As approx 50% isolates were NTM, it was 
imperative to distinguish the infectious patients with tuberculosis from the non- 
infectious patients with NTM. At that time, the implementation of a reliable means of 
liquid culture confirmation, which could be performed easily within a working day, 
meant hospital isolation rooms would be properly used for tuberculosis patients. 
Antituberculous drugs would be administered appropriately and patients with NTM 
disease would not have to unnecessarily endure any social stigma with respect to 
infection with TB. 
The most effective way to combat the spread of organisms and disease is through rapid 
diagnosis, thorough contact tracing and prompt initiation of appropriate therapy There 
is no simple diagnostic solution for the identification M. tuberculosis in clinical 
specimens and combinations of various technologies are required in order to achieve the 
CDC prevention recommendations (Tenover et al. 1993). In the following chapter the 
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utility of molecular methods to expedite diagnosis of tuberculosis by detecting specific 
MTB DNA is clinical specimens is investigated. 
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Chapter 4: Comparison of amplicor PCR and LCx-MT B assay for the detection of 
DNA in clinical specimens 
4.1 Amplicor PCR 
The Amplicor Mycobacterium tuberculosis Test is based on three major processes. 
Polymerase Chain Reaction (PCR) target amplification, hybridisation of the amplified 
product to a specific nucleic acid probe, and detection of the amplified product by 
colour formation (Saiki et al. 1985, Mullis et al. 1987). 
The development of a PCR assay involves identifying the particular region of the target 
DNA to be amplified, and synthesising two short biotinylated oligonucleotide primers 
that are complementary to the regions flanking the target sequence. In the reaction, 
these biotinylated primers will bind to the target region and then, catalysed by 
polymerase, extend in the 5' to 3' direction utilising excess deoxynucleotide 
triphosphates (dNTPs) in the reaction mixture thereby creating a biotinylated, 
complementary DNA sequence termed an amplicon. Oligonucleotide probes, specific 
for the amplicons, are bound to a microwell plate for capture for the amplicons. The 
detection molecule used in the assay is an avidin-horseradish peroxidase (Av-HRP) 
conjugate that binds to the plate-captured biotinylated amplicons. The substrates used 
for colour formation in the assay are H202 and tetramethylbenzidine (TMB). 
4.1.1 PCR Amplification Reaction 
Genus-specific primers located in a highly conserved region of the 16S ribosomal RNA 
(rRNA) gene of Mycobacterium are used to amplify a 584 base-pair sequence (Stahl et 
al. 1990, Boddinghaus et al. 1990). The DNA-containing sample and reagent mixture 
are heated to separate the double-stranded helix and expose the primer target sequences. 
As the mixture cools, the biotinylated primers anneal to their targets. The thermostable 
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DNA polymerase in the presence of deoxynucleoside triphosphates (dNTPs), including 
deoxyadenosine, deoxyguanosine, deoxycytidine and deoxyuridine (in place of 
thymidine) triphosphates, then extends the annealed primers along the target templates 
to produce amplicons. This process is repeated for a number of cycles, each cycle 
effectively doubling the amount of target DNA. Because the cycles are exponential in 
their amplification power, 20 cycles can theoretically result in a1 million-fold 
amplification, 30 cycles up to 1 billion-fold, all from a single copy of DNA. For this 
test, the required number of cycles has been determined to be 37. 
4.1.2 Hybridisation Reaction 
After the PCR amplification process, the amplicons are chemically denatured to form 
single strands that are added to a microwell plate (MWP) containing a bound, amplicon 
specific, oligonucleotide probe. This probe, specific for the M. tuberculosis complex, 
was selected from the hypervariable region of the 16S rRNA gene (Stahl et al. 1990, 
Boddinghaus et al. 1990). The biotin-labelled amplicons will then bind (hybridise) to 
the amplicon specific probe and thus be "captured" onto the plate. This specific 
hybridisation event increased the overall specificity of the test. 
4.1.3 Detection Reaction 
After unbound material is removed from the MWP by washing, an Av-HRP conjugate 
is added to the plate. The avidin binds to the biotin-labelled amplicons captured by the 
plate-bound probe. After unbound conjugate has been washed off, the bound Av-HRP 
conjugate is reacted with peroxide and TMB to form a colour complex. The reaction is 
stopped by the addition of weak acid, the optical density is measured in an automated 
microwell plate reader and the results are compared to the supplied cut-off value. 
Positive and negative controls were supplied with the test kit for reference. 
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4.1.4 Specificity of Reaction 
Selective amplification of target DNA from the clinical specimen in the Amplicor 
Mycobacterium tuberculosis Test is achieved by the use of AmpErase. AmpErase 
contains the enzyme Uracil N-Glycosylase (UNG) (Longo et al. 1990), which 
recognises and catalyses the destruction of deoxyuridine-containing DNA, but not 
thymidine-containing DNA. Deoxyuridine is not present in microbial DNA, but is 
always present in amplicons due to the use of deoxyuridine triphosphate (in place of 
thymidine triphosphate) as one of the dNTPs in the Master Mix reagent; thus, only 
amplicons will contain deoxyuridine. The presence of deoxyuridine in amplicons 
renders contaminating amplicons susceptible to destruction by AmpErase prior to the 
amplification of the target DNA. AmpErase catalyses the cleavage of an 
oligonucleotide at deoxyuridine residues by opening the deoxyribose chain at the 1 
position. The opened chain, when heated in the first thermal cycling step (at the 
alkaline pH of Master Mix), causes the amplicon's DNA chain to break at the position 
of the deoxyuridine, thereby rendering the DNA non-amplifiable. The UNG enzyme, 
which is inactive at temperatures above 55 degrees Celsius (i. e. throughout the thermal 
cycling steps), is then itself denatured by the addition of the Denaturation Solution 
immediately after the amplification step is completed, thereby preventing it from 
destroying any "true" amplified products of the test. The UNG enzyme in the Amplicor 
Mycobacterium tuberculosis Test has been demonstrated to inactivate up to 10 copies of 
deoxyuridine-containing M. tuberculosis amplified DNA. 
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4.2 Ligase Chain Reaction 
4.2.1 Specimen Preparation 
Specimen preparation is the first step of the LCx Mycobacterium tuberculosis assay. 
Firstly, potential inhibitors are removed by centrifuging and washing specimens 
followed by heat inactivating the mycobacteria. Mycobacterial DNA is then released 
from the Mtuberculosis complex by mechanical lysis making it accessible to the 
enzymes and other components of the LCR reaction. 
4.2.2 Amplification 
In the DNA amplification step, the prepared sample is added to the LCx MTB reaction 
mixture consisting of four oligonucleotide probes, thermostable ligase and polymerase, 
and individual nucleotides in buffer. The four oligonucleotide probes are designed in 
pairs that hybridise to complimentary single-stranded M. tuberculosis target sequences 
exposed in the sample preparation. During thermal cycling, the temperature is raised 
above the melting point of the hybridized amplification product causing it to dissociate 
from the original target sequence. Lowering the temperature allows more of the 
oligonucleotide probes to hybridise to the targets now available. The temperature 
continues to be cycled in this manner until sufficient numbers of target amplification 
product have accumulated in the LCx MTB reaction mixture. The number of targets 
increases exponentially with each thermal cycle. Thirty-seven thermal cycles are 
sufficient to achieve up to a billion-fold amplification in the number of target sequences 
which are then detected by the Microparticle enzyme Immunoassay. (MEIA) 
4.2.3 Detection 
The two pairs of oligonucleotide probes in the LCx MTB assay are labelled with 
immunoreactive groups called haptens. Each individual probe has either a capture 
hapten (recognised by an antibody attached to the MEIA microparticles) or a detection 
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hapten (recognised by an antibody conjugated to alkaline phosphatase). The probes are 
labelled such that, when they are joined during the LCR reaction, the amplification 
product has the capture hapten at one end and the detection hapten at the other. In the 
LCx analyser, an aliquot of the amplification product is automatically transferred to the 
reaction well. Here the microparticles coated with anti-capture hapten (rabbit) bind the 
amplification product as well as any unligated probes carrying the capture hapten. The 
reaction mixture is then automatically transferred to a glass fibre matrix to which the 
microparticle complexes bind irreversibly. A wash step removes the unligated probes 
having only the detection hapten. The bound microparticle complexes are then 
incubated with anti-detection hapten (rabbit): alkaline phosphatase conjugate which 
binds to the detection haptens. This antibody conjugate binds only to amplification 
product. The antibody conjugate can then be detected by the addition of the substrate, 
4-methylumbelliferyl phosphate, which is de-phosphorylated by alkaline phosphatase to 
produce 4-methylumbelliferone, fluorescence of which is measured by the MEIA 
optical assembly. 
4.2.4 Prevention of DNA contamination 
Amplification reactions such as LCx MTB are sensitive to accidental introduction of 
amplification product from previous amplification reactions as well as DNA from 
processed specimens. False positive results could occur if either the clinical specimens 
or the LCx MTB reagents used in the amplification reaction step become contaminated 
by accidental introduction of even a few molecules of amplification product. Measures 
to prevent DNA contamination in the laboratory include physically separating activities 
involved in performing LCx MTB, chemically inactivating amplification and complying 
to good laboratory practice. 
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4.3 Results 
Table 3 summarises the results of the 326 patient samples investigated in this study. In 
Group 1, of 74 specimens culture positive for MTB, 71 specimens were LCx-MTB 
positive. The three samples MTB culture positive and LCx-MTB negative were AFB 
smear negative. Two of these samples gave equivocal S/CO ratios (0.89 and 0.87) and 
the third sample (S/CO ratio 0.029) was culture positive in liquid media only after 30 
days. Sixty-five of seventy-four specimens culture positive for MTB were positive by 
the Amplicor PCR method (87.8%). Nine specimens (from five patients), 7 of which 
were AFB smear negative were Amplicor PCR negative. In one of these patients, a 
previous specimen was Amplicor PCR positive. AFB smear was positive in 46 (62%) 
of the 74 samples culture positive for MTB. In Group 2, the 68 samples from 46 
patients culture positive for NTM were all negative by both LCx-MTB and Amplicor 
PCR. In group 3, comprising 66 patient samples who had positive AFB smear and no 
growth on solid media alone, were 64 samples from 28 patients in which 
Mycobacterium avium complex (MAC) had been previously isolated and 2 samples 
from patients undergoing anti-tuberculous therapy with previous positive cultures for 
MTB. LCx-MTB was positive only in the two samples with prior isolation of MTB, 
Amplicor PCR was positive in one of these samples. In group 4, of 118 patient 
samples AFB smear negative and culture negative, two samples were positive by LCx- 
MTB with one of these samples also Amplicor PCR positive. This sample was from a 
known tuberculosis patient on anti-tuberculosis therapy. One sample had a S/CO ratio 
1.13 and was from a patient without clinical evidence of tuberculosis and was 
considered a false positive for LCx-MTB. The sensitivity, specificity, accuracy and 
predictive values of the molecular methods and AFB smear result in relation to culture 
are shown in Table 4. The NTM specimens (i. e. Group 2 specimens) were excluded in 
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the statistical analysis and comparisons were done on the remaining 258 specimens. In 
smear positive samples, LCx-MTB compared with culture showed a sensitivity of 100% 
and a specificity of 97.0%. Amplicor PCR versus culture had a sensitivity of 95.6% 
and specificity of 98.5% in smear positive specimens. In the 28 AFB smear negative 
culture positive specimens, LCx-MTB and Amplicor PCR had a sensitivity of 89.3% 
and 75% respectively and a specificity of 98.3% and 99.2% respectively. In all 
samples, LCx-MTB had the highest sensitivity of 95.9% while AFB smear had the 
lowest sensitivity of 62.2%. The sensitivity for Amplicor PCR was 87.8%. The 
specificity of Amplicor PCR was highest (98.9%), that of LCx-MTB second (97.8%) 
and that of AFB smear lowest at 64.1%. LCx-MTB had the highest accuracy (i. e. the 
proportion of all specimens that were correctly identified) of 97.3%. The accuracy of 
Amplicor PCR was 95.7% while that of AFB smear was 63.6 %. The proportion of test 
positives that were true positives (i. e. positive predictive value) was highest for 
Amplicor PCR (97%), and was lowest for AFB smear (41.1 %). That of LCx-MTB was 
94.7%. Similarly, the proportion of test negatives that were true negatives (i. e., 
negative predictive value) was also highest for Amplicor PCR (98.9%) and was lowest 
for AFB smear (80.8%). The negative predictive value for LCx-MTB was 98.4%. 
The results of the statistical significant tests applying the McNemar test to compare 
each diagnostic test against the others are shown in Table 5. The sensitivity of LCx- 
MTB was significantly greater than that of Amplicor PCR (0.025< P< 0.05), but there 
was no significant difference in their specificity (P > 0.10). Similarly, there was no 
difference in their accuracy (P > 0.05). However, both LCx-MTB and Amplicor PCR 
were significantly superior to AFB smear in terms of sensitivity, specificity and 
accuracy (P < 0.001) 
78 
Table 3. Comparison of LCx-MTB and Amplicor PCR with mycobacterial culture 
and microscopy 
Mycobacteria culture and No of No. LCx- No. Amplicor 
AFB smear result Samples MTB PCR Positive 
Positive 
Group MTB 46 46 44 
1 (AFB smear positive) 
MTB 28 25 21 
(AFB smear negative) 
All MTB positive cultures 74 71 65 
Group M. avium intracellulare 
2 scotochromogen 
M. fortuitum 
M. chelonae 
M. terrae 
M. kansasii 
ALL NTM 
40 0 
14 0 
30 
50 
50 
10 
68 0 
0 
0 
0 
0 
0 
0 
0 
Group No growth 
3 (on solid media alone) 
(AFB smear positive) 
Group No growth 
4 (on solid or liquid media) 
(AFB smear negative) 
Total 
66 2 
118 2 
326 75 
1 
1 
67 
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Table 4. Sensitivity, specificity, accuracy and predictive values of LCx-MTB, 
Amplicor PCR and AFB smear in the diagnosis of Mycobacterium tuberculosis. 
LCx- PCR AFB smear 
MTB (%) (%) 
Sensitivity 
Specificity 
Accuracy 
Positive Predictive 
Value 
Negative Predictive 
Value 
AFB + 100 95.6 
AFB - 89.3 75.0 
All specimens 95.9 87.8 
AFB + 97.0 98.5 
AFB - 98.3 99.2 
All specimens 97.8 98.9 
AFB + 98.2 97.0 
AFB - 96.6 94.5 
All specimens 97.3 95.7 
AFB + 95.8 97.8 
AFB - 92.6 95.5 
All specimens 94.7 97.0 
AFB + 100 97.0 
AFB - 97.6 94.4 
All specimens 98.4 98.9 
(%) 
62.2 
64.1 
63.6 
41.1 
80.8 
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Table 5. Statistical test* of significance of sensitivity and specificity of LCx- 
MTB, Amplicor PCR and AFB smear. 
PCR AFB Smear 
x2 P-value x2 P-value 
(a) Sensitivity 
LCx- 4.1 P<0.05 23.0 P<0.001 
MTB 
PCR -- 15.7 P<0.01 
(b) Specificity 
LCx- 0.5 P>0.10 56.4 P<0.001 
MTB (n. s) 
PCR -- 60.1 P<0.001 
(c) Accuracy 
LCx- 2.25 P>0.05 85.0 P<0.001 
MTB (n. s) 
PCR 60.1 P<0.001 
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4.3 Discussion 
Saudi Arabia still has a high incidence of tuberculosis despite the great decline from 
135 per 100,000 in 1980 to 18.6 per 100,000 in 1990. Highest figures have been 
reported from the Jeddah health region with an incidence rate of 63.4 per 100,000 
(Milaat et al. 1994). These figures represent an incidence 2-4 times greater than that of 
developed countries (Al-Kassimi 1994). In this patient population, patients with 
positive AFB smears and pulmonary symptoms with or without radiological findings 
are frequently started on anti-tuberculosis therapy pending the results of culture which 
may take up to 12 weeks. It has been observed in the Southern region of Saudi Arabia 
that up to 50% of healthy individuals harbour NTM in their mouths and throats (Nsanze 
et al. 1993). The high incidence of NTM complicates the diagnosis of tuberculosis and 
frequently results in the unnecessary administration of anti-tuberculosis drugs. 
Therefore tests which can provide a high specificity for MTB in smear positive 
specimens will prove cost effective in reducing use of anti-tuberculosis drugs, contact 
investigations and isolation facilities. The sample groups 2 and 3, comprising 
predominantly_samples with either positive NTM culture or prior history of NTM 
isolation demonstrate the high specificity of both molecular methods as no false 
positives results were observed. These samples highlight our experience in NTM 
culture and supports the report of Hoffner (1988), illustrating that liquid culture 
supports the growth of mycobacteria far more than Lowenstein Jensen alone, 
particularly in the isolation of Mycobacterium avium. 
In this study AFB smear was positive in 62% (46/75) of culture positive specimens for 
MTB. The sensitivity and specificity of the LCx-MTB assay in the smear positive 
samples were 100% and 97.0% respectively. In smear positive specimens, Amplicor 
PCR showed a sensitivity of 95.6% and specificity of 98.5%. The high sensitivity and 
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specificity of both the Amplicor PCR and LCx-MTB assays in smear positive 
specimens suggest that both can detect and differentiate MTB from NTM in a single 
respiratory specimen, hence greatly reducing the time of diagnosis of pulmonary 
tuberculosis. In contrast, the sensitivity of both assays was diminished in smear 
negative specimens. The sensitivity of the LCx-MTB and Amplicor PCR assays was 
reduced to 89.3% and 75.0% respectively in smear negative specimens, however the 
specificity of both assays remained high at 98.3% and 99.2% respectively. The LCx- 
MTB and Amplicor PCR positive but culture negative results observed in specimens 
from two patients, who had previously positive cultures and had anti-tuberculosis 
therapy support the findings of other investigators that DNA amplification techniques 
can detect non-viable organisms (D'amato et al. 1995, Kolk et al. 1992, Carpentier et al. 
1995). Both Amplicor PCR and LCx-MTB will differentiate equally and accurately 
between MTB and NTM which increases the reliability of these techniques. 
Six extrapulmonary pus samples from patients with abscesses were investigated as part 
of this study. In three of these samples, MTB was isolated and both PCR and LCx- 
MTB assays were positive. A sample of tissue from one of these patients was culture 
positive and negative for both Amplicor PCR and LCx-MTB. Previous studies on 
discrepant Amplicor PCR and culture results have attributed false negative results to the 
presence of inhibitors in both pulmonary and extrapulmonary specimens, sample 
variation, and reduced numbers of organisms (Beavis et al. 1995, D'Amato et al. 1995, 
Moore and Curry 1995, Tonjum et al. 1996). Moore and Curry in a retrospective and 
prospective study of 1009 specimens determined that only 7% of false negative PCR 
specimens were attributed to the presence of inhibitors. The three false negative LCx- 
MTB specimens were from AFB smear negative samples from three patients and were 
also negative by Amplicor PCR. Two of these samples which gave equivocal LCx- 
MTB results, were from patients that had prior positive MTB-LCx specimens. One 
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culture positive sample but LCx-MTB negative was only culture positive for MTB in 
liquid media after 30 days of incubation. This suggests that both false negative LCx- 
MTB and Amplicor PCR results may have been due to reduced numbers of organisms 
or sample variation. In patients with negative smear and radiological evidence of 
disease it would be advantageous to test multiple (at least two or three) (D'Amato et al. 
1995, Tonjum et al. 1996) respiratory samples to reduce the risk of a false negative 
result due to the low numbers of organisms particularly in severely 
immunocompromised AIDS population where AFB smear has low sensitivity (Bradley 
et al. 1996). The ability of Amplicor PCR to detect MTB is reduced when the number 
of organisms in the sample is scanty, particularly in smear negative paucibacillary 
samples (Cartuyvels et al. 1996). In a study by Schirm et al., comparing in-house PCR 
and Amplicor PCR with culture a sensitivity of 90% was obtained with in-house PCR as 
opposed to 60% with Amplicor PCR in smear negative specimens. The authors 
correlated the higher sensitivity with the in-house PCR in smear negative samples to the 
increased sample volume added to the amplification reaction in the in-house PCR 
(almost 5 times that of Amplicor PCR) (Shinn et al. 1995). The larger specimen 
volume (0.5m1) used in the LCx-MTB assay as recommended by the manufacturer 
probably contributes to the greater sensitivity observed. However, this may allow for 
higher concentrations of inhibitors in the reaction as shown by An et al. (1995). The 
use of two wash and centrifugation steps in the sample preparation for the LCx-MTB 
assay compared with the single sample wash in the Amplicor PCR assay is probably of 
major importance in the removal of inhibitors. Cartuyvels et al. (1996) suggested that 
the sensitivity of the Amplicor PCR assay may be enhanced by increasing the specimen 
volume. An increase in the sample volume e. g. from 0.1 ml to 0.5 ml would however 
necessitate a second wash step in the sample preparation of Amplicor PCR to aid 
inhibitor removal. Sample preparation in both methods is not technically demanding, 
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although specimens must be initially processed in a Class 1 Biological Safety Cabinet 
with strict adherence to the prescribed methodology. In this study, and as previously 
reported, Amplicor PCR is easily performed and results can be reported within one 8- 
hour shift (Beavis et al. 1995, D'Amato et al. 1995, Moore and Curry 1995). Similarly, 
in the MTB-LCx assay, a batch of 48 specimens including controls can be prepared 
within 2V2 hours. The amplification and detection steps are automated and require 
approximately one hour for each step. It is therefore possible to incorporate this assay 
into the normal laboratory workflow and report results within one 8-hour shift. 
In this study, the MTB-LCx assay showed greater sensitivity than the Amplicor PCR 
assay (P <0.05). The high specificity of both assays is of great benefit in differentiating 
MTB from NTM. In practical terms, the use of DNA amplification techniques allows 
for rapid and specific diagnosis of MTB, which in turn eliminates unnecessary 
administration of anti-tuberculosis therapy and isolation measures for NTM patients. 
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Chapter 5: Detection of Mycobacterium tuberculosis DNA in paraffin embedded 
tissues using the LCx-MTB assay 
5.1 Results 
The results from 100 paraffin embedded lymph nodes investigated in by PCR are shown in 
Table 6. Group 1 comprised 17 lymph nodes histologically compatible with tuberculosis 
in which AFB could be demonstrated and 4/17 (23.5%) samples yielded positive LCx 
MTB results. Group 2 comprised of 41 lymph nodes with a histological diagnosis of 
tuberculosis in the absence of AFB, LCx-MTB detected MTB DNA in 5/41(12.2%). In 
the Group 3 samples which were 42 lymph nodes with histological diagnoses other than 
tuberculosis, all gave negative results by LCx-MTB. The results of LCx-MTB are given 
according to the site of lymph node biopsy in Table 7. Of the nine samples in which MTB 
DNA could be detected by LCx-MTB, six were cervical lymph nodes. The other three 
lymph nodes positive for LCx-MTB were one axillary node, one abdominal lymph node 
and a thyroid lymph node. The S/CO rates for both the first round and second round 
amplifications of samples either initially reactive or equivocal are given in Table 8. All 9 
samples yielded high positive S/CO ratios after second round amplification. All control 
samples remained negative after both first and second round amplifications. 
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Table 6. First round LCx-MTB amplification results from embedded biopsy 
material according to histological diagnosis and AFB smear result. 
Lymph Nodes Histological Diagnosis LCR LCR Total 
Positive Negative 
Group 1 Tuberculosis 4 13 17 
AFB smear positive 
Group 2 Tuberculosis 5 36 41 
AFB smear negative 
Group 3 Histologically not 0 42 42 
tuberculosis 
100 
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Table 7. AFB smear and LCx"MTB results of histologically diagnosed 
tuberculous lymph nodes according to the site of biopsy. 
Lymph Node Biopsy Site AFB positive AFB negative LCR Positive 
Cervical (n=33) 13 20 6 
Axilla (n=6) 241 
Submandibular (n=5) 050 
Subclavical (n=5) 230 
Abdominal (n=7) 071 
Thyroid (n=1) 011 
Paraaortic (n=1) 010 
Total (n=58) 17 41 9 
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Table 8. Sample rate to Cutoff value (S/Co) ratios for both first and second round 
amplification with LCx-MTB for paraffin tissues extracts initially reactive (S/Co>1.0) 
or equivocal (S/Co >0.3). 
Sample No Lymph node AFB Initial S/CO Reamplified 
site smear ratio S/CO ratio 
10 Cervical Negative 0.39 5.88 
16 Thyroid Negative 0.44 6.12 
18 Cervical Positive 1.21 5.05 
20 Cervical Positive 2.18 6.12 
40 Abdominal Negative 1.51 4.88 
42 Axilla Positive 0.75 5.02 
50 Cervical Positive 1.07 6.05 
51 Cervical Negative 0.77 4.85 
54 Cervical Negative 0.71 5.12 
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5.2 Discussion 
In pulmonary tuberculosis, the "gold standard" for diagnosis is the culture of 
M. tuberculosis from sputum or bronchoalveolar lavage. In extrapulmonary tuberculosis, a 
negative culture is not necessarily incompatible with a histological diagnosis of 
tuberculosis since less than half of the lymph nodes are AFB culture positive (Goel et al. 
2001). The diagnosis of extrapulmonary tuberculosis is difficult, delayed in many cases 
and frequently made on circumstantial evidence alone. The clinical manifestations are 
varied and often mimic those of other diseases. The Zeihl-Neilsen smear is often negative 
and culture is prohibitively slow although definitive. In a proportion of cases, biopsy is 
required, particularly in the presence of a single enlarged node if there is no other helpful 
evidence to give a lead to the correct diagnosis. Culture of material biopsied should 
always be carried out in order to help in the diagnosis and management, although 
histological examination plays an important part in the diagnosis in many cases. Failure 
to make a diagnosis can have serious consequences such as development of meningitis or 
pericarditis for example. Conversely, blind treatment with anti-tuberculosis agents 
exposes the patient to the risk of unnecessary toxic effects of the drugs as well as possibly 
masking other infections which partially respond to the broad antibacterial action of 
rifampicin. Definitive proof of diagnosis requires culture, although time consuming, is 
essential for sensitivity testing to determine drug sensitivity or resistance. A negative 
culture however is not necessarily incompatible with the histological diagnosis as the 
lymph nodes may not necessarily contain live tubercle bacilli (Dandapat et al. 1990). 
Various investigators have applied PCR for the detection of M. tuberculosis DNA in 
paraffin embedded tissue samples with varying results and conclusions. Totsch et al. 
(1996) investigated 18 lymph nodes with BCG-induced granulatomatous lesions using 
three different PCR based assays. Firstly, when using a primer pair to obtain the large 439 
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base pair sequence of the gene encoding the 65 kd mycobacterial surface antigen common 
to all mycobacteria (Shinnick 1987), poor sensitivity was observed. No positive results 
were obtained when a single lymph node section was investigated but when five sections 
were investigated mycobacterial DNA was detected in only one out of 18 cases (5.6%; 
Totsch et al. 1996). A PCR assay based on the amplification of the 123 base pair IS6110 
insertion DNA sequence has been shown to be highly specific and sensitive for the 
detection of mycobacterial DNA in sputum specimens culture positive for M tuberculosis 
(Eisenach et al. 1991). Totsch et al. (1996) also applied this technique to investigating 18 
cases of BCG-induced lymphadenitis and detected a positive result in 12 out of 18 cases 
(66.7%) when investigating one section per lymph node and could demonstrate 
mycobacterial DNA in 16 out of 18 (88.9%) cases when five sections were investigated. 
This suggests there was inadequate DNA material in a single section. When nested 
(reamplification) PCR was performed on only one section, mycobacterial DNA was 
detected in 16 out of 18 cases (88.9%). They observed that the amount of amplification 
product obtained by nested PCR was generally higher than in the other two single round 
PCR techniques and, furthermore, the sensitivity of the molecular techniques could be 
increased by the combined use of the 123bp assay and nested PCR. They concluded that 
the detection of mycobacterial DNA depends on the number of sections examined i. e. the 
amount of DNA in the sample. This is probably because bacterial foci are unevenly 
distributed in the routinely processed tissues. In the present study, five sections were used 
for the investigations. From our results, it appears that five sections did not provide 
adequate DNA material for amplification. 
Diaz et al. (1996) set out to develop a PCR targeting the IS6110 insertion sequence for the 
detection of M. tuberculosis DNA in paraffin-embedded tissues in which granulomas were 
found in order to evaluate its sensitivity and specificity in the diagnosis of tuberculosis. 
They obtained a sensitivity of 100% in biopsy material from lymph nodes, liver and lungs 
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which were culture positive for M. tuberculosis, although the number of samples examined 
was small (n=11). The method of DNA extraction used by Diaz et al. was similar to that 
employed in our study involving incubation with proteinase K and extraction with 
chloroform isopropyl alcohol and precipitation of DNA with sodium acetate. In their 
experiments, 0.5 to 2mg of extracted DNA from biopsy samples was used to run the PCR. 
The amplification step however involved 45 cycles. When they combined the group of 
tuberculous and possibly tuberculous hepatic granulomas, the sensitivity of the PCR assay 
was 53%, while the specificity was 96%. They suggested that the sensitivity of 
mycobacterial culture, regarded as the "gold standard" was low at least in hepatic 
granulomas and that the reason that some samples from clinically tuberculous patients 
gave a negative PCR result in hepatic granulomas may be related to the paucity of 
mycobacteria in the tissue. They concluded that the PCR assay was useful in the 
diagnosis of tuberculosis from paraffin embedded biopsies, but still far from optimal for 
the accurate diagnosis of hepatic granuloma of tuberculous origin. 
Popper et al. (1994) used PCR targeting IS6110 and could demonstrate Mtuberculosis in 7 
out of 7 samples (100%) of paraffin embedded tissue with positive AFB stain. In the 
present study, LCx-MTB was positive in 4/17 (23.5%) of AFB smear positive specimens 
and 5/41 (12.2%) in AFB smear negative specimens. Overall, in histologically diagnosed 
cases of tuberculous lymphadenitis, the sensitivity of the LCx-MTB was 15.5% (9/58). 
However, the specificity of the LCx-MTB was 100% (0/42; Table 6). A reamplification of 
all samples might have given better results with the LCx-MTB in this study. The benefits 
of a second amplification step are evident in the results presented in Table 8 as all of the 
equivocal and low positive results yielded strongly positive rates on reamplification. A 
reamplification step, however, requires the first round amplification vial to be opened and 
an aliquot removed. This allows for contamination of the laboratory with target DNA 
which could also contaminate the second round amplification vials with amplicons causing 
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false positive results. The results obtained in the present study using LCR were not as 
favourable as in previous studies (Totsch et at. 1996, Diaz et at. 1996, Popper et al. 1994). 
There are several possible explanations. Firstly, the 123 base-pair insertion sequence 
IS6110 has been shown to be present in M tuberculosis strains from 1-24 copies (Plikaytis 
et at. 1991) as opposed to the gene encoding for protein antigen B which is present in a 
single copy (Burczak et al. 1995). Since the repetitive element IS6110 is present in 
multiple copies in most strains of M. tuberculosis, this may contribute to the improved 
sensitivity observed by other investigators. Secondly, the size of the target DNA sequence 
may also contribute to the sensitivity of a PCR based assay as shown by Totch et at.. 
(1996) when comparing the PCR sensitivity using the relatively large 439bp sequence 
(sensitivity of 5.6%) and the smaller 123bp insertion sequence (sensitivity 88.9%). This 
may be of particular importance when archive material is used. Greer et al. (1991) 
reported that the viability of DNA in tissue embedded with paraffin decreases according to 
the nature and duration of exposure to preservatives. This is of particular importance if 
the quality of fixation has been sub-optimal or if the archive material has been stored for 
more than five years (Greer et at. 1991). In this study, however, all lymph node tissue 
used in the study was stored for less than three years. Thirdly, the low positive rates 
observed after first round amplification may be associated with the DNA extraction 
protocol. In the DNA extraction procedure employed in this study, both bacterial and 
cellular DNA would be extracted and precipitated. Due to the paucity of mycobacterial 
DNA in tissue samples we have effectively a "needle in the haystack" scenario, with a 
relatively small quantity of bacterial DNA extracted into a pool of cellular DNA. The 
presence of a large amount of cellular DNA may interfere with the binding of the four 
oligonucleotide probes to the target template without actually inhibiting the binding. Thus 
only small amounts of DNA would be amplified which may be below the limit of 
sensitivity for detection. In this study, this aspect was investigated by spiking AFB smear 
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positive LCx-MTB negative lymph node extracts with MTB DNA and amplifying the 
sample. In all cases, the spiked samples yielded positive results. If the presence of 
cellular DNA does play an interfering role in the amplification of the mycobacterial DNA 
then a method of purifying the relatively low molecular weight mycobacterial DNA from 
the high molecular weight cellular DNA may contribute to an improved sensitivity. 
Silica based mini-columns for cleanup/purification have been developed by several 
companies including Qiagen Co. (Hilden, Germany) and Machery Nagel (Duren, 
Germany) if incorporated into the DNA extraction sample preparation methodology, may 
enhance the extraction process to provide a better yield of bacterial DNA free of inhibitors 
sample which could be more readily detected with the LCx-MTB probes or by another 
PCR method ideally targeting IS6110. 
Despite the reduced sensitivity for detecting Mtuberculosis DNA by LCx-MTB in this 
study, LCx-MTB still has the potential for the detection of mycobacterial DNA in lymph 
node samples of tuberculous patients and is highly specific. It appears that with the 
present methodology of LCx-MTB, further studies are still required to improve its 
sensitivity in paraffin-embedded sections. As observed in previous studies, there is a lack 
of "gold standard" in the diagnosis of tuberculous lymphadenopathy, as culture is 
frequently found insensitive in determining the aetiology of the lesion. This will no doubt 
affect the proper evaluation of molecular techniques. 
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Chapter 6. Development of RT PCR TaqMan assay for the direct detection of 
MTB-DNA in clinical specimens and paraffin embedded tissues compared with the 
Abbott LCx-MTB assay. 
6.1 Principle of TaqMan Assay 
Figure 1. shows TaqMan probes which are linear DNA probes with a fluorophore, 
usually at the 5' end of the probe and a quencher, either internal or at the 3' end. As 
long as the probe is intact, regardless of whether it is hybridised with the target or free 
in solution, no fluorescence is observed from the fluorophore. During the combined 
annealing - extension step of PCR, the primers of the TaqMan probe hybridize with the 
target. The DNA polymerase displaces the TaqMan probe by 3 or 4 nucleotides and the 
5' exonuclease activity of the DNA polymerase separates the fluorophore from the 
quencher (Livak et al. 1995). Fluorescence can be detected during each PCR cycle, and 
fluorescence accumulates during the course of PCR (Heid et al. 1996). Both primer and 
probe must hybridize to the target for amplification and cleavage to occur. The 
fluorescence signal is generated only if the target sequence for the probe is amplified 
during PCR. Because of these requirements, non-specific amplification is not detected. 
During PCR, the multiplexer detects an argon ion laser through fiber optic cables that 
terminate above each position on the 96-well plate. The light passes through the 
MicroAmp optical caps and, for 25 milliseconds, the laser excites the fluorescent dyes 
present in each well. Fibre optic cables collect the fluorescence emission between 
500nm and 660nm from each of the wells, with a complete collection of data from all 
wells every 7 seconds. A system of lenses, filters, and a dichroic mirror focus the 
fluorescence emission into a spectrograph. The spectograph separates the light (based 
on wavelength) into a predictably spaced pattern across a charge-coupled device (CCD) 
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camera. The sequence detection application collects the fluorescent signals from the 
CCD camera and applies data analysis algorithms. The threshold cycle (Ct) occurs 
where the sequence detection application begins to detect the increase in signal 
associated with exponential growth of the PCR product. The Ct is dependant on the 
starting template copy number, the efficiency of both the DNA amplification and PCR 
system and the cleavage of the TaqMan fluorogenic probe (Bassam et al. 1996). 
Figure 2. shows the TaqMan probe and primer binding sites corresponding to the target 
region IS6110 (bases are numbered as for the sequence with the Genbank accession no. 
X17348) and Figure 3 shows a typical printout. 
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Figure 1. Schematic representation of the TaqMan assay. The TaqMan probe 
fluoresces when the 5' nuclease activity of the DNA polymerase separates the 
fluorophore from quencher. 
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Figure 2. TaqMan probe and primer binding sites correspondings to the target 
region IS6110 (bases are numbered as Cor the sequence with the (; enbank accession no. 
Xl 7348). 
1 cgatgaaccq ccccggcatg tccggagact ccagttcttg gaaaggatgg ggtcatytca 
61 ggtggttcat cgaggaggta cccgccggag ctgcgtgagc gggcggtgcg gatggtcgca 
121 gagatccgcg gtcagcacga ttcggagtgg gcagcgatca gtgaggtcgc ccgtctactt 
181 ggtgttggct gcgcggagac ggtgcgtaag tgggtgcgcc aggcgcaggt cgatgccggc 
241 gcacggcccg ggaccacgac cgaagaatcc gctgagctga agcgcttagc ggcgggacaa 
301 cgccgaattg cgaagggcga acgcgatttt aaagaccgcg tcggctttct tcgcggccga 
361 gctcgaccgg ccagcacgct aattaacggt tcatcgccga tcatcagggc caccgcgagg 
421 gccccgatgg tttgcggtgg ggtgtcgagt cgatctgcac acagctgacc gagctgggtg 
481 tgccgatcgc cccatcgacc tactacgacc acatcaaccg ggagcccagc cgccgcgagc 
541 tgcgcgatgg cgaactcaag gagcacatca gccgcgtcca cgccgccaac tacggtgttt 
IS6110 fwd OP IS6110 probe 
OP 
601 acggtgcccg caaagtgtgg ctaaccctga accgtgaggg catcgaggtg gccagatgca 
4 
IS6110 rev 
661 ccgtcgaacg gctgatgacc aaactcggcc tgtccgggac cacccgcggc aaagcccgca 
721 ggaccacgat cgctgatccg gccacagccc gtcccgccga tctcgtccag cgccgcttcg 
781 gaccaccagc acctaaccgg ctgtgggtag cagacctcac ctatgtgtcg acctgggcag 
841 ggttcgccta cgtggccttt gtcaccgacg cctacgtcgc aggatcctgg gctggcgggt 
901 cgcttccacg atggccacct ccatggtcct cgacgcgatc gagcaagcca tctggacccg 
961 ccaacaagaa ggcgtactcg acctgaaaga cgttatccac catacggata ggggatctca 
1021 gtacacatcg atccggttca gcgagcggct cgccgaggca ggcatccaac cgtcggtcgg 
1081 agcggtcgga agctcctatg acaatgcact agccgagacg atcaacggcc tatacaagac 
1141 cgagctgatc aaacccggca agccctggcg gtccatcgag gatgtcgagt tggccaccgc 
1201 gcgctgggtc gactggttca accatcgccg cctctaccag tactgcggcg cgtcccgcc 
1261 ggtcgaactc gaggctgcct actacgctca acgccagaga ccagccgccg gctgaggtct 
1321 cagatcagag agtctccgga ctcaccgggg cggttcacga 
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Figure 3. Printout ofTaqMan assay showing the real time accumulation of' 
fluorescence with subsequent PCR cycles. The 't'hreshold cycle (('t) is the cycle at 
which fluorescence can be detected above the baseline. 
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6.2 Results 
Table 9 summarises the results of the 167 patient samples investigated in this 
comparative study. Group 1, comprised 35 AFB smear positive respiratory specimens 
culture positive for MTB. Of these, all samples were TaqMan IS6110 positive (100%). 
34 of 35 samples were also positive using LCx-MTB. One sample AFB smear positive, 
MTB-culture positive was negative by the LCx-MTB assay (see investigation of this 
isolate in chapter 7). In Group 2,23 AFB smear negative, MTB culture positive 
processed respiratory specimens were evaluated. Using the TaqMan assay, 13 of these 
samples (56.5%) yielded positive results, 2 (8.7%) samples gave equivocal results and 
8 (34.8%) samples were negative. 6 (26%) positive, 15 (65%) negative and 2 (43.5%) 
equivocal results were obtained using the LCx-MTB assay for the Group 2 samples. In 
Group 3, the 18 samples culture positive for NTM were all negative by both LCx-MTB 
and TaqMan IS6110 methods. In group 4, comprising 50 patient samples which were 
culture negative for all mycobacteria were negative by both LCx-MTB and TaqMan 
IS6110 methods. Group 5, comprised 41 paraffin embedded tissue samples which were 
investigated by both methods. Table 10 gives the nucleic acid amplification results for 
the 19 samples confirmed culture positive for MTB, 12 samples culture negative for 
MTB and the 10 paraffin embedded tissues samples for which culture was not 
performed. In all 19 MTB culture positive paraffin tissue samples, the TaqMan assay 
yielded a positive result (100%). The LCx-MTB assay gave positive results in 14 of 19 
samples (73.7%). Equivocal results were obtained in 4 of 19 samples (21%) and one 
sample was negative (5.2%) using the LCx-MTB assay. Negative results were obtained 
for all of the 12 samples (100%) MTB-culture negative, using both the LCx-MTB and 
TaqMan assays. In the 10 paraffin tissues for which MTB culture was unknown, 
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positive results were obtained in 5 samples using the TaqMan assay and 4 samples 
using the LCx-MTB assay. 
The limit of sensitivity of the TaqMan assay was determined by quantifying 1137Rv 
control DNA quantified by spectrophotometry (section 12.14.9). 100µl of a 1: 1000 
dilution of H37Rv was loaded into a cuvette in the spectrophotometer and using A260 
was quantitated as 620ng/ml of DNA. Table 11 shows the serial dilutions of the H37Rv 
DNA against TaqMan Threshold cycle (Ct) to determine the limit of sensitivity of the 
assay as 62 fg/ml. 
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Table 9. Comparison of TaqMan Assay and Abbott LCx-MTB Assay 
Abbott LCx-MTB Taqman Assay 
Pos Neg Equiv Pos Neg Equ Total 
Iv 
Group1: AFB smear pos, 34 1 0 35 0 0 35 
Culture pos for MTBC 
Group 2: AFB smear neg, 6 15 2 13 8 2 23 
Culture pos for MTBC 
Group 3: Samples culture 0 18 0 0 18 0 18 
pos for NTM 
Group 4: AFB smear neg, 0 50 0 0 50 0 50 
Culture neg for 
mycobacteria 
Group 5: Paraffin 17 20 4 23 18 0 41 
embedded tissue samples 
Totals 167 
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Table 10. Results of LCx-MTB and TaqMan assays compared with MTB-culture 
for the Paraffin Embedded Tissue samples in Group S. 
Abbott LCx-MTB IS6110 TaqMan 
Assay As ay 
Paraffin embedded Pos Equiv Neg Pos Neg Total 
tissues 
Patient tissue samples 14 4 1 19 0 19 
(MTB culture 
positive) 
Patient tissue samples 0 0 12 0 12 12 
(MTB culture 
negative) 
Patient tissue samples 4 0 6 5 5 10 
(MTB culture 
unknown) 
41 
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Table 11. Serial dilutions of the H37Rv DNA against TaqMan Threshold cycle 
(Ct) to determine the limit of sensitivity of the assay. 
Dilution of H37Rv Quantity of DNA TaqMan Assay 
extract Ct value 
1: 1000 (10) 620ng/ml 16.09 
1: 10,000 (104) 62ng/ml 19.29 
1: 100,000 (105) 6.2ng/ml 23.36 
1: 1,000,000 (106) 620pg/ml 26.65 
1: 10,000,000 (101) 62pg/ml 29.57 
1: 100,000,000 (108) 6.2pg/ml 32.13 
1: 1,000,000,000 (109) 620fg/ml 36.57 
1: 10,000,000,000 (1010) 62fg/ml 39.60 
1: 100,000,000,000 (1011) 6.2fg/ml 40.0 
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6.3 Discussion 
This investigation has confirmed previous results given in this study that direct nucleic 
acid methods show high sensitivity and specificity in AFB smear positive samples 
which are culture positive for MTB. The TaqMan assay, yielded positive results for all 
AFB smear positive, MTB culture positive samples investigated. The LCx-MTB assay 
gave similar results except for a single AFB smear positive, MTB culture positive 
sample in which MTB specific DNA could not be detected. The failure of the LCx- 
MTB assay to detect MTB DNA in this sample is discussed in detail in Chapter 7. 
In contrast, the ability to use nucleic acid testing in samples where AFBs cannot be 
demonstrated on microscopy is limited. In the 23 AFB smear negative MTB culture 
positive samples MTB DNA was detected in 56.6% of samples by the TaqMan assay 
and in only 26% of samples using LCx-MTB assay. Although the TaqMan assay 
performed better than the LCx-MTB in its ability to detect MTB DNA in smear 
negative samples, neither method could be recommended as a diagnostic tool because 
of the low negative predictive values of both tests. The high specificity of both assays 
is highlighted in the results of Group 3 and Group 4 samples which investigated 
samples either culture negative for mycobacteria or culture positive for NTM only. 
Negative results were for all Group 3 and 4 samples using both assays. 
Mycobacterial DNA extraction from samples and removal of PCR inhibitors prior to 
amplification are key components in the development of a sensitive assay. The aim of 
the extraction method is to capture as much of the mycobacterial DNA as possible from 
the sample under investigation and endeavour to place as much of the extracted DNA as 
possible into the amplification tube. Recent studies have shown that the use of silica 
membranes can aid the removal of sample inhibitors without the need for use of the 
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toxic substances as employed in the phenol chloroform method (Boddinghaus et al 
2001). 
In the present study a standardised approach to sample preparation was developed so 
that all samples from processed pulmonary and extrapulmonary sediments, and paraffin 
tissues could be processed similarly. Lysis was achieved by incubation of the sample 
material in a proteinase K/ SDS solution. Clearly, additional time is required for 
proteinase K to digest tissue samples than digested respiratory sediments but otherwise 
the DNA extraction is uniform for all samples. Appropriate conditions for binding of 
DNA to the silica membrane in the NucleoSpin Tissue columns (Macherey-Nagel, 
Duren, Germany) were created by the addition of chaotrophic salts and ethanol to the 
lysate. The binding process is reversible and specific to nucleic acids. Contaminants 
were removed by subsequent washing with two different buffers. Pure genomic DNA 
was finally eluted under low ionic strength. This step allows for the extracted DNA to 
further concentrated by eluting with a small volume of elution buffer. In each 
extraction 100µ1 was used as the final elution volume. 
The introduction of new fluorescent detection systems, such as molecular beacons 
(Piatek et al. 1998), light cycler methodology ( Taylor et al. 2001) , and TaqMan 
probes (Desjardin et al. 1998) have been introduced as a simple means of real time 
quantification of PCR products. These systems rely on quenching fluorescence energy 
transfer among molecules and have proven to be sensitive, specific and highly 
discriminative, enabling automated and simultaneous detection of multiple targets in 
closed tube format (Garcia-Quintanilla et al 2002). Quantification of PCR products 
occurs in real time during the amplification process, with no post amplification handling 
being necessary. This eliminates potential sources of carryover contamination and 
reduces the handling time (Desjardin et al. 1998). 
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In this study TaqMan probes were chosen as the platform for the fluorogenic assay best 
suited for detection of MTB DNA in clinical samples due to the ability to add a large 
volume of template and thereby increase the sensitivity of the assay. The light cycler 
methods use a low volume (approx 10µl) capillary tube for the PCR reaction ( Taylor et 
al. 2001) which limits the ability to add more than 5µl of extracted DNA template. In 
contrast, the TaqMan assay can be performed in a 50µ1 tube format and this allows for 
the addition of up to 3Oµ1 of template for each reaction. This ability is particular 
important when investigating DNA extracts of paraffin tissues which are often 
paucibacillary. 
Hermans et al (1990) suggests that 20 MTB bacteria theoretically correspond to 
approximately 100fg of chromosomal DNA (Hermans et al. 1990). The limit of 
sensitivity of the Taqman assay in this study was estimated at 62fg. This means that a 
minimum of 10-20 copies of the extracted DNA needs to present in each amplification 
tube in order to detect a PCR product. This further highlights the importance of a high 
yielding DNA extraction method and the ability to add as of the extract to the 
amplification tube as possible. The target chosen for the TaqMan assay was the 
transposon IS6110 which is present in multiple copies in the majority of strains 
(Fomukong et al. 1998) 
The main advantage to the use of IS6110 its presence in multiple copies which serves 
as a form of "internal amplifier" by providing multiple primer/probe binding sites for 
each chromosomal copy of DNA. This aspect is probably more relevant in paraffin 
embedded tissues where the DNA may become degraded or fragmented due to fixation 
with formalin (Salian et al 1998). Hence, a target which is present in multiple copies 
has a better chance over a single target such as protein antigen B used in the LCx-MTB 
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assay. This observation alone may have contributed to the improved detection of MTB 
DNA by the TaqMan assay in the paraffin embedded tissues investigated in Group 5. 
The major problem with both the TaqMan and LCx-MTB assays is the inability to 
detect for inhibition in a single tube. However, the results of this study suggest that 
inhibition of PCR is not a problem using the TaqMan assay as all of the AFB smear 
positive, MTB culture positive samples were detected. Similarly all of the paraffin 
embedded tissues samples for which the culture was known yielded the expected results 
with the TaqMan assay. Previous work (Chapter 5) did not identify inhibition in 
extracted paraffin tissues as a problem when assayed using the LCx-MTB. Clearly, 
inhibition could be monitored by testing samples in duplicate with an aliquot of MTB 
DNA spiked in a duplicate amplification tube to determine if the added DNA could be 
amplified. Although providing additional useful information such an inhibition control 
assay would double the cost of the assay per sample. An alternate approach would be to 
develop a multiplex assay using two probes labelled with different fluorophores in a 
single tube with one probe targeting and MTB specific sequence and another targeting 
a Mycobacterium genus specific region. When applied to an AFB smear positive sample 
a PCR product should be detectable with both probes confirming MTB or with the 
genus probe alone indicating a NTM. Garcia-Quintanilla et al. (2002) developed a 
multiplex assay targeting single copy sequences in the 16S rDNA gene and only 
obtained a sensitivity of 90 % in AFB smear positive samples. Any direct nucleic acid 
amplification method must have a sensitivity and specificity of 100% when being 
applied to AFB smear positive samples in order to be used a reliable diagnostic tool. 
Garcia-Quintanilla et al. (2002) stated that the selection of different quenching 
molecules for each probe used reduced the sensitivity of their assay. In addition the use 
of single copy targets may also have contributed to the reduced sensitivity. 
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The ideal assay needs to be able to detect and differentiate MTB from NTM in AFB 
smear positive samples and monitor the reaction for the presence of inhibitors that were 
not removed by the sample preparation steps. The use of dual tube RT amplification for 
each sample with a single TaqMan probe in each tube, one targeting the IS6110 region 
as tested in this study and, one targeting the 16S rDNA region as proposed by Garcia- 
Quintanilla et al. (2002). In such an assay a PCR product should be detected in at least 
one of two amplification tubes for each AFB smear positive sample investigated. 
Failure to detect any PCR products would indicate the presence of inhibition or a 
sample preparation failure. Detection of a PCR product in both amplification vials 
would confirm the presence of MTB DNA. Although there are advantages to using 
IS6110 as a amplification target in detecting strains of MTB with multiple copies it is 
important to be aware of occasional strains which do not contain this transposon (Yuen 
et al. 1993). Similarly, users of the commercial systems need to be aware of potential 
mutations or deletions at primer or probe binding sites which may lead to false negative 
results. All nucleic acid amplification results for MTB should be qualified with a 
comment indicating that amplifications tests should be interpreted in conjunction with 
other available clinical information. 
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Chapter 7 Failure of the LCx MTB assay to detect MTB specific DNA In an AFB 
smear positive, MTB culture positive sample. 
7.1 Case History 
The patient was a 47 year-old Canadian born male who had resided in Australia since 
the age of four years. He presented to a hospital emergency room where he reported a 
two-month history of lethargy, fatigue, night sweats and a cough productive of sputum. 
There was no known contact with tuberculosis. The patient consumed more than 50 
standard alcoholic drinks weekly and smoked tobacco heavily. Marked weight loss was 
apparent. Chest radiograph revealed patchy airspace consolidation and cavitation in the 
left upper lobe. The patient was admitted to hospital, and three early morning sputum 
samples were collected on consecutive days. 
7.2 Laboratory Investigation 
Sputum samples were decontaminated concentrated by centrifugation and inoculated 
onto Lowenstein Jensen slopes and into liquid medium (as described in sections 2.1 and 
2.2). Three concentrated sediments were stained by the Ziehl-Neelson method (section 
2.3) which showed 2+ (1-10 bacilli in 10 oil immersion fields) AFB. An LCx-MTB 
assay was performed according to manufacturers' instructions. By relating the LCx 
MTB Assay results for the specimen to the cutoff value (CO), the presence or absence 
of Mtuberculosis complex DNA was determined. An S/CO reading of 0.04 was 
obtained, indicating a negative result. 
The strain was isolated after 12 days incubation and direct microscopy revealed AFB 
showing good serpentine cording. The organism was confirmed as M. tuberculosis 
complex by MTB specific probe (Accuprobe; Gen Probe, San Deigo, Calif. ) (section 
2.7). MTB complex speciation tests identified the organism as M tuberculosis. The 
organism accumulated niacin, produced pyrazinamidase, reduced nitrate and was 
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susceptible to 10pg/ml thiophene-2-carbooxylic acid hydrazide (Wayne 1974, Wayne et 
al. 1976). Susceptibility testing was performed using the BACTEC 460 radiometric 
assay proportion method (Siddiqi 1996) and the strain was susceptible to rifampicin, 
isoniazid, ethambutol and streptomycin. A stored aliquot of the sediment was retested 
by the LCx-MTB assay in parallel with an aliquot of sediment spiked with a control 
strain of MTB (H37Rv). A negative LCX-MTB result was obtained on retesting the 
sediment and the spiked sample showed no evidence of inhibition. A sample of the 
culture was tested by the LCX-MTB assay and a negative result was obtained. The test 
was repeated with the culture spiked with an aliquot of H37Rv to exclude the possibility 
of the culture being inhibitory to the assay and a positive result for the assay was 
observed. It was postulated there was a mutation in one or more of the probe binding 
sites and the reason for the false negative result was investigated. 
7.3 Results 
The previously described primers MT1 and MT2 (Sjobring et al. 1990) were used to 
amplify a 419bp product overlapping the 44bp target of the LCx-MTB assay. PCR was 
performed as previously described (Sjobring et al. 1990) and yielded a 419bp product 
with H37Rv and no product with the LCx-MTB negative strain (Figure 4). An 
additional primer was designed using Primer Express Version 1.5 (Applied Biosystems, 
Foster City, Calif. ) outside the 419bp region of the protein antigen b gene: pab4 5'- 
GAGCCTGATCGCACCCATC-3'. PCR was performed using a combination of 
primers MT1 and pab4 and a product of 719 bp in the patient strain was detected when 
the expected product size was 1245bp (Figure 4). DNA sequencing was performed on 
the 719 bp product to determine the region of DNA deletion (section 2.16). Figure 5 
shows a schematic representation of the 499 bp deletion in the protein antigen B gene 
corresponding to bases 328 to 827. Figure 6 indicates the location of the primers used, 
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the probe binding sites for the LCx probes, and the region of deletion detected in the 
pab gene (Genbank accession M30046) of this strain. VNTR typing (section 2.18) was 
performed on this strain and profile of 42453 was obtained. 
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Figure 4. Ethidium bromide stained agarose gels. 
Gel A corresponds to 744 bp P('l( products obtained using primers M"I'I and IIA134 for 
the patient strain (P'I'). No P('R products were obtained for the control strain 1137Rv. 
Gel 13 shows 419bp P('R product obtained using primers M'I'I and M'l'2 fin- the control 
strain l I37Rv and the absence of a product with the patient strain (P'I') 
A 13 
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Figure 5. Schematic diagram showing the LCx-MTB assay probe binding sites, 
primer binding sites (MT1, MT2 and pab4) and the region of deletion in the protein 
antigen B gene of a strain of M. tuberculosis. 
MTI LCx robe binding site MT2 PAS}4 
233bp 347.390bp 649 by 1476bp 
328bp 499bp deletion 827bp 
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Figure 6. Location of the primers used, the probe binding sites fir the IA'x probes, 
and the region of'deletion detected in the pab gene (Genbank accession M30046) of "I 
strain of MvcOhuctcrilnf tlncwrculosis. 
I tgttcttcga cggcaggctg gtggaggaag ggcccaccga acagctgttc tcctcgccga 
61 agcatgcgga aaccgcccga tacgtcgccg gactgtcggg ggacgtcaag gacgccaagc 
121 gcggaaattg aagagcacag aaaggtatgg cgtgaaaatt cgtttgcata cgctgttggc 
181 cgtgttgacc gctgcgccgc tgctgctagc agcggcgggc tgtggctcga aaccaccgag 
M'I' 1 ---> 
241 cggttcgcct gaaacgggcg ccggcgccgg tactgtcgcg actacccccg cgtcgtcgcc 
301 ggtgacgttg gcggagaccg gtagcacgct gctctacccg ctgttcaacc tgtggggtcc 
LCX probe target -> 
361 ggcctttcac gagaggtatc cgaacgtcac gatcaccgct cagggcaccg gttctggtgc 
<--I, CX probe target 
421 cgggatcgcg caggccgccg ccgggacggt caacattggg gcctccgacg cctatctgtc 
481 ggaaggtgat atggccgcgc acaaggggct gatgaacatc gcgctagcca tctccgctca 
541 gcaggtcaac tacaacctgc ccggagtgag cgagcacctc aagctgaacg gaaaagtcct 
601 ggcggccatg taccagggca ccatcaaaac ctgggacgac ccgcagatcg ctgcgctcaa 
F- MT2 
661 ccccggcgtg aacctgcccg gcaccgcggt agttccgctg caccgctccg acgggtccgg 
721 tgacaccttc ttgttcaccc agtacctgtc caagcaagat cccgagggct ggggcaagtc 
781 gcccggcttc ggcaccaccg tcgacttccc ggcggtgccg ggtgcgctgg gtgagaacgg 
841 caacggcggc atggtgaccg gttgcgccga gacaccgggc tgcgtggcct atatcggcat 
901 cagcttcctc gaccaggcca gtcaacgggg actcggcgag gcccaactag gcaatagctc 
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961 tggcaatttc ttgttgcccg acgcgcaaag cattcaggcc gcggcggctg gcttcgcatc 
1021 gaaaaccccg gcgaaccagg cgatttcgat gatcgacggg cccgccccgg acggctaccc 
1081 gatcatcaac tacgagtacg ccatcglcaa caaccggcaa aaggacgccg ccaccgcgca 
1 141 gaccttgcag gcatttctgc actgggcgat caccgacggc aacaaggcct cgttcctcga 
1201 ccaggttcat ttccagccgc tgccgcccgc ggtggtgaag ttgtctgacg cgttgatcgc 
1261 gacgatttcc agctagcctc gttgaccacc acgcgacagc aacctccgtc gggccatcgg 
1321 gctgctttgc ggagcatgct ggcccgtgcc ggtgaagtcg gccgcgctgg cccggccatc 
1381 cggtggttgg gtgggatagg tgcggtgatc ccgctgcttg cgctggtctt ggtgctggtg 
1441 gtgctggtca tcgaggcgat gggtgcgatc aggctcaacg ggttgcattt cttcaccgcc 
<-- pab4 
1501 accgaatgga atccaggcaa cacctacggc gaaaccgttg tcaccgacgc gtcgcccatc 
1561 cggtcggcgc ctactacggg gcgttgccgc tgatcgtcgg gacgctggcg acctcggcaa 
1621 tcgccctgat catcgcggtg ccggtctctg taggagcggc gctggtgatc gtggaacggc 
1681 tgccgaaacg gttggccgag gctgtgggaa tagtcctgga attgctcgcc ggaatcccca 
1741 gcgtggtcgt cggtttgtgg ggggcaatga cgttcgggcc gttcatcgct catcacatcg 
1801 ctccggtgat cgctcacaac gctcccgatg tgccggtgct gaactacttg cgcggcgacc 
1861 cgggcaacgg ggagggcatg ttggtgtccg gtctggtgtt ggcggtgatg gtcgttccca 
1921 ttatcgccac caccactcat gacctgttcc ggcaggtgcc ggtgttgccc cgggagggcg 
1981 cgatcgggaa ttc 
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7.4 Discussion 
The investigation of this strain of Mycobacterium tuberculosis was undertaken to 
resolve the reason why a AFB smear positive, MTB culture positive sample could not 
be detected by the LCx-MTB assay in chapter 6. The LCx-MTB assay has been in use 
in several Australian laboratories for several years and has proved to be a highly reliable 
test in detecting MTB specific DNA in smear positive respiratory specimens (Lumb et 
al. 1999). It was therefore important to ascertain the reason for the failure and to try an 
investigate how commonly patients were infected with strains of MTB which could 
gave false negative results using the LCx-MTB assay. The LCx-MTB assay has been 
used by several Australian Reference Laboratories as a primary diagnostic tool for the 
direct detection of MTB DNA in clinical samples. 
Although, the patient in this case investigation was Canadian born, he had resided in 
Australia since he was 4 years of age. He had no history of overseas travel and was 
therefore presumed to have acquired his tuberculosis locally. It was of public health 
interest to determine if there were local clones of MTB circulating in Australia which 
could not be detected by the LCx-MTB assay. 
The target nucleic acid sequence for the LCx-MTB assay is found within the single 
copy chromosomal gene protein antigen b (pab) (Bengard-Andersen et al. 1989). The 
LCx-MTB assay uses four oligonucleotides probes labelled with either a capture or 
detection hapten to amplify a 44-bp fragment of the pab gene (bases 347 to 390) 
(Lindbrathen et al. 1997). PCR was performed to endeavour to amplify a product 
outside the LCx-MTB probe binding sites using previously published primers sequences 
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used by Sjobring et al. (1990). When no product could be amplified, an additional 
primer was designed in order to amplify a larger product. PCR performed with primers 
MT1 and pab4 yielded a product approximately 500 bp smaller than expected. DNA 
sequencing and subsequent comparison with the Genbank published sequence for 
protein antigen B showed a deletion of 499bp of DNA spanning the LCx-MTB probe 
binding sites. This is the first report of a DNA deletion in the pab gene of MTB. These 
findings explained the LCx-MTB failure in this instance. 
The incidence of such circulating clones among Queensland patients was further 
investigated by performing VNTR typing. A VNTR profile of 42453 was obtained. 
Examination of the database of Queensland VNTR profiles (1999 -2001) was 
undertaken to determine whether there were other MTB strains with the same VNTR 
profile which could harbour the same deletion. Only one epidemiologically unrelated 
strain with the same VNTR profile was detected. MTB DNA could be detected in this 
strain using the LCx -MTB assay indicating that the deletion in the pab gene was not 
present. This finding laid to rest public health concerns that strains with a deletion in 
the pab gene were a common finding. 
All nucleic acid testing methods have the potential to give false negative results due to 
mutations which may arise at primer or probe binding sites. This patient was unaffected 
by the delayed laboratory diagnosis of tuberculosis as treatment for tuberculosis 
proceeded despite a negative LCx-MTB assay. 
At the end of 2002, the LCx-MTB assay was withdrawn from sale in Australia. Abbott 
Diagnostics cited unresolvable manufacturing problems. 
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Chapter 8: Utility of Line Probe assay in detection of Rifampicin resistant strains 
of Mycobacterium tuberculosis in Jeddah, Saudi Arabia. 
8.1 Assay Background 
The INNO LiPA Rif TB assay based on the reverse hybridization principle is a kit used 
to detect mutations in the rpoB gene of M. tuberculosis (Cooksey et al. 1997). 
Oligonucleotide probes are immobilised as parallel lines at known locations on a 
nitrocellulose strip are hybridized under strictly controlled conditions with a 256-bp 
fragment of rpoB biotinylated PCR product. Five partially overlapping probes (Si 
through S5) of 19 to 23 bases were designed. These S probes exclusively hybridize to 
the wild-type sequence. If a mutation is present in one of the five regions, the 
corresponding probe will be prevented from hybridizing under the stringent 
hybridization and washing conditions used in the assay (Hirano et al. 1999). In addition 
four R probes (19 or 23 bases) were designed. These R probes, probes R2, R4a, R4b 
and R5 hybridize with amplicons carrying the following mutations. Asp-516-Val, His- 
526-Tyr, His-526-Asp and Ser-531-Leu respectively (Hirano et al. 1999). 
8.2 Results 
Figures 7A and 7B. show schematic representations of the Line Probe Assay results on 
18 samples of rifampicin resistant M. tuberculosis. All of the eighteen rifampicin 
resistant strains of M. tuberculosis tested were multi-drug resistant. Table 12 shows the 
drug susceptibility pattern for each strain. The mutations detected in the rpoB gene for 
each strain are given in Table 12 with the VNTR profile for each strain. 9 of 18 strains. 
(50%) carried the mutation Ser-531-Leu. Six isolates (33%) had a His-526-Tyr 
mutation, two (11.1%) had a Asp-516-Val mutation and one (5.6%) had a His-526-Asp 
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mutation. VNTR analysis of the rifampicin resistant strains showed clusters of VNTR 
profiles associated with distinct resistance mutations. Six isolates yielded a VNTR 
profile of 22431 and all demonstrated the mutation Ser-531-Leu. Five strains with 
VNTR profile 42235 showed a His-526-Tyr mutation. 
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Figure 7A and 7B. Schematic representations of the Line Probe Assay results on 18 
samples of Rifampicin resistant M. tuberculosis. 
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Figure 7B. samples 11-18 
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Table12. Table shows VNTR profile, drug susceptibility pattern, and mutations 
detected using the LiPA Assay on 18 rifampicin resistant strains of Mtuberculosis. 
Line 
probe 
VNTR Susceptibility Profile* Mutation 
RI I S E Z 
1 21333 R R R S S F1034 Asp-516-Val 
2 22231 R R R I I 18205 Ser-531-Leu 
3 22431 R R S S S 16448 Ser-531-Leu 
4 22431 R R S S S 17971 Ser-531-Leu 
5 22431 R R R S I 18569 Ser-531-Leu 
6 22431 R R R I R 17720 Ser-531-Leu 
7 22431 R R R R R 18544 Ser-531-Leu 
8 22431 R R R R S 16522 Ser-531-Leu 
9 22434 R R R S S 19211 His-526-Tyr 
10 32233 R R S S S F1030 Ser-531-Leu 
11 32233 R R S S S 16488 Ser-531-Leu 
12 32433 R R R S S F1023 Asp-516-Val 
13 42235 R R R R S 18086 His-526-Tyr 
14 42235 R R S S S F1012 His-526-Tyr 
15 42235 R R S S S F1038 His-526-Tyr 
16 42235 R R R S S 19774 His-526-Tyr 
17 42235 R R R R R 17569 His-526-Tyr 
18 42435 R R R R R 18572 His-526-Asp 
* Rifampicin (RI), Isoniazid (I), Streptomycin (S), Ethambutol (E), Pyrazinamide (Z) 
Resistant (R), Susceptible (S), Intermediate (I) 
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8.3 Discussion 
The use of conventional culturing methods in the diagnosis and susceptibility testing of 
tuberculosis is protracted, and can take up to 12 weeks before a prediction of a 
resistance pattern can be made (Pretorius et al. 1996). This has negative consequences 
for the treatment of infected individuals, and can contribute to the spread of multi-drug 
resistant organisms. Spontaneous mutations that lead to drug resistance occur rarely in 
M. tuberculosis, and multi-drug regimens can prevent the emergence of clinical drug 
resistance. The problem of resistance results from treatment which is inadequate, often 
because of irregular drug supply, inappropriate regimens or poor compliance. (Hirano et 
al. 1999). Rifampicin resistance is the most common primary drug resistance observed 
in Saudi Arabia (Ellis et al. 1996) and is also associated with resistance to isoniazid in 
90% of cases (Drobniewski et al. 1998). As most multi-drug resistant strains are 
resistant to rifampicin, the rapid detection of mutations, 95% of which occur within an 
81bp region of the rpoB gene, corresponding to codons 507 to 533, may be used for the 
presumptive identification of MDR tuberculosis. Different groups from diverse regions 
of the world have thus far reported 65 substitutions, 12 deletions and 4 insertions in the 
rifampicin resistance determining region of the rpoB gene based on DNA sequence 
analysis (Mani et al. 2001). Therefore, if all of these substitutions occurred with equal 
frequency, the only useful means of predicting rifampicin resistance would be by DNA 
sequencing. The most common mutations occurs with codon 531(TCG) Serine to 
(TTG) Leucine. This mutation accounted for 9 of 18 rifampicin resistant strains (50%) 
investigated in this study. This mutation has been reported as the most common 
alteration in the rpoB from several geographical regions. It has been reported to be 
responsible for conferring rifampicin resistance in 53.5% strains isolated in Africa 
(Rossau et al. 1997), 46.8% of 77 Asian strains (Hirano et al. 1999), 48.5% strains from 
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Australia (Yuen et al. 1999), 53.7 % strains from Brazil (Valim et al. 2000), 56.7% 
strains from Italy (Piatek et al. 1998), 36.1% strains from Germany (Rinder et al. 1997), 
34.4% of strains in the United States (Williams et al. 1994), 47.1% of strains from 
Greece (Matsiota-Bernard et al. 1998), 53% of strains from India (Mani et al. 2001), 
46.3% of strains from Turkey (Cavusoglu et al. 2002) .A transition mutation 
in codon 
526 (CAC) His to (TAC) Tyr was detected in 6 of 18 strains (33.3%). 2 strains (11.1%) 
showed a transition in codon 516 (GAC) Asp to (GTC) Val. A transition mutation in 
codon 526 (CAC) His to (GAC) Asp was detected a single strain (5.6%). The 
mutations observed in this study, corresponding to codons 531,526 and 516 have been 
shown to be the most commonly identified from several geographic regions. (Bartfai et 
al. 2001). The InnoLipa kit appears ideal for use in Saudi Arabia as a screen for multi- 
drug resistance as the resistance probes could detect a mutation in each of the strains 
investigated in this study, and all strains were resistant to isoniazid in addition to 
rifampicin. VNTR analysis on each of the rifampicin resistant strains found 3 clusters of 
VNTR profiles; 22431 (6 strains), 42235 (5 strains) and 32233 (2 strains). In each of 
these clusters the same mutations in the rpoB gene were observed suggesting that there 
may be primary transmission of multi-drug resistant tuberculosis occurring in Saudi 
Arabia. A combination of resistance mutation detection and a PCR based typing 
strategy may together provide a simple approach to detect drug resistance as early as 
possible. The ability to rapidly identify a potential multi-drug resistant strain based on 
its VNTR profile may be useful strategy to control the further transmission of drug 
resistant strains, in countries like Saudi Arabia where resistance is common. 
The inability to detect resistance early is one of the major threats to tuberculosis 
treatment and control programs. It would not be currently feasible to test all 
tuberculosis cases using Lipa and therefore any strategy which can predict patient 
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groups with high frequencies of multidrug resistance can contribute to the control of 
transmission of multi-drug resistant strains. The results of this study suggest, that the 
application of the Lipa assay could be selectively used when a VNTR profile suggest an 
epidemiological link with circulating resistant strains. This approach could reduce the 
time to detect multi-drug resistant tuberculosis from weeks to only a few days. The 
utility of VNTR as a routine typing strategy is investigated in the following chapter. 
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Chapter 9: Diversity of strains of Mycobacterium tuberculosis isolated in 
Queensland, Australia and Jeddah, Saudi Arabia based on Variable numbers of 
Tandem DNA repeats typing 
9.1 Assay Background 
Repetitive units of DNA ranging from 40-100bp are often found as tandem repeats 
dispersed in the intergenic regions of the M. tuberculosis genome. The methodology of 
Frothingham et al. (1998) uses PCR to amplify these repetitive sequences to determine 
length polymorphisms in the five most variable loci. Based on the number of repeat 
sequences at each locus a numeric profile can be generated for each strain. Thus, the 
type strain M. tuberculosis H37Rv has the profile 33433 using these loci, and Mbovis 
BCG Pasteur has a profile 55623. H37Rv has three copies of a 75bp repeat at locus 
ETR-A, three copies of 57bp repeat at locus ETR-B, four copies of a 58bp repeat at 
locus ETR-C, three copies of a 77 bp repeat at ETR-D, and three copies of a 53bp 
repeat at ETR-E. These regions are difficult to amplify as they have a very high GC 
content, with lots of repetition and long strings of GC sequence. Loci ETR B, ETR C, 
ETR D, and ETR E contain some strong hairpin sequences which are more easily 
amplified when 4% dimethyl sulphoxide (DMSO) is incorporated into the reaction 
mixture. Stutter bands or ladder bands were observed during the PCR reactions. These 
stutter bands consist of multiple bands on the gel, corresponding to additions or 
deletions of one or more tandem repeat units, in addition to the correct band size. These 
bands are presumed to be due to strand slippage of the DNA polymerase enzyme during 
PCR. As PCR favours smaller products, once slippage occurs, a single molecule of a 
smaller size product may catch up or even exceed the correct product. Therefore, if 
stutter bands are present the darkest band could not be presumed to be the correct 
product size. A template dilution of 1: 1000 with sterile water reduced the incidence of 
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stutter bands and allowed for a clear visualisation of a single product for each locus. 
The method has been shown to be highly reproducible but some potential sources of 
error have been identified. Overreading reactions with stutter bands, clerical errors in 
sizing bands, and mislabelling errors associated with the DNA preparation, PCR 
reaction or gel loading steps. In order to improve the accuracy of the method all gels 
were read blind by three readers. Results were entered individually onto a spreadsheet. 
Obvious clerical errors were re-read but other discrepant results were retested. Known 
allele positive controls were incorporated into each PCR run and negative controls were 
incorporated into each run. ETR-D is a locus described by Supply et al. 1997. 
Although H37Rv has three complete copies of a 77 bp repeat at this locus, most clinical 
isolates have a 24bp deletion in one of the tandem repeats. This deletion can be 
detected on agarose gels. Thus, H37Rv has three copies of ETR-D and yields a 310bp 
product, while other three copy strains yield a 286bp product. This polymorphism may 
provide some additional discriminative value but has not been utilised in this 
investigation. Examples of PCR products at each loci are given in Figures 8-12, 
corresponding to ETR A -E, respectively. Table 13 shows calculations of the number of 
DNA repeats at each VNTR loci for each of the strains of MTB depicted in Figures 8- 
12. Table 14 represents the expected PCR product size for the different VNTR 
polymorphisms - Allele product size in bp (Frothingham et al. 1998). 
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Figure 8. P('R products for F'IR-A on 21%, agarose gel stained with ethidium 
bromide. Calculations of the product size and number of repeats at this locus are given. 
ýh ý) Iaddcr 1234561 addo 
Lane Product size No of repeats 
1 
2 
3 
570 
495 
495 
4 495 
5 495 
6 570 
7 345 
8 420 
9 420 
10 495 
5 
4 
4 
4 
4 
5 
2 
3 
3 
4 
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Figure 9. I VR products for FTR-13 on 2'%o agarose gel stained with ethidium 
bromide. Calculations of the product size and number of repeats at this locus are given. 
L 
c 
I 
D 
I Luddcr 123 ý1 ý6 ia, Mci / 
Lane 
1 
2 
3 
Product size 
406 
235 
235 
4 349 
5 235 
6 292 
7 235 
8 235 
9 292 
10 292 
() 
No of repeats 
5 
2 
2 
4 
2 
3 
2 
2 
3 
2 
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Figure 10. PCR products for F'I'R-C on 2`%, agarosc gel stained with cthidium 
bromide. Calculations of the product size and number of repeats at this locus are given. 
Ladder 123456 Ladder %ö ýý 
Lane Product size No of repeats 
I 
2 
3 
334 
276 
276 
5 
4 
4 
4 334 
5 276 
6 276 
7 276 
8 
5 
4 
4 
4 
218 3 
9 276 
10 276 
4 
4 
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Figure 1 1. PCR products fir FIR-I) on 2'%% agarose gel stained with ethidium 
bromide. Calculations of the product size and number of repeats at this locus are given. 
Ladder 1234SUI. addci 7h ýý 
Lane Product size No of repeats 
1 
2 
3 
132 
363 
286 
4 363 
5 286 
6 594 
7 286 
8 286 
9 310 
10 286 
I 
4 
3 
4 
3 
7 
3 
3 
3 
3 
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Figure 12. PCR products I'M F'I'R-F on 2% agarosc gel stained with cthidiunm 
bromide. Calculations of the product size and number of repeats at this locus are given. 
H 
ý 
LJ 77 
Ll 
I 
ý! I 
I addcr 1234561 addct 7 15 9 
Lane 
1 224 
2 224 
3 383 
4 277 
5 330 
6 277 
7 224 
8 224 
9 224 
10 330 
Product size No of repeats 
3 
3 
6 
4 
5 
4 
3 
3 
3 
5 
I..., i 
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Table 13. Examples of VNTR profiles from agarose gels depicted in figures 8-12 
No ETR-A ETR-B ETR-C ETR-D ETR-E Profile Strain type 
1 5 5 5 1 3 55513 BCG 
2 4 2 4 4 3 42443 
3 4 2 4 3 6 42436 Beijing variant 
4 4 4 5 4 4 44544 
5 4 2 4 3 5 42435 Beijing 
6 5 3 4 7 4 53474 
7 2 2 4 3 3 22433 
8 3 2 3 3 3 32333 Haarlem 
9 3 3 4 3 3 33433 H37Rv 
10 4 2 4 3 5 42435 Beijing 
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Table 14. Table of VNTR Polymorphisms - Allele product size in bp 
(Frothingham et al. 1998) 
No of ETR A ETR B ETR C ETR D ETR E 
repeats 
1 270 178 102 156 118 
2 345 235 160 233 171 
3 420 292 218 310 224 
4 495 349 276 387 277 
5 570 406 334 464 330 
6 645 463 392 541 383 
7 720 520 450 618 436 
8 795 577 508 695 489 
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9.2 Results 
9.2.1 Saudi Arabian Results 
The VNTR method was applied to 85 isolates of M. tuberculosis isolated from different 
Saudi patients at The King Khalid national Guard Hospital, Jeddah, Saudi Arabia as a 
means of identifying clustering and resulted in 38 distinct profiles. Twenty-four 
patients yielded unique VNTR profiles. Sixty-one of 85 patients (72%) were found in 
clusters of two or more strains. The most common profile observed in the Jeddah 
population was VNTR profile 42235 accounting for 15 of 85 (17.6%) of strains. The 
Haarlem variant strain accounted for 12 of 85 (14%) of strains. Profile 22431 was 
unique to the Saudi Arabia study and was associated with 6 multidrug resistant strains 
of MTB. Only 2 of 85 (2.3%) strains of the Beijing family were found. 
9.2.2 Queensland Results 
201 M. tuberculosis strains isolated between 2000-2001 at the Queensland 
Mycobacterium Reference Laboratory were characterised by VNTR typing. 11 clusters 
of 3 or more isolates were identified. A further 8 clusters of two isolates were observed 
and 46 unique VNTR profiles were observed. Overall, 77% of the strains were found in 
clusters of two or more strains. Table 15 shows patients country of birth or ethnicity 
with the number of Mtuberculosis strains clustered by VNTR typing with 3 patients or 
more. The largest cluster observed accounted for 36 (18%) strains with VNTR profile 
42435 belonged to the Beijing family. In this cluster of 36 patients, 10 were 
Caucasians, 14 patients were from SE Asian countries, a further 10 were from Papua 
New Guinea and two patients were indigenous Australians. A variant of the Beijing 
family with VNTR profile 42436 (Bifani et al. 1999) was observed in 11 isolates. Of 
these eleven isolates, 10 were patients from Papua New Guinea and one patient was an 
Australian Caucasian. Both of the Beijing family profiles together accounted for 23.4% 
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of all isolates. A further two clusters 32333 and 32433 accounted for 24% of all 
strains. Table 16 shows the diversity of VNTR profiles encountered in Queensland. 45 
unique VNTR profiles were observed among the 201 strains of M. tuberculosis 
investigated. A further 8 clusters of only two patients were observed. 
9.2.3 VNTR profiles common to both study groups. 
The Haarlem variant strain was the most common profile observed in both groups and 
accounted for 26 of 201 (12.9%) of the Queeensland strains and 12 of 85 (14.1%) of the 
Saudi strains. The most common profile among the Saudi strains was 42235. This 
strain was isolated in Queensland from 5 of 201 (2.5%) of patients including 3 patients 
from the Indian sub continent, 1 patient of Middle-East origin and 1 Caucasian. 
9.2.4 VNTR analysis using ETR loci A-F and MIR U loci 10,16, and 40 
77 strains of Mycobacterium tuberculois isolated from patients in Queensland during 
2002 were evaluated using a combination of VNTR targeting ETR loci (A-F) and 
MIRU 10,16,40. Figure 13 is a dendrogram showing the relatedness of strains. 19 
(24.8%) Beijing family strains (42435) were identified. The additional loci 
differentiated these strains into 7 distinct profiles with 424353333 accounting for 9 
strains (47%). The 5 Beijing variant strains were further subdivided into 3 clusters. 14 
Haarlem family strains (32333) were differentiated into 7 distinct profiles and the 10 
Haarlem variant strains (32433) were subdivided into 9 distinct profiles using the 
combined ETR/MIRU analysis. Overall, 33 of 77 strains (43%) were clustered in 
groups of two or more strains. 44 of 77 (57%) strains showed unique profiles. Table 17 
Shows the allelic profile frequencies of the 77 strains investigated by VNTR 
combination of ETR and MIRU. 54 different profiles were identified in the dataset. 
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Table 15. VNTR profiles based on ethnicity. Table shows the relationship of 
VNTR profiles in clusters of three or more strains observed in either of Queensland 
population or the Saudi Arabian study samples. 
Ethnicity 
VNTR 
Profile 
No of 
strains 
Caucasians Indian sub- 
continent 
SE 
Asia 
Papua 
New 
Guinea 
Indigenous 
Australian 
Middle 
East 
African South 
American 
Saudi 
Arabia 
22431 1 1 6 
32432 3 1 - 2 - - - - - 1 
52234 - 4 
22432 4 3 - - I - - - - - 
42235 5 1 3 - - - 1 - - 15 
42433 2 2 4 
42453 6 2 - 4 - - - - - - 
31433 7 1 2 2 - 2 - - - 1 
22433 8 6 - 1 1 - - - 3 
46464 11 2 - 6 2 1 - - - - 
32333 
Haarlem 
22 9 - 2 3 5 - 3 - 3 
32433 
Haarlem 
variant 
26 9 - 1 2 13 - - 1 12 
42435 
Beijing 
36 10 - 14 10 2 - - - 2 
42436 
Beijing 
variant 
11 1 - - 10 - - - - - 
*includes Australian and overseas born 
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Table 16. Unique and shared VNTR profiles compared with ethnicity. Common 
profiles observed between Saudi strains and the Queensland strains are highlighted in 
bold. 
Australian profiles Country of Origin Saudi Arabian Profiles 
12433 
21233 Caucasian 
21333 (2) 
21432 Caucasian 
21433 Caucasian 
22231 
22232 (2 strains) Australian aboriginal 
22333 (2 strains) Caucasian 
22431 Chinese 
22434 Caucasian 22434 (2) 
22533 Papua New Guinea 
31333 (2 strains) Caucasian / Taiwanese 
31332 
31433 
32233 Unknown 32233 (2) 
32234 
32235 United Arab Emirates 32235 (2) 
32265 
32332 Caucasian 
32423 
32432 
32434 Caucasian 
32443 Caucasian 
33432 Vietnamese 
34435 Vietnamese 
36433 Australian aboriginal 
41433 Caucasian 
42232 
42234 Somali 42234 (2) 
42243 
42323 (2 strains) Papua New Guinea 
42333 
42423 Iraqi 
42425 (2 strains) Caucasian / Korean 
42432 
42433 2strains Latvian / Caucasian 
42434 (2 strains) Burmese / Thai 
42443 
42438 Caucasian 
42445 Korean 
42464 Filipino 
42535 Caucasian 
42735 Somali 
43235 
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43333 
44235 2 
44435 Papua New Guinea 
44464 Filipino 
45453 Unknown 
45463 Filipino 
45464 ((2 strains) Thai / Filipino 
46424 Australian aboriginal 
46454 Caucasian 
46484 Filipino 
47464 Filipino 
49464 Filipino 
51464 SriLankan 
51643 Caucasian 
52435 Thai 
54445 Vietnamese 
61464 Caucasian 
62235 
62416 
62433 
62466 
64475 Vietnamese 
64485 
64543 Australian aboriginal 
65416 
74455 Indian 
74475 Vietnamese 
74495 Vietnamese 
83475 Vietnamese 
84233 
84234 
84415 
84575 Vietnamese 
94235 Australian aboriginal 
94254 Indian 
94264 Indonesian 
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Figure 13. Dendrogram* showing relatedness of 77 strains of MTB evaluated by a 
combination of ETR and MIRU analysis. 
TN993 (3,2,3,3,3,3,4,3,4) 
5519 (3,2,3,3,3,3,4,3,4) 
48 (3,2,3,3,3,3,4,3,4) 
6768 (1,2,3,3,3,3,4,3,4) 
12172 (3,2,3,3,3,3,4,32) 
11433 (3,2,3,3,3,3,4,3,2) 
11085 (3,2,3,3,3,3,4,3,3) 
8520 (3,2,3,3,3,3,4,3,3) 
6768 (3,2,3,3,3,3,4,3,3) 
7250 (3,2,3,3,3,3,4,3,5) 
12245 (3,2,3,3,3,3,5,3,4) ý 
9703 (3,2,3,3,3,3,5,3,3) 
3358 (3,2,3,3,3,3,5,3,3) 
2363 (3,2,3,3,3,3,5,3,3) 
TN 1088 (3,2,3,3,3,2,4,3,5) 
TN1037 (3,2,4,3,3,3,2,3,4) 
TN765 (3,2,4,3,3,3,3,3,4) 
12780 (3,2,4,3,3,3,3,3,2) 
TN496 (3,2,4,3,3,3,3,1,4) 
2924 (3,2,4,3,3,3,3,1,4) 
11938 (3,2,4,3,3,3,3,2,4) 
Jý 852 (3,2,4,3,3,3,4,2,4) 
L-ý- 3927 (3,2,4,3,3,3,3,2,1) 
5090 (3,2,4,3,3,1,4,3,4) ý 
2557 (3,2,4,3,3,4,4,3,4) 
4478 (3,3,3,3,3,3,3,3,1) 
12690 (3,1,4,3,3,2,2,3,1) ý 
230 (3,1,4,3,3,2,2,3,3) 
TN1032 (2,2,2,3,2,2,4,3,4) ý 
7095 (22,2,1,2,2,4,3,4) 
2236 (2,1,2,3,3,3,4,3,3) 
13150 (4,2,4,3,6,32,3,3) 
10479 (4,2,4,3,5,3,2,3,3) 
12476 (4,2,4,3,5,3,2,3,4) 
11016 (42,4,3,5,32,3,4) 
6992 (4,2,4,3,5,3,2,3,4) 
4508 (4,2,4,3,5,32,3,4) 
7390 (42,4,3,6,32,3,4) 
2830 (42,4,3,6,32,3,4) 
2205 (42,4,3,6,3,2,3,4) 
6986 (42,4,3,4,3,2,3,4) 
11480 (4,2,4,3,5,3,3,3,3) 
10599 (4,2,4,3,5,3,3,3,3) 
9150 (42,4,3,5,3,3,3,3) 
6975 (42,4,3,5,3,3,3,3) 
6134 (4,2,4,3,5,3,3,3,3) 
4811 (4,2,4,3,5,3,3,3,3) 
3493 (4,2,4,3,5,3,3,3,3) 
3362 (4,2,4,3,5,3,3,3,3) 
2351 (4,2,4,3,5,3,3,3,3) 
2382 (4,2,4,3,5,3,3,3,4) 
5437 (4,2,4,3,3,3,3,3,3) 
7656 (42,4,3,5,2,3,3,3) ý 
4421 (4,2,4,3,52,3,3,3) 
1557 (42,4,3,5,4,3,3,3) 
7809 (4,2,4,3,5,3,3,2,3) 
453 (32,4,3,4,3,3,3,3) 
1277 (422,3,5,3,6,4,3) 
12943 (32,4,4,4,3,32,4) 
11458 (22,4,3,3,3,3,42) 
7435 (2,2,4,3,3,3,3,3,1) 
568 (22,4,3,3,3,32,5) 
8356 (42,4,4,3,3,3,3,5) 
7725 (42,4,4,32,3,32) 
5754 (42,4,3,62,3,32) 
13045 (4,6,4,6,4,3,4,32) 
4265 (4,6,4,8,4,3,4,32) 
4394 (4,6,4,8,4,3,1,32) 
11997 (4,6,4,4,4,3,4,3,2) 
321 (4,6,4,8,4,3,4,32) 
12165 (4,5,4,6,42,4,32) 
2159 (4,5,4,6,3,3,4,32) 
10452 (8,4,4,6,2,3,4,3,3) 
2209 (6,4,4,8,52,4,32) 
373 (62,4,6,5,3,42,3) 
2510 (6,1,4,6,8,3,4,3,3) 
1008 (6,1,4,8,6,3,3,3,4) 
1 0.9 0.8 0.7 06 05 04 03 0.2 0.1 0 
Unkage Distance 
See Section 2.20.7 
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Table 17. Allelic profile frequencies of the 77 strains investigated by VNTR 
combination of ETR and MIRU analysis. 54 different profiles in dataset (displayed in 
descending order of frequency) 
Profile (ETR A, ETR B, ETR C, ETR D, 
ETR E, ETR F, MIRU 10, MIRU 16, 
MIRU 40) 
Frequency % of dataset 
4,2,4,3,5,3,3,3,3 9 11.69 
4,2,4,3,5,3,2,3,4 4 5.19 
3,2,3,3,3,3,4,3,4 3 3.90 
4,2,4,3,6,3,2,3,4 3 3.90 
3,2,3,3,3,3,5,3,3 3 3.90 
3,2,3,3,3,3,4,3,3 3 3.90 
3,2,4,3,3,3,3,1,4 2 2.60 
4,6,4,6,4,3,4,3,2 2 2.60 
4,2,4,3,5,2,3,3,3 2 2.60 
3,2,3,3,3,3,4,3,2 2 2.60 
3,1,4,3,3,2,2,3,3 1 1.30 
4,6,4,8,4,3,4,3,2 1 1.30 
6,2,4,6,5,3,4,2,3 1 1.30 
3,2,4,3,4,3,3,3,3 1 1.30 
2,2,4,3,3,3,3,2,5 1 1.30 
3,2,4,3,3,3,4,2,4 1 1.30 
6,1,4,6,6,3,3,3,4 1 1.30 
4,2,2,3,5,3,6,4,3 1 1.30 
4,2,4,3,5,4,3,3,3 1 1.30 
4,5,4,6,3,3,4,3,2 1 1.30 
6,4,4,6,5,2,4,3,2 1 1.30 
2,1,2,3,3,3,4,3,3 1 1.30 
4,2,4,3,5,3,3,3,4 1 1.30 
6,1,4,6,6,3,4,3,3 1 1.30 
3,2,4,3,3,4,4,3,4 1 1.30 
3,2,4,3,3,3,3,2,1 1 1.30 
4,6,4,6,4,3,1,3,2 1 1.30 
3,3,3,3,3,3,3,3,1 1 1.30 
3,2,4,3,3,1,4,3,4 1 1.30 
4,2,4,3,3,3,3,3,3 1 1.30 
4,2,4,3,6,2,3,3,2 1 1.30 
1,2,3,3,3,3,4,3,4 1 1.30 
4,2,4,3,4,3,2,3,4 1 1.30 
2,2,2,1,2,2,4,3,4 1 1.30 
3,2,3,3,3,3,4,3,5 1 1.30 
2,2,4,3,3,3,3,3,1 1 1.30 
4,2,4,4,3,2,3,3,2 1 1.30 
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4,2,4,3,5,3,3,2,3 1 1.30 
4,2,4,4,3,3,3,3,5 1 1.30 
8,4,4,6,2,3,4,3,3 1 1.30 
4,2,4,3,5,3,2,3,3 1 1.30 
2,2,4,3,3,3,3,4,2 1 1.30 
3,2,4,3,3,3,3,2,4 1 1.30 
4,6,4,4,4,3,4,3,2 1 1.30 
4,5,4,6,4,2,4,3,2 1 1.30 
3,2,3,3,3,3,5,3,4 1 1.30 
3,1,4,3,3,2,2,3,1 1 1.30 
3,2,4,3,3,3,3,3,2 1 1.30 
3,2,4,4,4,3,3,2,4 1 1.30 
4,2,4,3,6,3,2,3,3 1 1.30 
3,2,4,3,3,3,3,3,4 1 1.30 
3,2,4,3,3,3,2,3,4 1 1.30 
3,2,3,3,3,2,4,3,5 1 1.30 
2,2,2,3,2,2,4,3,4 1 1.30 
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9.3 Discussion. 
9.3.1 VNTR typing in Saudi Arabia 
Saudi Arabia, although underdeveloped technically, has a high per capita income, free 
treatment for active cases and compulsory screening of foreign workers. Saudi Arabia 
has an unreliable notification system for tuberculosis cases and to date no molecular 
epidemiological investigations have been undertaken in Saudi Arabia as a means of 
defining the relationship between mycobacterial strains and to clarify the epidemiology 
of tuberculosis (El-Kassimi 1994). This study over a two-year period highlighted the 
need to define the epidemiology of tuberculosis in Jeddah in order to plan strategies to 
control the disease. By investigating the DNA fingerprints in a population it is possible 
to gain an improved understanding of the bacterial transmission dynamics. It is hoped 
that a better understanding of the dissemination of the bacteria in a defined populations 
will improve the detection of new cases and the control of disease transmission. This 
approach involved fingerprinting all the mycobacteria in a population, assuming that 
unique strains are reactivated whereas shared strains were recently transmitted. The 
VNTR method was applied to 85 isolates of M. tuberculosis isolated from different 
Saudi patients at The King Khalid national Guard Hospital, Jeddah, Saudi Arabia as a 
means of identifying clustering and resulted in 38 distinct profiles. Twenty-four 
patients yielded unique VNTR profiles. Sixty-one of 85 patients (72%) were found in 
clusters of two or more strains. While the unique VNTR profiles clearly reflect 
different strains, the VNTR clustering amongst the remaining 61 patients must be 
interpreted with caution. The most common profile observed in the Jeddah population 
was VNTR profile 42235 accounting for 15 of 85 (17.6%) of strains. This profile was 
the most common profile accounting for 23 of 118 patients (19.5%) found in a study by 
Gasgoyne-Binzi et al. at the Leeds General Infirmary (LGI), England. The LGI serves 
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a large immigrant community from the Indian subcontinent with a high incidence of 
tuberculosis. This profile has previously been detected in a patient from India (Kremer 
et al. 1999) but was not detected in studies from Sicily (Sola et al. 2001) or Tanzania 
(Barlow et al. 2001). These studies suggest a strong geographical association of this 
profile with the Indian subcontinent. 
Saudi Arabia imports labour from the Indian Subcontinent for construction, gardening, 
cleaning and unskilled manual labour. These temporary workers are housed in crowded 
conditions and have limited access to good health care. In this setting it is likely that 
Indian subcontinent strains of tuberculosis have been transmitted to Saudi Arabian 
nationals. Further evidence of the clonal association of this VNTR profile with the 
Indian subcontinent is evident in the analysis of VNTR profiles from Queensland, 
Australia. Of the 201 strains typed by VNTR, 5 strains showed the profile 42235. Four 
of these patients were of Indian subcontinent origin and one patient was Australian 
born. Another significant cluster of strains accounting for 12 of the 85 (14%) strains 
investigated gave the profile 32433. A third cluster accounting for 6 of the 85 strains 
(7%) with VNTR profile 22431 was associated with a group of strains which were all 
multi-drug resistant. This profile has not been reported in any other studies to date. 
This finding suggests that this strain may have been associated with transmission of 
multi-drug resistant tuberculosis. In a setting such as Saudi Arabia where drug 
resistance is common (Ellis et al. 1996, Al-Rubaish et al. 2001, Khan et al. 2001) 
VNTR typing can be a useful tool in rapidly identifying circulating clones of multidrug 
resistant strains of M. tuberculosis. 
9.3.2 VNTR Typing in Queensland 
Queensland has a low tuberculosis incidence rate (2.69 per 100,000 population in 1998) 
with the highest incidence occurring in migrants from high prevalence countries 
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followed by indigenous Australian-born people (Ward et al. 2001). Among non- 
indigenous Australians, tuberculosis most often occurs among elderly males, largely 
due to reactivation of latent tuberculosis. The general impression has been that most 
cases in Queensland are due to reactivation of latent infection acquired many years 
earlier, when TB was more prevalent, in Australian-born population or in the country of 
origin in overseas born people. Transmission within Queensland has usually been 
considered to occur in micro-epidemics as small clusters, particularly in indigenous 
communities but also in other social clusters. 201 Mtuberculosis strains isolated 
between 2000-2001 at the Queensland Mycobacterium Reference Laboratory were 
characterised by VNTR typing. 11 clusters of 3 or more isolates were identified. A 
further 8 clusters of two isolates were observed and 45 unique VNTR profiles were 
observed. Overall, over 80% of the strains were found in clusters of two or more 
strains. The largest cluster observed accounted for 36 (18%) strains with VNTR profile 
42435 belonged to the Beijing family. In this cluster of 36 patients, 10 were 
Caucasians, 14 patients were from SE Asian countries, a further 10 were from Papua 
New Guinea and two patients were indigenous Australians. A variant of the Beijing 
family with VNTR profile 42436 (Bifani et al. 1999) was observed in 11 isolates. Of 
these, 10 were from patients from Papua New Guinea and one patient was an Australian 
Caucasian. Both of the Beijing family profiles together accounted for 23.4% of all 
isolates. A further two clusters 32333 and 32433 accounted for 24% of all strains. 
9.3.3 Haarlem family 
Profile 32333 corresponds to the Haarlem family strains which seem to be widespread 
globally. Strains with this genotype were designated the Haarlem family because the 
first recognised strain was isolated from a patient living in Haarlem, Netherlands 
(Kremer et al. 1999). In this study, the author refers to profile 32433 as a Haarlem 
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variant strain as it differs from the Haarlem family by one repeat at ETR-C and like the 
Haarlem family strains appear to be globally disseminated. Only a few population 
based epidemiological studies have been carried out using VNTR typing. In Sicily, 
Sola et al. evaluated the genetic diversity of 104 strains of M. tuberculosis using both 
VNTR typing and spoligotyping (Sola et al. 2001). This study found 14/104 strains 
corresponded to the Haarlem family and a further 12/104 strains demonstrated the 
Haarlem variant VNTR profile. Together these two profile accounted for 25% of strains 
isolated in Sicily (Sola et al. 2001). Similarly a study in England using VNTR typing 
as means of rapid identification of laboratory contamination with M. tuberculosis found 
the Haarlem and Haarlem variant strains accounted for 17% of all strains investigated 
(Gascoyne-Binzi et al. 2001). VNTR typing was applied to 66 strains of M. tuberculosis 
isolated from the French Caribbean between 1998-1999. Using VNTR typing alone 48 
(73%) were grouped into twelve clusters. The most predominant cluster accounting for 
36% of strains was VNTR allele 32333 corresponding the Haarlem family Glade (Filliol 
et al. 2000). Only 2 of the 66 strains (3%) demonstrated the Haarlem variant profile. 
Similar results were observed in a study of 93 strains from Tanzania where only 2 
strains (2.2%) were typed as Haarlem strains and 9.7% of strains were of the Haarlem 
variant (Barlow et al. 2001). Amongst the 201 Queensland strains typed by the VNTR 
method 22 (11%) were Haarlem strains and 26 (13%) were Haarlem variant strains. 
These strains were predominately found in Caucasian and indigenous Australian 
patients. These studies suggest that there is a predominance of M. tuberculosis isolates 
with similar VNTR profiles within discrete geographical areas and that evolution of 
these strains is being reflected by the VNTR profiles in the community. 
Fillol et al. (2000) found VNTR typing poor in discriminating the 24 Haarlem Glade 
strains which could be further subdivided into 10 distinct subtypes by spoligotyping. In 
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6 out of 12 (50%) cases, VNTR-defined clusters were further subdivided by 
spoligotyping, whereas 7 out of 18 (39%) spoligotyping defined cases were further 
subdivided by VNTR typing (Filliol et al. 2000). This study shows that a secondary 
typing method is needed to subdivide this Glade. Further studies using additional VNTR 
loci may allow for more discrimination of strains in this group. 
9.3.4 Being family 
The "Beijing Family" of Mycobacterium tuberculosis isolates have shown little genetic 
diversity by several typing techniques (van Soolingen et al. 1995). This group of 
genetically related strains are the predominant strains in China and are highly prevalent 
in South-East Asia (Torrea et al. 1995, Palittapongarnpim et al. 1997). Van Soolingen 
et al. reported that strains of the Beijing family were found to dominate in China and 
surrounding countries, including Korea, Mongolia and Thailand whereas Beijing strains 
were rarer in the Middle East, Africa, south America and Europe. The Beijing family of 
strains was defined as containing only 9 of the 43 spacer sequences by spoligotyping 
and a 3.6kb PvuII fragment by IS1081 fingerprinting (van Soolingen et al. 1995). All 
Beijing stain families have a deletion that includes spacers 1-34, but they also have 
multiple IS6110 insertions (15 to 21) (Beggs et al. 2000). In 1999, Kremer et al. 
compared the degree of discriminatory power of several different typing methods in a 
interlaboratory study of 90 strains of Mtuberculosis. The eight "Beijing family" 
strains investigated as part of this study originated from four Southeast Asian countries 
and South Africa and were identical when evaluated with six genetic markers. The 
IS6110 and spoligotyping patterns of these strains were clearly distinct and the VNTR 
profiles (Profile number 42435) were identical and distinct from all other strains. It is 
postulated that these strains, although disseminated globally, have expanded clonally 
from a recent common ancestor. (Kremer et al. 1999). The Beijing strain of M. 
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tuberculosis is reported most commonly in the Beijing area of China, accounting for 
92% of strains. These strains have been dominant since the 1950's and have remained so 
in the 1990's in East Asia (van Soolingen et al. 1995, Qian et al. 1999). 70% of strains 
from M. tuberculosis isolates in Hong Kong represent the Beijing genotype. (Chan et al. 
2001) Anh et al. recently reported that 53% of new tuberculosis cases from Vietnam 
were the Beijing genotype and were associated with patients of a younger age and, in 
isolates from Ho Chi Minh City, with resistance to isoniazid and streptomycin. (Anh et 
al. 2000). Prodinger et al. found the Beijing genotype in 44% of 204 M. tuberculosis 
isolates from Thailand (Prodinger et al. 2001). These figures are consistent with the 
original description of the Beijing family of strains in 1995, where 37% of Thai isolates 
were Beijing family strains (van Soolingen et al. 1995) and a subsequent IS6110 RFLP 
analysis of 80/211(38%) isolates from central Thailand collected in 1994-1995 which 
belonged to the Beijing family (Palittapongarnpim et al. 1997) Members of the Beijing 
genotype have increasingly been found outside of Asia, in particular in South Africa 
and the United States where they have been implicated in several outbreaks. (van 
Soolingen 2001). The incidence of the Beijing family strains have been found to 
varying degrees in other geographical areas. 
In Saudi Arabia only 2.3% of strains belonged to the Beijing Family. 5.3% of strains 
typed as Beijing family in a study of 118 cases from northern England (Gasgoyne-Binzi 
et al. 2001). No Beijing family strains were detected in molecular epidemiological 
investigations in Tanzania (Barlow et al. 2001) or from Sicily (Filliol et al. 2001). 
Among the Queensland strains investigated, 36 (8%) of strains were Beijing family 
strains. Of these 36 patients, 12 were from South East Asian countries, 10 were from 
Papua New Guinea, 10 were Caucasians and 2 were indigenous Australians. A variant 
of the Beijing family which differs by one allele at ETR-E, profile 42436, previously 
reported from Vietnam (Bifani et a!. 1999) was another clustered strain from the 
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Queensland study accounting for 5.5% of all strains investigated. This Beijing variant 
was isolated from 11 patients, 10 patients from Papua New Guinea and from one 
Australian born patient. .A total of 38 strains of M. tuberculosis from Papua New 
Guinea patients were typed as part of the study and 20 (53%) strains belonged to the 
Beijing family. The incidence of the Beijing family strains in Papua New Guinea is 
extremely high and equal to that reported from Vietnam (Anh et al. 2000). Le et al. 
found 80% of 168 strains in South Vietnam were the Beijing Genotype and significantly 
associated with younger aged patients (Le et al. 2000). Such evidence suggests that the 
Beijing genotype is emerging as an important component of the tuberculosis 
transmission pattern in Vietnam. A recent report of 119 pulmonary isolates of 
Mtuberculosis in the Archangel Oblast, Russia from 1998 and 1999 found 44.5% of 
strains were of the Beijing Genotype with 43.4% of these strains being multidrug 
resistant. (Toungoussova et al. 2002) In an earlier report of M. tuberculosis isolation 
between 1995-1997 from 74 patients in the Archangel Oblast, only 8.1% of strains were 
the Beijing genotype suggesting that the present high incidence represents recent 
transmission. (Toungoussova et al. 2002). A study by Caminero et al, in the Gran 
Canaria Island gives further support to the ability of this genotype to rapidly 
disseminate in a community. In this study from 1993-1996,566 Mtuberculosis isolates 
were analysis by IS6110 RFLP. The largest cluster contained 75 cases and was caused 
by a strain of the Beijing genotype which was introduced in 1993. It was subsequently 
found increasingly from 5.5% of patients 1993,8.1% in 1994,16.4% in 1995 and 
27.1% of patients in 1996 (Caminero et al. 2001). The "W" strain , which caused a 
large outbreak of multidrug resistant tuberculosis in New York City and other cities in 
the United States and which accounted for 25% of all multidrug resistant cases in the 
1990s also belongs to the Beijing family (Bifani et a!. 1996, Bifani et al. 1999). The 
Beijing genotype has been documented to be associated with drug resistant tuberculosis 
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in Europe and South Africa (Portaels et al. 1999, van Rie et al. 1999). These reports 
and the results from the present study of Queensland strains document the Beijing 
genotype as the predominant strain found in distinct geographic locations. One 
potential explanation for this is that these strains have selective advantages over other 
Mtuberculosis genotypes in the ability to gain resistance and to interact with the host 
immune defence system (Glynn et al. 2002). Chance would predict that a few strains 
would eventually emerge as predominant in any given population, but this cannot 
explain how a single genotype has become predominant in many different, 
geographically separate populations. This implies that the Beijing genotype may have 
some advantage over other strains in its ability to be transmitted and cause disease. Anh 
et al. (2000) reported that Beijing family isolates were more commonly isolated from 
patients vacinated with BCG suggesting that BCG-induced immunologic protection 
may not protect against these strains (Anh et al. 2000). Other researchers have argued 
against any selective advantage, as Beijing isolates have spread widely in the United 
States, where BCG vaccination is not used (Bifani et al. 2002). However, BCG 
vaccination may accelerate the dominance of this family in regions once the strains 
have been introduced (Drobniewski et al. 2002). VNTR analysis will be a useful tool in 
monitoring further outbreaks of Beijing genotypes or in detecting any increase in the 
Beijing genotype in a given population. 
9.3.5 Other common profiles 
A predominant VNTR family of strains of Mycobacterium tuberculosis has been 
reported from South Asian patients. Gascoyne-Binzi et al. found profile 42235 to be a 
heterogeneous group of strains which predominates in patients from India and Pakistan. 
In this Queensland study, 5 patients were identified with profile 42235. Three of these 
patients were of Indian subcontinent origin, one patient was Iranian and another was 
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Australian born. 11 patients in this study shared profile 46464. Five of these patients 
were from the Philippines, one Malaysian, three from Papua New Guinea and two were 
Australian born. Of the 201 MTBC isolates investigated as part of this study only four 
strains were identified as Mafricanum and all strains shared the profile 46464. 
VNTR typing provides a useful platform to monitor distinct geographical populations 
for evidence of increased transmissions of a particular strain. It is important to ascertain 
whether the common circulating strains in a population are a result of virulence factors 
associated with a particular strain, host or environmental factors and more long term 
studies are required to determine increased rates of transmission amongst circulating 
strains in a population. Studies using VNTR have proved useful in determining genetic 
relationships between M tuberculosis strains (Namwat et al. 1998, Frothingham et al. 
1999). VNTR typing is not as discriminatory as the standard IS6110 RFLP typing 
(Frothingham et al 1998, Kremer et al. 1999) but provides for a rapid reproducible 
typing profile which serves a useful first step approach to strain discrimination and 
conventional contact tracing. VNTR typing however, is particularly useful for isolates 
with low copy numbers of IS6110 (Namwat et al. 1998). It is evident that a unique 
VNTR profile is evidence that transmission is not clustered among patients. In these 
cases no secondary typing method is warranted. VNTR typing is a useful tool in 
monitoring the incidence and transmission of clonal strains such as the Beijing family 
and provides a means of rapidly assessing any increase of transmission within a 
geographical region associated with this clone. This method has the ability to identify 
potential multi-drug resistant strains rapidly according to VNTR clusters. In this study 
almost 50% of strains were clustered amongst the Beijing and Haarlem families and 
variants by VNTR typing but clearly targeting additional polymorphic loci is needed to 
improve its discriminatory power. The addition of ETR F and MIRU loci to the VNTR 
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profile to generate a9 digit profile showed a significant increase in discriminatory 
power when applied to 77 strains of MTB isolated in Queensland in 2002. Using the 
additional loci both Beijing and Haarlem family strains could be readily differentiated 
into distinct profile clusters. The greatly improved discrimination of common family 
strains with the ETR/MIRU VNTR analysis reduces the need for secondary typing 
strategies to confirm clustering of strains. 
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Chapter 10 General discussion 
This study highlights the developments in tuberculosis diagnosis which have enhanced 
mycobacteriology services in wealthy countries over the last decade. Current diagnostic 
techniques for tuberculosis in all its forms are too slow, too expensive, and are ill- 
adapted to conditions in developing countries which bear the highest burden of 
tuberculosis. The major reasons for the current tuberculosis pandemic are the lack of an 
effective vaccine, the means to diagnose infection quickly and accurately and drugs 
specifically targeting the organism in the host. Diagnosis, in the majority of the world 
still relies on the 100 year old technique of acid-fast microscopy (Perkins 2000). 
Globally, DOTS has been endorsed by WHO as the preferred model for the monitoring 
and treatment of tuberculosis. (Bayer et al. 1995). The most controversial element of 
the DOTS model is reliance upon sputum microscopy, not culture for diagnosis. The 
two major drawbacks of microscopy are its insensitivity and inability to identify drug- 
resistant strains of TB (Iseman 2002). Sputum microscopy is insensitive, requires 
multiple visits, performs poorly in many HIV-coinfected patients and is inadequate for 
paediatric or extrapulmonary tuberculosis (Perkins et al. 2002). Microscopy in 
developing nations is typically performed on unconcentrated sputum using ZN stains. 
Unfortunately, this system only detects patients with very extensive, typically cavitary 
lung disease (Iseman 2002). Inability to detect drug resistance is the other drawback of 
microscopy. In the DOTS model, drug resistance is inferred by failure to respond to 
treatment, typically after 6 months of therapy. The obvious problems which arise from 
this approach are progressive damage to the lungs, even death from uncontrolled 
disease and or ongoing transmission of drug resistant organisms. 
One of the most important technical advances for mycobacterial laboratories has been 
the development of nucleic acid amplification assays for the detection of M. 
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tuberculosis DNA in clinical specimens. However, this study and previous reports have 
found nucleic acid amplification more sensitive than microscopy but less sensitive than 
culture (Pfyffer 1999, Roth et al. 1997). From a diagnostic point of view, tuberculosis 
remains a low prevalence condition in developed countries and the fastest way to 
improve test performance in these countries is to select patients for testing in whom 
results will have a high predictive value (Perkins 2000). 
Since this work was started there have been a large number of reports on the use of 
molecular methods for identification and typing of MTB. In November 2002 an entire 
issue of the CDC journal Emerging Infectious Diseases (Volume 8, No 11, November 
2002) was devoted to this disease which emerged some 15,000 to 35,000 years ago, in 
an effort to understand the transmission dynamics (Navin et al. 2002). In 1996, CDC 
established the national tuberculosis and genotyping network in the United States to 
perform a prospective five year study on the usefulness of genotyping Mycobacterium 
tuberculosis isolates to TB control programmes (Crawford et al. 2002). The results of 
that study have now been published and a major weakness in the programme was the 
variability in the IS6110 fingerprinting method and the difficulty of combining and 
analyzing DNA fingerprint images from multiple laboratories (Bradden et al. 2002). 
Approximately 20 percent of all isolates constituted low copy numbers (i. e. less than 
six) of IS6110 strains which are not well discriminated by this method. (Bradden et al. 
2002). The subjective nature of genotype interpretation and lack of specificity for some 
isolates may have resulted in some patients being misclassified as clustered or not 
(Crawford et al. 2002). In addition, the stability of IS6110 RFLP fingerprinting and its 
adequacy for tracking epidemiological links remains under debate based on studies of 
the rates of IS6110 changes in serial patient isolates (Alito et al. 1999, Cave et al. 1994, 
de Boer et al. 1999, Savine et al. 2002). McNabb et al. (2002) reported another major 
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limitation was the time required for obtaining results. In order for DNA fingerprinting 
to provide value to routine contact investigations, molecular data must be available in a 
timely manner such that the information can be used by tuberculosis programme 
managers in the investigation of clusters (Mc Nabb et al. 2002). 
MIRU-VNTR typing has recently been proposed as a new basis for global analysis of 
MTB molecular epidemiology and population genetics (Mazars et al. 2001). MIRU loci 
have shown greater stability than IS6110 RFLP patterns (Savine et al. 2002), they have 
a discriminatory power close to that of IS6110 RFLP (Supply et al. 2001), and perform 
significantly better than IS6110 RFLP when strains contain a low copy number of 
IS6110 (Supply et al. 2000). The stability of these loci may help clarify the definition of 
exogenous reinfection, which is currently based on observation of changes of at least 
three or four bands in IS6110 patterns (Warren et al. 2002). This issue is particularly 
important for accurate estimation of success rates of tuberculosis control programmes 
and for the evaluation of clinical trials of new therapies (Savine et al. 2002) This 
approach has several advantages over IS6110 RFLP typing in that it is PCR based and 
can be performed on mycobacterial colonies without extensive extraction protocols and 
requires sizing of amplified products only by gel electrophoresis. The method has 
successfully been automated by combining analysis of multiplex PCRs on a 
fluorescence based DNA analyser (Supply et al. 2001). 
MIRU analysis alone shows greater discrimination than VNTR typing targeting ETR A- 
E (Supply et al. 2001). The major problem with MIRU analysis is that it cannot be 
directly related to other studies on VNTR typing because of the different loci targeted.. 
The 12 polymorphic loci targeted by MIRU analysis are all not as polymorphic as ETR 
A-E. Each of the ETR loci contain at least six alleles (Frothingham et al. 1998). In 
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contrast, some of the MIRU loci are reported to demonstrate only 2 or 3 alleles (e. g. 
MIRU 2,20,24,27). It would appear counter- productive to implement a typing 
scheme which would selectively exclude the more polymorphic VNTR loci. Cowan et 
al. has suggested that MIRU typing could become more discriminative by the addition 
of ETR loci A-C (Cowan et al. 2002). Clearly such an approach would improve the 
discriminatory power of the method but would require fifteen individual PCR reactions 
for each strain. Although this approach could provide useful epidemiological 
information in real-time it would require significant labour and reagent costs. The 
approach used in this study combined the ETR loci and the more polymorphic MIRU 
loci in order to use the simplest approach to achieve maximal epidemiological 
information. In this study, ETR F and three MIRU loci 10,16 and 40 were selected 
because of their numbers of polymorphic alleles and that the described primer set 
utilised the same PCR conditions as ETR A-E (Mazars et al. 2000). A major advantage 
of VNTR typing is the ability to readily identify the clonal family strains including the 
Haarlem and Beijing clades which are identified by characteristic spoligotypes. The 
MIRU loci used in addition to ETR A-E allowed for good discrimination amongst both 
Beijing and Haarlem family strains. This strategy provides a useful platform to monitor 
distinct geographical populations for evidence of increased transmissions of a particular 
strain. It is important to ascertain whether the common circulating strains in a 
population are a result of virulence factors associated with a particular strain or host and 
or environmental factors. 
The results of this study support the combined use of ETR and MIRU loci as an 
efficient alternative to IS6110 RFLP or MIRU analysis alone as an exclusion/inclusion 
method for tracking ongoing transmission. In cases where ETR/MIRU VNTR profiles 
are identical, IS6110 RFLP could be used as a second line analysis to investigate 
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potential epidemiological links between isolates. The two-step strategy would be 
expected to increase the accuracy of outbreak investigations and to considerably 
accelerate epidemiological studies of M. tuberculosis in real time. Whichever method is 
applied for global epidemiology of tuberculosis it needs to be easily performed by all 
public health laboratories and consistently over a long period. 
10.1 Future Developments 
Mycobacterium tuberculosis, is one of the most successful and scientifically 
challenging pathogens of all time. The complete 4.41Mb genome sequence is available 
for H37Rv, the paradigm strain for the slow-growing M. tuberculosis complex. 
Bioinformatic analysis led to the identification of approximately 4000 genes in the 
genome sequence, and provided fresh insight into the biochemistry, physiology, genetic 
and immunology of the tubercule bacilli (Cole et al. 1998). Information obtained is 
catalysing the conception of new therapeutic measures against tuberculosis, and 
enhancing our understanding of the biology of the aetiologic agent. Functional genomic 
approaches are increasingly being utilised to translate this linear sequence information 
into new therapies and diagnostics. Such strategies include the study of transcriptional 
regulation using DNA microarrays and differential protein expression using proteomics. 
10.2 DNA arrays 
DNA arrays are miniaturized checkerboards, each square containing a spot of DNA 
representing an individual gene and in sum representing the entire bacterial genome. 
An array that represents the entire genome of M. tuberculosis is 20x 20mm, and contains 
one spot for each of the 3924 genes of Mtuberculosis. (Small et al. 1999). 
This technique allows detection of genetic variation at various genomic sites 
simultaneously by analysis of hybridization of mycobacterial DNA on high-density 
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oligonucleotide arrays containing thousands of DNA oligonucleotides on a limited 
surface. This technology has successfully been applied for monitoring gene expression 
and screening of mutations and polymorphisms in several human and viral genes. 
(Kozal et al. 1996, Lockhart et al. 1996). This approach has been used to examine the 
genetic variation amongst M. bovis BCG vaccine daughter strains in comparison with 
H37Rv (Gordon et al. 1999). Troesch et al. has exploited the use of DNA arrays to 
interrogate the sequence of regions from the 16SrRNA and rpoB loci to simultaneously 
identify and determine rifampicin resistant alleles. (Troesch et al. 1999) Other 
investigators have used mycobacterial DNA arrays for simultaneous genotyping and 
species identification (Gingeras et al. 1998). With these arrays, it would be possible to 
compare different strains of M. tuberculosis. This approach could be used to develop 
new diagnostics to differentiate individuals who are affected with tuberculosis from 
those already vaccinated. 
10.3 Proteomics 
The vast amount of information generated by the various genome sequencing projects 
has set the framework for experimentation and data analysis at genome-wide scales to 
fully elucidate the biology of M. tuberculosis. Proteomics analyses the complement of 
proteins expressed by a genome. Unlike genomes, proteomes are dynamic and change 
with tissue and time. Proteomics is a useful approach to identify immunodominant 
molecules. Through the use of 2-D protein maps of the subcellular fractions of 
Mtuberculosis, recent publications have demonstrated the feasibility of developing a 
tuberculosis antigen test in either sputum or serum to detect M. tuberculosis infection in 
a suspected patient and to monitor response to drug treatment. (Landowski et al. 2001) 
Landowski et al. suggest that immunodetection of elevated levels of circulating antigen 
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85 (Ag85) in serum by dot immunoblotting could provide a simple, rapid, and 
inexpensive diagnostic test for active tuberculosis. 
10.3 Future Challenges 
These major technical advances using array technology or proteomics may improve our 
ability to detect Mtuberculosis by detecting DNA or measuring protein expression. 
Additional technical progress is needed to refine, simplify and improve the performance 
of new TB diagnostics and to adapt them to laboratory conditions in developing 
countries. However, as none of the recently developed methods are ideal either due to a 
lack of sensitivity, resistance mechanisms which cannot be determined for all strains, 
strain discrimination methods which either over predict transmission or lack 
discriminatory power makes it evident that different tools will need to be applied to 
diagnose tuberculosis more efficiently in the future. 
160 
References 
1. Abe C, Hosojima S, Fukasawa Y, Kazumi Y, Takahashi M, Mori T. Comparison of 
MB-Check, BACTEC, and egg-based media for recovery of mycobacteria. J Clin. 
Microbiol 1992; 30: 878-81 
2. Al-Kassimi FA. Review of tuberculosis in Saudi Arabia. Saudi Med J 1994; 15: 
192-195 
3. Al-Rubaish AM, Madania AA, Al-Muhanna FA. Drug resistance pulmonary 
tuberculosis in the Eastern Province of Saudi Arabia. Saudi Med J 2001; 22: 776- 
779 
4. Al-Orainey IO, Saeed ES, El-Kassimi FA, Al-Shareef N. Resistance to 
antituberculosis drugs in Riyadh, Saudi Arabia. Tubercule 1989; 70: 207-10 
5. Altamirano M, Kelly A, Wong A, Bessuille E, Black W, Smith J. Characterization 
of a DNA probe for detection of Mycobacterium tuberculosis complex in clinical 
samples by polymerase chain reaction. J Clin Microbiol 1992; 30: 2173-2176 
6. An Q, Buxton A, Hendricks A, Robinson L, Shah J, Lu L, Vera-Garcia M, King W, 
Olive DM. Comparison of amplified Qß replicase and PCR assays for detection of 
Mycobacterium tuberculosis. J Clin Microbiol 1995; 33: 860-867. 
161 
7. Anh DD, Borgdorff MW, Van LN, Lan NT, Van Gorkom T, Kremer K, van 
Soolingen D. Mycobacterium tuberculosis genotype Beijing emerging in Vietnam. 
Emerg Infect Dis 2000; 6: 302-305. 
8. Anon. National action plan to combat multiple-drug resistant tuberculosis. MMWR 
1992; 41: 11 
9. Anon. Global Project on Antituberculosis Drug resistance Surveillance. Guidelines 
for surveillance of drug resistance in tuberculosis. 2001 WHO/CDS/TB 2001. 
Geneva: World Health Organization. 
10. Ausina V, Gamboa F, 1 Gazapo E, Manterola JM, Lonca J, Matas L, Manzano JR, 
Rodrigo C, Cardona PJ, Padilla E. Evaluation of the semiautomated Abbott LCx 
Mycobacterium tuberculosis assay for direct detection of Mycobacterium 
tuberculosis in respiratory specimens. J Clin Microbiol 1997; 35: 1996-2002. 
11. Aranez A, Liebana E, Pickering X, Novoa C, Mateos, A, Dominguez. Use of 
polymerase chain reaction in the diagnosis of tuberculosis in cats and dogs. 
Veterinary Record. 1996; 138: 276-280 
12. Banjeree A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins 
D, de Lisle G, Jacob WR. Jr. inhA, a gene encoding a target for isoniazid and 
ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-230 
13. Barany F. Genetic disease detection and DNA amplification using cloned 
thermostable ligase. Proc Natl Acad Sci USA 1991; 88: 189-193 
162 
14. Barlow REL, Gascoyne-Binzi DM, Gillespie SH, Dickens A, Qamer S, Hawkey 
PM. Comparison of variable number tandem repeat and IS6110-restriction fragment 
length polymorphism analyses for discrimination of high-and Low-copy-number 
IS6110 Mycobacterium tuberculosis isolates. J Clin Microbiol 2001; 39: 2453-2457 
15. Bassam BJ, Allen T, Flood S, Stevens J, Wyatt P, Livak KJ. Nucleic acid sequence 
detection systems: Revolutionary automation for monitoring and reporting PCR 
products. Australasian Biotechnology 1996; 6: 285-294 
16. Bartfai Z, Somoskovi A, Kodmon C, Szabo N, Puskas E, Kosztolanyi L, Farago E, 
Mester J, Parsons L, Salfinger M. Molecular characterization of rifampin-resistant 
isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the 
Line Probe Assay. J Clin Microbiol 2001; 39: 3736-3739 
17. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an 
idea. Lancet 1995; 345: 1545-1548 
18. Beavis KG, Lichty MB, Jungkind DL, Giger 0. Evaluation of Amplicor PCR for 
direct detection of Mycobacterium tuberculosis from sputum specimens. J Clin 
Microbiol 1995; 33: 2582-86 
19. Beggs ML, Eisenach KD, Cave MD. Mapping of IS6110 insertion sites in two 
epidemic strains of Mycobacterium tuberculosis. J Clin Microbiol 2000; 38: 2923- 
2938 
163 
20. Behr MA, Hopewell PC, Paz A, Kawamura LM, Schecter GF, Small PM. 
Predictive value of contact investigations for identifying recent transmission of 
Mycobacterium tuberculosis. Am J Respir Crit Care Med 1998; 158: 465-469 
21. Bengard Andersen A, Hansen EB. Structure and mapping of antigenic domains of 
protein gene b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis. 
Infect Immun 1989; 57: 2481-2488 
22. Benjamin WH, Waites KB, Beverly A, Gibbs L, Waller M, Nix S, Moser SA, 
Willert M. Comparison of the MB/BacT system with a revised antibiotic 
supplement kit to the BACTEC 460 system for detection of mycobacteria in clinical 
specimens. J Clin Microbiol 1998; 36: 3234-3238 
23. Benjamin WH Jr., Lok KH, Harris R, Brook N, Bond L, Mulcahy D, Robinson N, 
Pruitt V, Kirkpatrick DP, Kimerling DP, Kimerling ME, Dunlap NE. Identification 
of a contaminating Mycobacterium tuberculosis strain with a transposition of an 
IS6110 insertion element resulting in an altered spoligotype. J Clin Microbiol 2001; 
39: 1092-1096 
24. Bifani PJ, Plikaytis BB, Kapur V, Stockbauer K, Pan X, Lutfey ML, Moghazeh SL, 
Eisner W, Daniel TM, Kaplan MH, Crawford JT, Musser JM, Krieswirth BN. 
Origin and interstate spread of a New York City multi-drug resistant 
Mycobacterium tuberculosis clone family. JAMA 1996; 275: 452-457. 
25. Bifani PJ, Nathema B, Liu Z, Moghazeh SL, Shopsin B, Tempalski B, Driscoll J, 
Frothingham R, Musser JM, Alcabes P, Kreiswirth BN. Identification of aW variant 
164 
outbreak of Mycobacterium tuberculosis via population-based molecular 
epidemiology. JAMA 1999; 282: 2321-2327 
26. Bifani P, Moghazeh S, Shopsin B, Driscoll J, Ravikovitch A, Kreiswirth B. 
Molecular characterization of Mycobacterium tuberculosis H37Rv/Ra variants: 
Distinguishing the mycobacterial strain. J Clin Microbiol 2000; 38: 3200-3204. 
27. Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN. Global dissemination of the 
Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002; 10: 
45-52 
28. Birkenmeyer L, Mushahwar IK. DNA probe amplification methods. J Virol 
Methods 1991; 35: 117-126 
29. Bishai WR, Graham NMH, Harrington S, Pope DS, Hooper N, Astemborski J, 
Sheely L, Vlahov D, Glass GE, Chaisson RE. Molecular and geographic patterns of 
tuberculosis transmission after 15 years of directly observed therapy. JAMA 1998; 
280: 1679-1684 
30. Bloom, B. R., Murray, C. J. L. Tuberculosis: Commentry on a reemergent killer. 
Science 1992; 257: 1055-64 
31. Bloom BR (ed). 1994 Tuberculosis: Pathogenisis, protection and control. ASM 
press, Washington DC. 
165 
32. Boddinghaus B, Rogall T, Flohr T, Blocker H, Bottger EC. Detection and 
identification of mycobacteria by amplification of rRNA. J Clin Microbiol 1990; 28: 
1751-1759 
33. Boddinghaus B, Wichelhaus TA, Brade V, Bittner T. Removal of PCR inhibitors by 
silica membranes: Evaluating the Amplicor Mycobacterium tuberculosis kit. J Clin 
Microbiol 2001; 39: 3750-3752 
34. Bradden CR, Templeton GL, Cave MD, Valway S, Onorato IM, Castro KG, Moers 
D, Yang Z, Stead WW, Bates JH. Interpretation of restriction fragment length 
polymorphism analysis of Mycobacterium tuberculosis isolated from a state with a 
large rural population. J Infect Dis 1997; 175: 1446-1452 
35. Bradden CR, Crawford JT, Schable BA. Quality Assessment of Mycobacterium 
tuberculosis genotyping in a large laboratory network. Emerg Infect Dis 2002; 8: 
1210-1215 
36. Bradley S P, Reed S L, Catanzaro A. Clinical efficacy of the amplified 
Mycobacterium tuberculosis direct test for the diagnosis of pulmonary tuberculosis. 
Am J Respir Crit Care Med 1996; 153: 1606-1610 
37. Brundney K, Bobkin J. Resurgent tuberculosis in New York City: human 
immunodeficiency virus, homelessness, and the decline of tuberculosis control 
programs. Am Rev Respir Dis 1992; 144: 745-749 
166 
38. Burczak JD, Ching SF, Hu HY, Lee H. 1995 Ligase chain reaction for the detection 
of infectious Agents. In: Molecular methods for Virus Detection. eds. Wiedbrauk D, 
and Farkas DH. Academic Press Inc. 
39. Butcher PD, Hutchinson NA, Doran TJ, Dale JW. The application of molecular 
techniques to the diagnosis and epidemiology of mycobacterial diseases. J App 
Bacteriol 1996; 81: 53S-71S 
40. Caminero JA, Pena MJ, Campos-Herrero MI, Rodriguez JC, Garcia I, Cabrera P, 
Lafoz C, Samper S, Takiff H, Alfonso 0, Pavon JM, Torres MJ, van Soolingen D, 
Enarson DA, Martin C. Epidemiological evidence of the spread of a Mycobacterium 
tuberculosis strain of the Beijing Genotype on Gran Canaria Island. Am J Respir 
Crit Care Med 2001; 164: 1165-1170 
41. Carpentier E, Drouillard B, Dailloux M, Moinard D, Vallee E, Dutilh B, Maugein J, 
Bergogne-Berezin E, Carbonnelle B. Diagnosis of Amplicor Mycobacterium 
tuberculosis test: a multicenter study. J Clin Microbiol 1995; 33: 3106-3110. 
42. Cartuyvels R, De Ridder C, Jonckheere S, Verbist L, Van Eldere J. Prospective 
clinical evaluation of Amplicor Mycobacterium tuberculosis PCR test as a screening 
method in a low-prevalence population. J Clin Microbiol 1996; 34: 2001-2003 
43. Cave MD, Eisenach K, Templeton G, Salfinger M, Mazurek G, Bates JH, Crawford 
JT. Stability of DNA genotype pattern produced with IS6110 in strains of 
Mycobacterium tuberculosis. J Clin Microbiol 1994; 32: 262-266 
167 
44. Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A. Characterization of rpoB mutations 
in rifampicin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey 
by DNA sequencing and line probe assay. J Clin Microbiol 2002; 40: 4435-4438 
45. Centres for Disease Control and Prevention. Provisional cases of selected notifiable 
diseases, United States, weeks ending Dec27,1997 and Dec 28,1996 (52nd week). 
Morbid Mortal Weekly Rep 1997; 46: 1261 
46. Chan MY, Borgdorff M, Yip CW, de Haas PE, Wong WS, Kam KM, van Soolingen 
D. Seventy percent of Mycobacterium tuberculosis isolates in Hong Kong represent 
the Beijing genotype. Epidemiol Infect 2001; 127: 169-17. 
47. Ching S, Lee H, Hook EW, Jacobs NR, Zenilman J. Ligase chain reaction for the 
detection of Neisseria gonorrhoea in urogenital swabs. J Clin Microbiol 1995; 33: 
3111-3114 
48. Chretien J. Propos. Vol 1.1998 Andre Harle- Bethune, France 
49. Clarridge JE, Shawar RM, Shinnick TM, Plikaytis BB. Large-scale use of 
polymerase chain reaction for the detection of Mycobacterium tuberculosis in a 
routine mycobacteriology laboratory. J Clin Microbiol 1993; 31: 2049-2056. 
50. Collins, F. M. The immunology of Tuberculosis. Am Rev Respir Dis 1982; 125: 42- 
49 
168 
51. Colville A. Retrospective review of culture-positive mycobacterial lymphadenitis 
cases in children in Nottingham, 1979-1990. Eur J Clin Microbiol Infect Dis 1993; 
12: 192-195 
52. Cowan LS, Mosher L, Diem L, Massey JP, Crawford JT. Variable-number tandem 
repeat typing of Mycobacterium tuberculosis isolates with low copy numbers of 
IS6110 by using mycobacterial interspersed repetitive units. J Clin Microbiol 2002; 
40: 1592-1602. 
53. Cooksey RC, Morlock GP, Glickman S. and Crawford JT. Evaluation of a line 
probe assay kit for characterization of rpoB mutation in rifampicin-resistant 
Mycobacterium tuberculosis isolates from New York City. J Clin Microbiol 1997; 
35: 1281-1283 
54. Crawford JT, Braden CR, Schable BA, Onorato IM. National tuberculosis 
genotyping and surveillance network: Design and methods. Emerg Infect Dis 2002; 
8: 1192-1196 
55. Cutler RR, baithun SI, Doran HM, Wilson P. Association between the histological 
diagnosis of tuberculosis and microbiological findings. Tuber Lung Dis 1994; 75: 
75-79 
56. Dale JW, Mat Nor R, Ramayah S, Tang TH, Zainuddin ZF. Molecular 
epidemiology of tuberculosis in Malaysia. J Clin Microbiol 1999; 37: 1265-1268 
169 
57. D'Amato RF, Wallman AA, Hochstein LH, Colaninno PM, Scardamaglia M, Ardila 
E, Ghouri M, Kim K, Patel RC, Miller A. Rapid diagnosis of pulmonary 
tuberculosis by using Roche Amplicor Mycobacterium tuberculosis PCR test. J Clin 
Microbiol 1995; 33: 1832-1834 
58. Dandapat MC, Mishra BM, Dash SP, Kar PK. Peripheral lymph node tuberculosis: a 
review of 80 cases. Br J Surg 1990; 77: 911-912 
59. Daniel TM. The rapid diagnosis of tuberculosis: a selective review. J Lab Clin 
Microbiol 1990; 116: 277-82 
60. Davis J. Inactivation of antibiotics and the dissemination of resistance genes. 
Science 1994; 264: 375-382 
61. de Barbeyrac B, Rodriguez P, Dutilh B, Le Roux P, Bebear C. Detection of 
Chlamydia trachomatis by ligase chain reaction compared with polymerase chain 
reaction and cell culture in urogenital specimens. Genitourin Med 1995; 71: 382-6 
62. de Boer AS, Borgdorff MW, de Haas PEW, Nagelkerke NJD, van Embden JDA, 
van Soolingen D. Analysis of rate of change of IS6110 RFLP patterns of 
Mycobacterium tuberculosis based on serial patient isolates. J Infect Dis 1999; 180: 
1238-1244 
63. de Beenhouwer H, Lhiang Z, Jannes G, Mijs W, Machtelinckx L, Rossau R, Traore 
H, Portaels F. Rapid detection of rifampicin resistance in sputum and biopsy 
170 
specimens from tuberculosis patients by PCR and line probe assay. Tubercule 
1995; 76: 425-430 
64. Desjardin LE, Chen Y, Perkins MD, Teixeira L, Cave MD, Eisenach KD. 
Comparison of the ABI 7700 system (TaqMan) and competitive PCR for 
quantification of IS6110 DNA in sputum during treatment of tuberculosis. J Clin 
Microbiol 1998; 36: 1964-1968 
65. Dessen A, Quemard A, Blanchard JS, Jacobs WR Jr, Sacchettini JC. Crystal 
structure and function of the isoniazid target of Mycobacterium tuberculosis. 
Science 1995; 267: 1638-1641 
66. Diaz ML, Herrera T, Lopez-Vidal Y, Calva JJ, Hernandez R, Palacios GR, Sada E.. 
Polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA in 
tissue and assessment of its utility in the diagnosis of hepatic granulomas. J Lab 
Clin Med 1996; 127: 359-363 
67. Dille BJ, Butzen CC, Birkenmeyer LG. Amplification of Chlamydia trachomatis 
DNA by ligase chain reaction. J Clin Microbiol 1993; 31: 729-31 
68. Donnabella V, Martiniuk F, Kinney D, Bacerdo M, Bonk S, Hanna B, Rom WN. 
Isolation of the gene for the ß subunit of RNA polmerase from rifampicin-resistant 
Mycobacterium tuberculosis and identification of new mutations. Am J Respir Cell 
Mol Biol 1994; 11: 639-643. 
171 
69. Drobniewski FA, Wilson SM. The rapid diagnosis of isoniazid and rifampicin 
resistance in Mycobacterium tuberculosis -a molecular story. J Med Microbiol 
1998; 47: 198-196. 
70. Drobniewski F, Balabanova Y, Ruddy M, Weldon L, Jeltkova K, Brown T, 
Malomanova N, Elizarova E, Melentyey A, Mutovkin E, Zhakharova S, Fedorin I. 
Rifampin- and multidrug- resistant tuberculosis in Russian civilians and prison 
inmates: Dominance of the Beijing strain family. Emerg Infect Dis 2002; 8; 1320- 
1326 
71. Eisenach KD, Sifford MD, Cave MD, Bates JH, Crawford JT. Detection of 
Mycobacterium tuberculosis in sputum samples using polmerase chain reaction. 
Am Rev Respir Dis 1991; 144: 1160-1163 
72. Ellis ME, Al-Hajjar S, Bokhari H, and Qadri SMH. High proportion of multi-drug 
resistant Mycobacterium tuberculosis in Saudi Arabia. Scand J Infect Dis 1996; 28: 
591-595 
73. Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Clin 
Microbiol Rev 1996; 9: 177-215 
74. Fang Z, Forbes KJ. Mycobacterium tuberculosis preferential loicus (ipl) for 
insertion into the genome. J Clin Microbiol. 1997; 35: 479-481 
172 
75. Filliol I, Ferdinand S, Negroni L, Sola C, Rastogi N. Molecular typing of 
Mycobacterium tuberculosis based on variable number of tandem DNA repeats used 
alone and in association with spoligotyping. J Clin Microbiol 2000; 38: 2520-2524 
76. Freidig EE, McClure S P, Wilson W R, Banks P M, Washington J A. Clinical 
histologic microbiologic analysis of 419 lymph node biopsy specimens. Rev Infect 
Dis 1986; 8: 322-328 
77. Frothingham R, Meeker-O'Connell WA. Genetic diversity in the Mycobacterium 
tuberculosis complex based on variable numbers of tandem DNA repeats. 
Microbiology 1998; 144: 1189-1196 
78. Frothingham R, Strickland PL, Bretzel G, Ramaswamy S, Musser JM, Williams 
DL. Phenotypic and genotypic characterization of Mycobacterium africanum 
isolates from West africa. J Clin Microbiol 1999; 37: 1921-1926. 
79. Fomukong N, Beggs M, el Hajj H, Templeton G, Eisenach K, Cave MD. 
Differences in the prevalences of IS6110 insertion sites in Mycobacterium 
tuberculosis strains: low and high copy number of IS6110. Tuber Lung Dis 1998; 
78: 109-116 
80. Forbes BA, Hicks KE. Ability of PCR assay to identify Mycobacterium tuberculosis 
in BACTEC 12B vials. J Clin Microbiol 1994; 32: 1725-1728 
81. Garcia-Quintanilla A, Gonzalez-Martin J, Tudo G, Espasa M, Jimenez de Anta MT. 
Simultaneous identification of Mycobacterium genus and Mycobacterium 
173 
tuberculosis complex in clinical samples by 5'-exonuclease fluorogenic PCR. J Clin 
Microbio12002; 40: 4646-4651. 
82. Gascoyne-Binzi, DM, Barlow REL, Frothingham R, Robinson G, Collyns TA, 
Gelletlie R, Hawkey PM. Rapid identification of laboratory contamination with 
Mycobacterium tuberculosis using variable number tandem repeat analysis. J Clin 
Microbiol 2001; 39: 69-74 
83. Gingeras TR, Ghandour G, Wang E, Berno A, Small PM, Drobniewski F, Alland D, 
Desmond E, Holodniy M, Drenkow J. Simultaneous genotyping and species 
identification using hybridization pattern recognition analysis of generic 
Mycobacterium DNA arrays. Genome Res 1998; 8: 435-438 
84. Glynn JR, Bauer J, de Boer AS, Borgdorff MW, Fine PEM, Godfrey-Faussett P, 
Vynnycky E. Interpreting DNA fingerprint clusters of Mycobacterium tuberculosis. 
Int J Tuberc Lung Dis 1999; 3: 1055-1060 
85. Glynn JR, Whitely J, Bifani PJ, Kremer K, Van Soolingen D. Worldwide 
occurrence of Beijing /W strains of Mycobacterium tuberculosis: A systematic 
review. Emerg Infect Dis 2002; 8: 843-849 
86. Godfrey-Faussett P, Stoker NG, Scott JAG, Pasvol G, Kelly P, Clancy L. DNA 
fingerprints of Mycobacterium tuberculosis do not change during the development 
of rifampicin resistance. Tubercule 1994; 74: 240-243 
174 
87. Goel MM, Ranjan V, Dhole TN, Srivastava AN, Mehrotra A, Kushwaha MR, Jain 
A. Polymerase chain reaction vs. conventional diagnosis in fine needle aspirates of 
tuberculous lymph nodes. Acta Cytol 2001; 45: 333-340. 
88. Gordon SV, Brosch R, Billault A, Gamier T, Eiglmeier K, Cole ST. Identification 
of variable regions in the genomes of tubercule bacilli using bacterial artificial 
chromosome arrays. Mol Microbiol 1999; 32: 643-655 
89. Goyal M, Young D, Zhang Y, Jenkins PA, Shaw RJ. PCR amplification of variable 
sequence upstream of katG Gene to subdivide strains of Mycobacterium 
tuberculosis complex. J Clin Microbiol 1994; 32: 3070-3071 
90. Greer C E, Petersen S L, Kiviat N B, Manos M M. PCR amplification from 
paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol 
1991; 95: 117-124. 
91. Groenen PM, Bunschoten AE, van Soolingen D, van Embden JD. Nature of DNA 
polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; 
application for strain differentiation by a novel typing method. Mol Microbiol 1993; 
10: 1057-1065. 
92. Gutierrez MC, Vincient M, Aubert D, Bizet J, Gaillot 0, Lebrun L, Le Pendeven C, 
Le Pennec MP, Mathieu D, Offredo C, Pangon B, Pierre-Audigier C. Molecular 
fingerprinting of Mycobacterium tuberculosis and risk factors for tuberculosis 
transmission in Paris, France, and surrounding area. J Clin Microbiol 1998; 36: 486- 
492. 
175 
93. Hayden JD, Ho SA, Hawkey PM. The promises and pitfalls of PCR Rev Med 
Microbiol 1991; 2: 129-37 
94. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome 
Res 1996; 6: 986-994 
95. Hermans PWM, Schuitema ARJ, van Soolingen D, Verstynen CPHJ, Bik EM, 
Thole JER, Kolk AHJ, van Embden JDA. Specific detection of Mycobacterium 
tuberculosis complex strains by polymerase chain reaction. J Clin Microbiol 1990; 
28: 1204-1213 
96. Hermans PWM, van Soolingen D, Bik EM, de Haas PEW, Dale JW, van Embden 
JDA. Insertion element IS987 from Mycobacterium tuberculosis BCG is located in 
a hot-spot integration region for insertion elements in Mycobacterium tuberculosis 
conmplex strains. Infect Immun 1991; 59: 2695-2705 
97. Hermans PW, van Soolingen D, van Embden JDA. Characterization of a major 
polymorphic tandem repeat in Mycobacterium tuberculosis and its potential use in 
the epidemiology of Mycobacterium kansasii and Mycobacterium gordonae. J 
Bacteriol 1992; 174: 4157-4165 
98. Hermans PWM, Messaddi F, Guebrexabher H, van Soolingen D, de Haas PE, 
Heersma H, de Neeling H, Ayoub A, Portaels F, Frommel D. Analysis of the 
population structure of Mycobacterium tuberculosis in Ethopia, Tunisia and the 
176 
Netherlands: usefulness of DNA typing for global tuberculosis epidemiology. J 
Infect Dis 1995; 171: 1504-1513. 
99. Heym B, Honore N, Truffot-Pernot, Banerjee A, Schurra C, Jacobs WR Jr, van 
Enbden JDA, Grosset JH, Cole ST. Implications of multidrug resistance for the 
future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 
1994; 344: 293-298. 
100. Hirano K, Abe C, Takahashi M. Mutations in the rpoB gene of rifampin- 
resistant Mycobacterium tuberculosis strains isolated mostly in asian coutries and 
their rapid detection by line probe assay. J Clin Microbiol 1999; 37: 2663-2666. 
101. Honore N, Bergh S, Chanteau S, Doucet-Populaire F, Eiglmeier K, GarnierT, 
Georges C, Launois P, Limpaiboon T, Newton S, Niang K, del Portillo P, Ramesh 
GR, Reddi P, Ridel PR, Sittisombut N, Wu-Hunter S, Cole ST. Nucleotide 
sequence of the first cosmid from the Mycobacterium leprae genome project: 
structure and function of the Rit-Str regions. Mol Microbiol 1993; 7: 207-214 
102. Hyman CL, Kamholz SL. The approach to multiple-drug-resistant tuberculosis. 
PCCU 1993; 9: 2-6 
103. Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J 2002; 
20: Suppl. 87s-94s. 
177 
104. Jarallah JS, Elias AK, Al Hajjaj MS, Bukhari MS, Al Shareef AHM, and Al- 
Shammari SA. High rate of rifampicin resistance of Mycobacterium tuberculosis in 
the Taif region of Saudi Arabia. Tubercule Lung Dis 1992; 73: 113-115 
105. Jones WD Jr, Greenberg J. Modification of methods used in bacteriophage 
typing of Mycobacterium tuberculosis isolates. J Clin Microbiol 1978; 7: 467-469. 
106. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper 
S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. Simultaneous 
detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and 
epidemiology. J Clin Microbiol 1997; 35: 907-914. 
107. Kapur V, Li 11, Mamrick MR, Plikaytis BB, Shinnick TM, Telenti A, Jacob WR 
Jr, Banerjee A, Cole S, Yuen KY. Rapid Mycobacterium species assignment and 
unambiguous identification of mutations associated with antimicrobial resistant 
Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 
1995; 119: 131-138. 
108. Kent, P. T., Kubica, G. P. Public health Mycobacteriology: A guide for the Level 
111 Laboratory. U. S. Department of Health and Human Services. 1985 Publication 
no. (CDC) 86-21654; 6: 57-68 
109. Khan MY, Kinsara AJ, Osoba AO, Wali S, Samman Y, Memish Z. Increasing 
resistance of Mtuberculosis to anti-TB drugs in Saudi Arabia. Int J Antimicrob 
Agents 2001; 17: 415-418. 
178 
110. Kheiry J, Ahmed ME. Cervical Lymphadenopathy in Khartoum. J Trop Med 
Hyg. 1992; 95: 416-419 
111. Kim BJ, Kim SY, Park BH, Lyu MA, Park IK, Bai, GH, Kim SJ, Cha CY and 
Kook CY. Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere 
with PCR-single strand conformation polynorphism analysis for rifampicin 
susceptibility testing. J Clin Microbiol 1997; 35: 492-494. 
112. Kochi A. The global tuberculosis situation and new control strategy of the 
World Health Organisation. Tubercule 1991; 72: 1-3. 
113. Kolk A, Schuitema A, Kuijper S, van Leeuwen J, Hermans PW, van Embden 
JD, Hartskeerl RA. Detection of Mycobacterium tuberculosis in clinical samples by 
using polymerase chain reaction and a nonradioactive detection system. J Clin 
Microbiol 1992; 30: 2657-2675. 
114. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, 
Morris D, Hubbell E, Chee M, Gingeras TR. Extensive polymorphisms observed in 
HIV-1 Glade B protease gene using high-density oligonucleotide arrays. Nat Med 
1996; 2: 753-759 
115. Kremer K, van Soolingen D, Frothingham R, Haas WH, Hermans PWM, Martin 
C, Palittapongarnpim P, Pilkaytis BB, Riley LW, Yakrus MA, Musser JM, van 
Embden JDA. Comparison of methods based on different molecular 
epidemiological markers for typing of Mycobacterium tuberculosis strains: 
179 
Interlaboratory study of discriminatory power and reproducibility. J Clin Microbiol 
1999; 37: 2607-2618 
116. Kupepina NE, Srevatasan S, Plikaytis BB, Bifani PJ, Connell ND, Donnelly RJ, 
van Soolingen D, Musser JM, Krieswirth BN. Characterization of the phylogenetic 
distribution and chromosomal insertion sites of five IS6110 elements in 
Mycobacterium tuberculosis: non random integhratuion in the dnaA-dnaN region. 
Tuber Lung Dis 1998; 79: 31-42 
117. Landowski CP, Godfrey HP, Bentley-Hibbert SI, Liu X, Huang Z, Sepulveda R, 
Huygen K, Gennaro ML, Moy FH, Lesley SA, Haak-Frendscho M. Combinatorial 
use of antibodies to secreted mycobacterial proteins in a host immune system- 
independant test for tuberculosis. J Clin Microbiol 2001; 39: 2418-2424 
118. Le TK, Bach KH, Ho ML, Le NV, Nguyen TN, Chevrier D, Guesdon JL. 
Molecular fingerprinting of Mycobacterium tuberculosis strains isolated in Vietnam 
using ISO 10 as probe. Tuber Lung Dis 2000; 80: 75-83 
119. Lester CW. Lymph node tuberculosis and treatment of accessable nodes. Am 
Rev Respir Dis 1951; 64: 691-694. 
120. Levy SB. Tuberculosis: Detecting multidrug resistance early. Lancet 1993; 341: 
664-665. 
121. Leowski, J. Tuberculosis control: The past, the present, the future. Bull NAT 
1988; 63: 43-45. 
180 
122. Lindbrathen A, Gaustad P, Hovig B, Tonjum T. Direct detection of 
Mycobacterium tuberculosis complex in clinical samples from patients in Norway 
by ligase chain reaction. J Clin Microbiol 1997; 35: 3248-3253. 
123. Livak KJ, Flood SAJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with 
fluorescent dyes at opposite ends provide a quenched probe system useful for 
detecting PCR product and nucleic acid hybridization. PCR Meth Appl 1995; 4: 
357-362 
124. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittman 
M, Wang C, Kobayashi M, Horton H, Brown EL. Expression monitoring by 
hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996; 14: 
1675-1680 
125. Longo MC, Berninger MS, Hartly JL. Use of uracil DNA glycosylase to control 
carryover contamination in polymerase chain reaction. Gene 1990; 93: 125-28. 
126. Lumb R, Davies K, Dawson D, Gibb R, Gottlieb T, Kershaw C, Kociuba K, 
Nimmo G, Sangster N, Worthington M, Bastian I. Multicentre evaluation of the 
Abbott LCx Mycobacterium tuberculosis ligase chain reaction assay. J Clin 
Microbiol 1999; 37: 3102-3107. 
127. Mani C, Selvakumar N, Narayanan S, Narayanan PR. Mutations in the rpoB 
gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. 
J Clin Microbiol 2001; 39: 2987-2990 
181 
128. Matsiota-Bernard P, Vrioni G, and Marinis E. Characterization of rpoB 
mutations in rifampicin-resistant clinical Mycobacterium tuberculosis isolates from 
Greece. J Clin Microbiol 1998; 36: 20-23. 
129. Mazars E, Lesjean S, Banuls A, Gilbert M, Vincent V, Gicquel B, Tibayrenc M, 
Locht C, Supply P. High-resolution minisatellite-based typing as a portable 
approach to global analysis of Mycobacterium tuberculosis molecular 
epidemiology. Proc Natl Acad Sci 2001; 98: 1901-1906 
130. McHugh TD, Gillespie SH. Nonrandom association of IS6110 and 
Mycobacterium tuberculosis: implications for molecular epidemiological studies. J 
Clin Microbiol 1998; 36: 1410-1413. 
131. McNabb SJN, Bradden CR, Navin TR. DNA fingerprinting of Mycobacterium 
tuberculosis: Lessons learned and implications for the future. Emerg Infect Dis 
2002; 8: 1314-1319 
132. Mendiola MV, Martin C, Otal I, Gicquel B. Analysis of regions responsible for 
IS6110 RFLPs in a single Mycobacterium tuberculosis strain. Res Microbiol 1992; 
143: 767-772 
133. Milaat W A, Ali A S, Afif H A, Ghabrah T M. Epidemiology of tuberculosis in 
Jeddah region, Saudi Arabia. Saudi Med J 1994; 15: 133-137. 
182 
134. Moore DF, Curry H. Detection and identification of Mycobacterium 
tuberculosis directly from sputum sediments by Amplicor PCR. J Clin Microbiol 
1995; 33: 2686-2691. 
135. Morgan MA, Horstmeier CD, DeYoung DR, Roberts GD. Comparison of 
radiometric method (BACTEC) and conventional culture media for the recovery of 
mycobacteria from smear-negative specimens. J Clin Microbiol 1983; 18: 384-388 
136. Morris S, Han Bai G, Suffys P, Portillo-Gomez, Fairchok M and Rouse D. 
Molecular mechanisms of multi drug resistance in clinical isolates of 
Mycobacterium tuberculosis. J Infect Dis 1995; 171: 954-960. 
137. Morrissey AB, Aisu TO, Falkinham JO, Eriki PP, Ellner JJ, Daniel TM. 
Absence of Mycobacterium avium complex in patients with AIDS. J Aquired 
Immune Defic Syndr 1992; 5: 477-478 
138. Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase 
catalysed reaction. Methods Enzymol. 1987; 155: 335-350 
139. Musser JM. Antimicrobial agent resistance in mycobacteria: Molecular genetic 
insights. Clin Microbiol Rev 1995; 8: 496-514 
140. Namwat W, Luangsuk P, Palittapongarnpim P. The genetic diversity of 
Mycobacterium tuberculosis strains in Thailand studied by amplification of DNA 
segmentscontaining direct repetitive sequences. Inter J Tuberc Lung Dis 1998; 2: 
153-159 
183 
141. Narita, M., Matsuzono Y., Sibata, M., Togashi, T. Nested amplification protocol 
for the detection of Mycobacterium tuberculosis. Acta Paediatr 1992; 81: 997-1001 
142. Nash KA, Gaytan A, and Inderlied CB. Detection of rifampicin resistance in 
Mycobacterium tuberculosis by means of a rapid, simple, and specific RNA/RNA 
mismatch assay. J Infect Dis 1997; 176: 533-536 
143. Naumann L, Jaeger H, Lang E, Lehn N, Linde HJ, Oros H, Pausch G, Poppinger 
J, Schwarz A, Vilsmeier S, Resischl U. Evaluation of MB Redox - comparison of a 
new liquid medium with solid media and the BACTEC 460. Lab Med 1997; 21: 31- 
34. 
144. Navin TR, McNabb SJN, Crawford JT. The continued threat of tuberculosis. 
Emerg Infect Dis 2002; 11: 1187 
145. Neimark H, Ali Baig M, Carleton S. Direct identification and typing of 
Mycobacterium tuberculosis by PCR. J Clin Microbiol 1996; 34: 2454-2459 
146. Nolte FS, Metchock B. Mycobacteria. In: Murray PR, Baron EJ, Haller MA, 
Tenover FC, Yolken RH. Eds. Manual of Clinical Microbiology, 6th ed. 1995. 
American Society for Microbiology, Washington. D. C. 
147. Noordhoek G, Kolk A, Bjune G, Catty D, Dale J, Fine P, Godfrey-Faussett P, 
Cho S, ShinnickT, Svenson S, Wilson S, van Embden J. Sensitivity and specificity 
184 
of PCR for detection of Mycobacterium tuberculosis: a blind comparison of seven 
laboratories. J Clin Microbiol 1994; 32: 277-284 
148. Nsanze H, Usmani M, Goodwin CS, Chema Y, Fletcher S. Pattern of 
Mycobacterial infections in the United Arab Emirates. Emirates Med J 1993; 
11: 108-113. 
149. Onwubalili JK. Current concepts on the immunology of tuberculosis. Post Grad 
Doc Mid East 1995; 13: 422-27 
150. Otal I, Samper S, Asensio MP, Vitoria MA, Rubio MC, Gomez-Lus R, Martin 
C. Use of a PCR method based on IS6110 polymorphismfor typing Mycobacterium 
tuberculosis strains from BACTEC cultures. J Clin Microbiol 1997; 35: 273-277 
151. Palittapongarnpim P, Luangsook P, Tansuphaswadikul S, Chuchottaworn C, 
Prachaktam R, Sathapatayavongs B. Restriction fragment length polymorphism 
study of Mycobacterium tuberculosis in Thailand using IS6110 as probe. Int J 
Tuberc Lung Dis 1997; 1: 370-376 
152. Park WH, Krumwiede C Jr. The relative importance of the bovine and human 
types of tubercule bacilli in the different forms of human tuberculosis. Am J Pathol. 
1910; 23: 205-368 
153. Perkins MD. New diagnostic tools for tuberculosis. Int J Tuber Lung Dis 2000; 
4: S182-S188 
185 
154. Pfyffer GE, Cieslak C, Welsher HM, Kissling P and ISsch-Gerdes. Comparison 
of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid 
culture for the recovery of acid-fast bacilli. J Clin Microbiol 1997; 35: 2229-2234. 
155. Pfyffer GE. Nucleic acid amplification for mycobacterial diagnosis. J Infect. 
1999; 39: 21-26. 
156. Piatek AS, Tyagi S, Pol AC, Telenti A, Miller LP, Kramer FR, Alland D. 
Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium 
tuberculosis. Nat Biotechnol 1998; 16: 359-363 
157. Plikaytis B B, Eisenach K E, Crawford J T, Shinnick T M. Differentiation of 
Mycobacterium tuberculosis and Mycobacterium bovis BCG by a polymerase chain 
reaction. Mol Cell Probes 1991; 5: 215-219. 
158. Podzorski, R. P. and Persing, D. H . 1995 Molecular 
detection and Identification 
of Microorganisms. In: Manual of Clinical Microbiology 6thed, ASM press 
Washington D. C. 
159. Popper H, Winter E, Hofler G. DNA of Mycobacterium tuberculosis in 
formalin-fixed, paraffin embedded tissues in tuberculosis and sarcoidosis detection 
by polymerase chain reaction. Am J Clin Pathol 1994; 101: 738-741 
160. Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in 
penitentiary hospitals and in the general population of the former Soviet Union. Int J 
Tuber Lung Dis 1999; 3: 362-365 
186 
161. Pretorius GS, Sirgel FA, Schaaf HS, van Helden PD, Victor TC. Rifampicin 
resistance in Mycobacterium tuberculosis - rapid detection and implications in 
chemotherapy. SAMJ 1996; 86: 50-55 
162. Prissick FH, Mason AM. Cervical lymphadenitis in children caused by 
chromogenic mycobacteria. Can Med Assoc J. 1956; 75: 798-803 
163. Prodinger WM, Bunyaratvej P, Prachaktam R Pavlic M. Mycobacterium 
tuberculosis isolates of Beijing genotype in Thailand. Emerg Infect Dis 2001; 7: 
483-484 
164. Qian L, Van Embden JD, Van Der Zanden AG, Weltevreden EF, Duanmu H, 
Douglas JT. Retrospective analysis of the Beijing family of Mycobacterium 
tuberculosis in preserved lung tissues. J Clin Microbiol 1999; 37: 471-474 
165. Rieder HL. Drug-resistant tuberculosis: issues in epidemiology and challenges 
for public health. Tubercule 1994; 75: 321-323 
166. Rinder H, Dobner P, Feldmann K, Rifai M, Bretzel G, Rusch-Gerdes S, Loscher 
T. Disequilibria in the distribution of rpoB alleles in rifampicin-resistant 
Mtuberculosis isolates from Germany and Sierra Leone. Microb Drug Resist 1997; 
3: 195-197 
187 
167. Rhee JT, Piatek AS, Small PM, Harris LM, Chaparro SV, Kramer FR, Alland D. 
Molecular epidemiologic evaluation of transmissibility and virulence of 
Mycobacterium tuberculosis. J Clin Microbiol 1999; 37: 1764-1770. 
168. Roberts GD, Goodman NL, Heifets L, Larsh HW, Lindner TH, McClatchy JK, 
McGlinnis MR, Siddiqi SH, Wright P. Evaluation of the BACTEC radiometric 
method for recovery of mycobacteria and drug susceptibility testing of 
Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin 
Microbiol 1983; 18: 689-696. 
169. Rogall T, Flohr T, Bottger EC. Differentiation of Mycobacterium species by 
direct sequencing of amplified DNA. J Gen Microbiol 1990; 136: 1915-1920 
170. Rohner P, Ninet B, Metral C, Emler S, Auckenthaler R. Evaluation of the 
MB/BacT system comparison to the BACTEC 460 system and solid media for 
isolation of mycobacteria from clinical specimens. J Clin Microbiol 1997; 35: 3127- 
3131 
171. Roring S, Scott A, Brittain D, Walker I, Hewinson G, Neill S, Skuce R. 
Development of variable-number tandem repeat typing of Mycobacterium bovis: 
Comparison of results with those obtained by using existing exact tandem repeats 
and spoligotyping. J Clin Microbiol 2002; 40: 2126-2133 
172. Ross BC, Raios K, Jackson K, Dwyer B. Molecular cloning of a highly repeated 
DNA element from Mycobacterium tuberculosis and its use as an epidemiological 
tool. J Clin Microbiol 1992; 30: 942-946 
188 
173. Ross B, Dwyer B. Rapid simple method of typing isolates of Mycobacterium 
tuberculosis by using polymerase chain reaction. J Clin Microbiol 1993; 31: 329- 
334. 
174. Rossau R, Traore H, De Beenhouwer H, Miljs W, Jannes G, de Rijk P, Portaels 
F. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization for the 
simultaneous detection of Mycobacterium tuberculosis complex and its resistance to 
rifampin. Antimicrob Agents Chemother 1997; 41: 2093-2098. 
175. Roth A, Schaberg T, Mauch H. Molecular diagnosis of tuberculosis: current 
clinical validity and future perspectives. E Respir J 1997; 10: 1877-1891 
176. Russell DG. Mycobacterium tuberculosis: Here today, and here tomorrow. Mol 
Cell Biol 2001; 2: 1-9 
177. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. 
Enzymatic amplification of beta-globin genomic sequences and restriction site 
analysis for diagnosis of sickle cell anaemia. Science 1985; 230: 1350-1354 
178. Salian NV, Rish JA, Eisenach KD, Cave MD, Bates JH. Polymerase chain 
reaction to detect Mycobacterium tuberculosis in histologic specimens. Am J Crit 
Care Med 1998; 158: 1150-1155. 
179. Savine E, Warren RM, van der Spuy GD, Beyers N, van Helden PD, Locht C, 
Supply P. Stability of variable-number tandem repeats of mycobacterial interspersed 
189 
repetitive units from 12 loci in serial isolates of Mycobacterium tuberculosis. J Clin 
Microbio12002; 40: 4561-4566 
180. Schirm J, Oostendorp LAB, Mulder JG. Comparison of Amplicor, In-House 
PCR, and conventional culture in the detection of Mycobacterium tuberculosis in 
clinical samples. J Clin Microbiol 1995; 33: 3221-3224. 
181. Schluger NW, Kinney D, Harkin TJ, Rom WN. Clinical utility of polymerase 
chain reaction in the diagnosis of infections due to Mycobacterium tuberculosis. 
Chest 1994; 105: 1116-1121 
182. Sewell DL, Rashad AL, Rouke Jnr. WJ, Poor SL, McCarthy JAC, Haller MA. 
Comparison of the Sept-Chek AFB and Bactec systems and conventional culture for 
the recovery of mycobacteria. J Clin Microbiol 1993; 31: 2689-2691. 
183. Shinnick T M. The 65 kilodalton antigen of Mycobacterium tuberculosis. 
J Bacteriol 1987; 169: 1088-1088. 
184. Siddiqi, S. H. 1996. BACTEC 460 TB system product and procedure manual. 
Revision E. 
185. Sjobring U, Mecklenburg M, Bengard Andersen A, Miomer H. Polymerase 
chain reaction for the detection of Mycobacterium tuberculosis. J Clin Microbiol 
1990; 28: 2200-2204. 
190 
186. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, Schecter 
GF, Daley CL, Schoolnik GK. The epidemiology of tuberculosis in San Francisco. 
A population based study using conventional and molecular motheds. N Engl J Med 
1994; 330: 1703-1709 
187. Small PM. Tuberculosis in the 21st centuary: DOTS and SPOTS. Int J Tuberc 
Lung Dis 1999; 3: 349-955 
188. Sneath PHA, Sokal RR. 1973. Numerical Taxonomy. WH Freeman and 
Company, San Francisco. 
189. Sneider DE, Raviglione M, and Kochi A. 1994. Global burden of tuberculosis, 
p. 3-11. In BR Bloom (ed). Tuberculosis: pathogenesis, protection and control. 
American Society for Microbiology, Washington, D. C. 
190. Sola C, Ferdinand S, Mammina C, Nastasi A, Rastogi N. Genetic diversity of 
Mycobacterium tuberculosis in Sicily based on spoligotyping and variable number 
of tandem DNA repeats and comparison with a spoligotyping database for 
population-based analysis. J Clin Microbiol 2001; 39: 1559-1565 
191. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 
1994; 264: 388-393 
192. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, 
Musser JM. Restricted structural gene polymorphism in the Mycobacterium 
191 
tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl 
Acad Sci USA 1997; 94: 9869-9874 
193. Stahl DA, Urbance JW. The division between fast- and slow-growing species 
corresponds to natural relationships anong the bacteria. J Bacteriol 1990; 172: 116- 
124 
194. Stanley J, Saunders N. DNA insertion sequences and the molecular 
epidemiology of Salmonella and Mycobacterium. J Med Microbiol 1996: 45; 236- 
251 
195. Styrt BA, Shinnick TM, Ridderhoff JC, Crawford JT, Tenover FC. Turnaround 
times for mycobacterial cultures. J Clin Microbiol 1997; 35: 1041-1042 
196. Summers GD, McNicol MW. Tuberculosis of superficial lymph nodes. Br J 
Dis Chest. 1980; 74: 369-373 
197. Supply P, Magdalena J, Himpens S, Locht C. Identification of novel intergenic 
repetitive units in a mycobacterial two-componentsystem operon. Mol. Microbiol 
1997; 26: 991-1003 
198. Supply P, Magdalena J, Himpens S, Locht C. Identification of novel intergenic 
repetitive units in a mycobacterial two-component system operon. Mol Microbiol 
1997; 26: 991-1003 
192 
199. Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B, Locht C. Variable human 
minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol 
Microbiol 2000; 36: 762-771 
200. Supply P, Lesjean S, Savine E, Kremer K, van Soolingen D, Locht C. 
Automated high-throughput genotyping for study of global epidemiology of 
Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. J 
Clin Microbiol 2001; 39: 3563-3571 
201. Taniguchi H, Aramaki H, Nikaido Y, Mizuguchi Y, Nakamura M, Koga Tand 
Yoshida S. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium 
tuberculosis. FEMS Microbiol Lett 1996; 144: 103-108 
202. Taylor MJ, Hughes MS, Skuce RA, Neill SD. Detection of Mycobacterium 
bovis in bovine clinical specimens using real-time fluorescence resonance energy 
transfer probe rapid-cycle PCR. J Clin Microbiol 2001; 40: 1272-1278 
203. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, 
Schoppfer K, Bodmer T. Detection of rifampicin-resistant mutations in 
Mycobacterium tuberculosis. Lancet 1993; 341: 647-650 (a) 
204. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T. Direct, 
Automated detection of rifampicin-resistant Mycobacterium tuberculosis by 
polymerase chain reaction and single stranded conformation polymorphism 
analysis. Antimicrob Agents Chemother 1993; 37: 2054-2058 (b) 
193 
205. Telenti A, Marchesi F, Balz M, Bally F, Bottger EC, Bodmer T. Rapid 
identification of mycobacteria to the species level by polymerase chain reaction and 
restriction enzyme analysis. J Clin Microbiol 1993; 31: 175-178 (c) 
206. Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B, Takiff HE, 
Cole ST. Genotypic assessment of isoniazid and rifampicin resistance in 
Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin 
Microbiol 1997; 35: 2054-2058 
207. Tenover FC, Crawford JT, Iluebner RE, Geiter LJ, Horsburgh CR Jnr, and Good 
RC. the resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 1993; 
31: 767-770. 
208. Thabit JH, Frandz A, Ibrahim B. Incidence of tuberculous neck masses in 
central zone of Saudi Arabia. Journal of the Royal College of Surgeons of 
Edinburgh. 1984; 29: 26 
209. Thibert L, Lapierre S. Routine application of High-Performance Liquid 
Chromatography for Identification of Mycobacteria. J Clin Microbiol. 1993; 31: 
1759-63 
210. Thompson M M, Underwood M J, Sayers R D, Dookeran R D, Bell P R. 
Peripheral tuberculosis lymphadenopathy: a review of 67 cases. Br J Surg 1992; 79: 
763-764 
194 
211. Toman K. Sensitivity, specificity and predictive value of diagnostic tests. Bull 
NAT 1981; 56: 18-28 
212. Tonjum T, Klintz L, Bergan T, Baann J, Furuberg G, Cristea M, Petrini B 
Hoffner S.. Direct detection in respiratory samples from patients in Scandinavia by 
polymerase chain reaction. Clinical Microbiology and Infection. 1996; 2: 127-131. 
213. Torrea, G., G. Levee, P. Grimont, C. Martin, S. Chanteau, and B. Gicquel. 
Chromosomal DNA fingerprint analysis using the insertion sequence IS6110 and 
the repetitive element DR as strain specific markers for epidemiological study of 
tuberculosis in French Polynesia. J. Clin. Microbiol 1995; 33: 1899-1904. 
214. Tortoli E, Lavinia F, Simonetti MT. Early detection of Mycobacterium 
tuberculosis in BACTEC cultures by ligase chain reaction. J Clin Microbiol 1998; 
36: 2791-2792. 
215. Totsch M, Bocker W, Brommelkamp E, Fille M, Kreczy A, Other D, Schmid 
KW, Dockhorn-Dworniczak. Diagnostic value of different PCR assays for the 
detection of mycobacterial DNA in granulomatous lymphadenopathy. J Pathol. 
1996; 178: 221-226. 
216. Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, 
Caugant DA. Spread of drug-resistant Mycobacterium tuberculosis strains of the 
Beijing genotype in the Archangel Oblast, Russia. 2002; 40: 1930-1937 
195 
217. Troesch A, Nguyen H, Miyada CG, Desvarenne S, Gingeras TR, Kaplan PM, 
Cros P, Mabilat C. Mycobacterium species identification and rifampin resistance 
testing with high density DNA probe arrays. J Clin Microbiol 1999; 37: 49-55 
218. Valim AR, Rossetti ML, Ribeiro MO, Zaha A. Mutations in the rpoB gene of 
multidrug-resistant Mycobacterium tuberculosis isolates from Brazil. J Clin 
Microbiol 2000; 38: 3119-3122. 
219. Valway SE, Sanchez MPC, Shinnick TF, Orme I, Agerton T, Hoy D, Jones JS, 
Westmoreland H, Onorato IM. An outbreak involving extensive transmission of a 
virulent strain of Mycobacterium tuberculosis. N Engl J Med 1998; 338: 633-639. 
220. van Embden JDA, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, 
Hermans PW, Martin C, McAdam TM, Shinnick TM, Small PM. Strain 
identification of Mycobacterium tuberculosis by DNA fingerprinting: 
recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406- 
409 
221. van Deutchkom H, Gerritsen JJ, van Soolingen D, van Ameijden EJC, van 
Embden JDA, Coutinho RA. A molecular epidemiological approach to studying the 
transmission of tuberculosis in Amsterdam. Clin Infect Dis 1997; 25: 1071-1077 
222. van Rie A, Warren RM, Beyers N, Gie RP, Classen CN, Richardson M, 
Sampson SL, Victor TC, van Helden PD. Transmission of a multidrug-resistant 
strain resembling "strain W" among noninstitutionalized, human immunodeficiency 
virus-seronegative patients. J Infect Dis 1999; 180: 1608-1615. 
196 
223. van Soolingen D, Qian L, de Haas PEW, Douglas JT, Traore H, Portaels F, 
Enkhsaikan D, Nymadawa P, van Embden JDA. Predominance of a singlegenotype 
of Mycobacterium tuberculosis in countries of East Asia. J Clin Microbiol 1995; 33: 
3234-3238 
224. van Soolingen D. Molecular epidemiology of tuberculosis and other 
mycobacterial infections: main methodologies and achievements. J Intern Med 
2001; 249: 1-26 
225. Vareldzis BP, Grosset J, de Kantor I, Crofton J, Laszlo A, Felten M, Raviglione 
MC, Kochi A. Drug-resistant tuberculosis: laboratory issues. Tubercule 1994; 74: 
1-7 
226. Ward J, Siskind V, Konstantinos A. Patient and health care system delays in 
Queensland tuberculosis patients, 1985-1998. Int J Tuberc Lung Dis 2001; 5: 1021- 
1027 
227. Wardle, E. N. Immunopathology of tuberculosis. Med. Dig. 1995; 21: 5-8 
228. Warren R, Richardson M, Sampson S, Hauman JH, Beyers N, Donald PR, van 
Helden PD. Genotyping of Mycobacterium tuberculosis with additional markers 
enhances accuracy in epidemiological studies. J Clin Microbiol 1996; 34: 2219- 
2224 
197 
229. Waterson SA, Wilson SM, Yates MD, Drobniewski FA. Comparison of three 
molecular assays for the rapid detection of rifampicin resistance in Mycobacterium 
tuberculosis. J Clin Microbiol 1998; 36: 1969-1973 
230. Wayne LG. Simple pyrazinamidase and urease tests for routine identification of 
mycobacteria. Am Rev Respir Dis 1974; 109: 147-151. 
231. Wayne LG, Engel HWB, Grassi C, Gross W, Hawkins J, Jenkins PA, Kappler 
W, Kleeberg HH, Krasnow I, Nel EE, Pattyn SR, Richards PA, Showalter S, 
Slosarek M, Szabo I, Tarnok I, Tsukamura M, Vergmann B, Wolinsky E. 1976. 
Highly reproducible techniques for use in systematic bacteriology in the genus 
Mycobacterium: Tests for niacin and catalase and for resistance to isoniazid, 
thiophene 2-carboxylic acid hydrazide, hydroxylamine and p-nitrobenzoate. Int J 
System. Bacteriol. 26: 311-318 
232. Ward J, Siskind V, Konstantinos A. Patient and health care system delays in 
Queensland tuberculosis patients, 1985-1998. Int J Tuberc Lung Dis 2001; 5: 1021- 
1027 
233. Warren RM, van der Spuy GD, Richardson M, Beyers N, Borgdorff MW, Behr 
MA, van Helden PD. Calculation of the stability of the IS6110 banding pattern in 
patients with persistent Mycobacterium tuberculosis disease. J Clin Microbiol 2002; 
40: 1705-1708 
234. Weiss R. 1991. A scramble for patent rights. Science 254: 1293 
198 
235. Woodhead M. New approaches to the rapid diagnosis of tuberculosis. Thorax 
1992; 47: 264 
236. Wild IN, Werely C, Beyers N, Donald P, van Helden PD. Oligonucleotide 
(GTG)5 as a marker for Mycobacterium tuberculosis strain identification. J Clin 
Microbiol 1994; 32: 1318-1321 
237. Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, Salfinger 
M, Nolan CM, Ade C, Sticht-Groh V, Gillis TP. Characterization of rifampicin- 
resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994; 38: 
2380-2386 
238. Wilson ML, Weinstein M P, Reimer LG, Mirrett S, Reller LB. Controlled 
comparison of the BacT/Alert and Bactec 660/730 nonradiometric blood culture 
systems. J Clin Microbiol 1992; 30: 323-329 
239. Wilson SM, Goss S, Drobniewski F. Evaluation of strategies for molecular 
fingerprinting for use in the routine work of a Mycobacterium Reference Unit. J 
Clin Microbiol 1998; 36: 3385-3388. 
240. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev 
RespirDis. 1979; 119: 107-159 
241. Wolinsky E. Mycobacterial lymphadentitis in children: a prospective study of 
105 nontuberculous cases with long term follow-up. Clin Infect Dis 1995; 20: 954- 
963 
199 
242. Woods G. Tuberculosis testing-what now? ASCP Draft Prac. Parameter. 1993; 7: 
1-6 
243. Wu DY, Wallace RB. 1989. The ligation amplification reaction (LAR) 
amplification of specific DNA sequences using sequental rounds of template 
dependant ligation. Genomics 4: 560-569. 
244. Yaganehdoost A, Graviss EA, Ross MW, Adams GJ, Ramaswamy S, Wanger 
A, Frothingham R, H. Soini H, Musser JM. Complex transmission dynamics of 
clonally related virulent Mycobacterium tuberculosis associated with barhopping by 
predominantly human immunodeficiency virus-positive gay men. J Infect Dis 1999; 
180: 1245-1251. 
245. Yeh RW, De Leon AP, Agasino CB, Hahn JA, Daley CL' Hopewell PC, Small 
PM. Stability of Mycobacterium tuberculosis DNA genotypes. J Infect Dis 1998; 
177: 1107-1111 
246. Yuen, L. K. W., Ross, B., Jackson, K. and Dwyer, B. Characterization of 
Mycobacterium tuberculosis strains from Vietnamese patients by Southern blot 
hybridization. J. Clin. Microbiol 1993; 31: 1615-1618 
247. Yuen LK, Leslie D, Coloe PJ. Bacteriological and molecular analysis of 
rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin 
Microbiol 1999; 37: 3844-3850 
200 
Appendix 1: List of publications and awards from this research 
Gilpin, C. M., Abdelaal, M., Osoba, A. O., Comparative study of Amplicor PCR 
and Ligase Chain Reaction for the direct detection of Mtuberculosis in clinical 
specimens. Clin Microbiol and Infect. 1997; 3(2): 158 
Poster presented at the 8th European Congress of Clinical Microbiology and infectious 
Diseases (ECCMID) Lausanne, Switzerland, May 1997 
Gilpin, C. M., Abdelaal, M. A., Oni, GA., Osoba A. O. Comparative study of Amplicor 
polymerase chain reaction and ligase chain reaction for direct detection of 
M tuberculosis in clinical specimens. Saudi Medical Journal. 1999; 20: 79-84. 
Gilpin, C. M., Gascoyne-Binzi, D. M., Barlow, R. E. L., Hawkey, P. M. VNTR typing of 
M. tuberculosis as a rapid means of characterising transmission of multi-drug resistant 
strains in Saudi Arabia. Micobiological Methods: 1999 
Gilpin C M, Dawson DJ, O'Kane G, Armstrong JG, Coulter C. Failure of commercial 
ligase chain reaction to detect Mycobacterium tuberculosis DNA from a patient with 
smear positive pulmonary tuberculosis due to a deletion of the target region. J Clin 
Microbiol 2002; 40: (6) 
Awards 
Scientific Award for publications of Abbott LCx Probe System Mycobacterium 
tuberculosis assay. Abstracts: 1ST Prize. 
Abstract presented at the 8t' European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID) Lausanne, Switzerland, May 1997 
201 
